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Chemistry

Bolstad, David B. Ph.D., July 2006

Synthesis of Novel 6-Nitroquipazine Analogs for Imaging the Serotonin
Transporter by Positron Emission Tomography
Chairperson: John M. Gerdes
A positron emission tomography (PET) imaging agent that can effectively
quantify the serotonin transporter (SERT) in brain regions with moderate to low
densities of SERT has yet to be identified. The recent literature has suggested
that the need for such an agent may be filled by a selective, high affinity SERT
ligand that displays extended in vivo kinetic profiles, concurrent with a reduction
of in vivo nonspecific binding. Recently, our group has identified 2’-alkyl-6nitroquipazine analogs as novel SERT ligands displaying very high affinity for
SERT (picomolar concentration range). We have utilized the 6-nitroquipazine
molecular construct for the development of new SERT PET imaging agents, by
generating a series of racemic 2’-alkyl-6-nitroquipazine analogs that can
incorporate the carbon-11 or the longer-lived fluorine-18 radionuclides. We
expect that the increased SERT affinity of our new ligands will afford more
efficacious SERT PET agents that can effectively quantify low density SERT
regions in living brain.
A large focus of the present study was to expand our initial racemic lead agents
by synthesizing each of them in enantiomerically pure form. Our synthetic
strategy utilized an efficient asymmetric synthesis of the piperazine head-group
from amino acid starting materials. The syntheses afforded non-radiolabelled
target ligands and the appropriate radioligand precursors in good yields.
Preliminary pharmacological data suggests a marked difference in binding affinity
between the enantiomers of our agents. Furthermore, using racemic amino
acids and the same asymmetric synthetic strategy, we were also able to
generate novel 2’-aryl-6-nitroquipazine analogs that were not synthetically
accessible using our derived methods for the 2’-alkyl agents.
The racemic radiotracer [18F]2’-(3-fluoropropoxymethyl)-6-nitroquipazine agent
was synthesized and evaluated in rat for initial radiotracer distribution. The
studies in rat have demonstrated favorable accumulation of the tracer in the brain
indicating efficient passage through the blood brain barrier. Furthermore, these
studies indicate the greatest concentration of radiotracer in regions of the brain
with known SERT density. The studies of the initial, racemic tracer have shown
that [18F]2’-(3-fluoropropoxymethyl)-6-nitroquipazine demonstrates potential as a
new SERT PET imaging agent.
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CHAPTER 1
INTRODUCTION, BACKGROUND AND PURPOSE

1.1

Serotonin Biology
Serotonin

(5-hydroxytryptamine,

5-HT)

1 is a biogenic indolamine

neurotransmitter that is present in the central nervous system (CNS) and
peripheral regions of both vertebrates and invertebrates. Within living systems,
serotonin is synthesized from L-tryptophan 2 in two steps (Figure 1.1). Step one
is an aromatic hydroxylation facilitated by tryptophan hydroxylase to provide 5hydroxytryptophan

3

that

undergoes

decarboxylation

by

amino

acid

decarboxylase to provide 5-HT 1.1

tryptophan
hydroxylase

NH.

HO.

2

3

amino acid
decarboxylase

HO.

NH2

1, Serotonin, 5-HT

Figure 1.1: The biosynthesis of serotonin.

Within the mammalian CNS, the serotonergic neurons are located
primarily in the raphe that is located within the brain stem. Neuronal projections
from the raphe extend to the cerebral cortex, hippocampus, hypothalamus and
thalamus thereby providing high densities of serotonergic neurons in these
regions.2 Interneuronal signaling with 5-HT occurs primarily at the synapse. The

1
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synapse is a junction between an axon terminal of one neuron (presynaptic
neuron) and the dendrite of another (postsynaptic neuron) (Figure 1.2).

Action Potential

Presynaptic Neuron
Synaptic
Vessicle

Ca2+ Influx

/ / i •*%

5-HT

Vesicular I
Transporter
Exocytosis
S eroto n in

Transporter
Synaptic Cleft

Postsynaptic Receptor
Activation
Postsynaptic Neuron

Response

Figure 1.2: A general representation of a serotonergic synapse.

The space between the neurons is approximately 20 nm and is called the
synaptic cleft. When an action potential traveling along the presynaptic neuron
reaches the axon terminal, voltage-gated Ca2+ channels in the membrane open
allowing for an influx of Ca2+ ions. The influx of calcium ions causes the synaptic
vesicles to fuse with the cellular membrane and release their neurotransmitter
contents (e.g. 5-HT, 1) into the synaptic cleft through the process of exocytosis.

2
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Once in the synaptic cleft, the neurotransmitters reach the postsynaptic neuron
through diffusion, and a response is afforded though activation of postsynaptic
receptor proteins.3

Following neurotransmission, transport proteins located

within the presynaptic membrane clear neurotransmitter from the synaptic cleft.
For 5-HT, the transport protein is the serotonin transporter (SERT, see Section
1.2 for a more detailed discussion). Once transported, 1 is packaged back into
vesicles through the action of a vesicular transporter. Additional removal of 1
from the synaptic cleft is facilitated by the oxidative degradation of 1 by
monoamine oxidase (MAO).1
A wide variety of serotonergic receptors exist in the CNS and in the
periphery.

Currently there are fourteen serotonin receptors that have been

identified and characterized to various extents.4 These receptors are grouped
into families based on their similar biochemical characteristics (primary structure,
genes), pharmacology and signaling mechanisms 4 Currently three functional
classes of serotonin receptors are known.

Most of the receptors (twelve of

fourteen) are G protein-coupled receptors, one is a ligand-gated ion-channel and
the last is the serotonin transporter (SERT). These receptors and a brief listing
of their known function^ are summarized in Table 1.1.2, 4-6

In peripheral

regions, serotonin receptors are found in blood platelets,7 the smooth muscle of
the digestive tract8 and circulatory system9 and on peripheral neurons where 5HT has been shown to have a role in pain signaling and analgesia following
tissue injury.10

3
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Table 1.1: A table of known serotonin receptors, their functional class, location in the
vertebrate/invertebrate body and associated functions.

Receptor

Type

Location

5-HT1A
5-HT1b

G-protein
G-protein

CNS-per
CNS-per

5-HT1d
5-HT1e
5-HT1f
5-HT2A
5-HT2B
5-HT2C

G-protein
G-protein
G-protein
G-protein
G-protein
G-protein

CNS-per
CNS
CNS-per
CNS-per
CNS-per
CNS

5-HT3
5 -HT 4
5-HTs
5-HT6

Ion Chan.
G-protein
G-protein
G-protein

CNS-per
CNS-per
CNS
CNS

5-HT7

G-protein

CNS-per

SERT

transporter

CNS-per

Functions
Sleep, anxiety, thermoregulation, depression
Migraine, vaso., aggression, bipolar disorder, gastric
motility
Migraine
Largely unknown
Migraine, vaso.
Schizophrenia, anxiety
Migraine, gastric motility, vaso., appetite
Depression, anxiety, obesity, cognition,
schizophrenia
IBS, emesis, cognition
IBS, gastric motility
Largely unknown
Bipolar disorder, Parkinson's, Alzheimer's, learning,
seizures, appetite
Sleep, migraine, depression, cognition,
schizophrenia, IBS
Uptake of 5-HT into cells

Key: G-Protein = G Protein-coupled receptor, ion chan. = ligand-gated ion channel, CNS =
central nervous system, per = periphery, vaso. = vasocon-striction, IBS = irritable bowel
syndrome

1.2

The Serotonin Transporter
The

serotonin

transporter

(SERT)

is

a

sodium/neurotransmitter symporter protein family (SNF).

member

of

the

The SNF proteins

utilize the co-transport of sodium and chloride ions down a concentration gradient
to provide the energy for transport of substrate.11 Other transport proteins in the
SNF family include those for the other biogenic amine neurotransmitters;
dopamine (dopamine transporter, DAT) and norepinephrine (norepinephrine
transporter, NET). Hydropathy analysis of the primary amino acid sequences of
the biogenic amine transport proteins predicts a common tertiary structure with
twelve transmembrane a-helical domains (TMD’s).

The SNF transporters are
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membrane bound and have their carboxy and amino terminals on the intracellular
(cytoplasmic) side of the membrane. The human SERT (hSERT) contains 630
amino acids.12
To date, a high-resolution molecular structure determination (e.g. x-ray
crystal structure) of SERT, or the other biogenic amine transporters, has yet to
be put forward. The majority of knowledge about SERT structure as it relates to
function comes from mutation studies probing the biochemical changes in
receptor function as a result of amino acid substitutions or deletions.13-18 Several
studies have used these results to model the transport binding region of SERT to
suggest the relative arrangements of the TMD’s.11,15
Recently, the structures of two major facilitator superfamily (MFS)
transport proteins, the glycerol-3-phosphate transporter (GIpT) and the lactose
permease (LacY), have been reported.19,20 Proteins of the MFS are related to
the SNF transporters structurally (12 TM D’s, intracellular amino and carboxi
termini) and functionally (ion coupled membrane transport proteins) and both
belong to the larger group of secondary transporters. Because of the structural
similarities between the MFS and SNF transporter families, the LacY tertiary
structure was recently utilized as a template to generate a refined threedimensional model of SERT.21
More recently, a prokaryotic homolog of the biogenic amine transporters
was crystallized and a structural determination made.22 The bacterial protein,
called LeuTAa, is a sodium dependent transport protein that is responsible for the
movement of leucine into bacterial cells.

LeuTAa is suggested as a better

5
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template for modeling SERT, relative to GIpT and LacY, because of its
corresponding dependence on sodium ions for transport of substrate.

However,

no refined SERT protein models, that utilize LeuTAa as a design template, have
yet come forward in the literature.
Developing a cogent understanding of the three-dimensional structure of
SERT will provide insight into functional aspects of the protein and also provide a
tool for the design and synthesis of new SERT ligands.

1.3

The Serotonin Transporter and Disease
Serotonin 1 has been well documented as having a key role in the

pathology of certain CNS related disorders.23, 24 It has been suggested that the
amount (density) of cell-surface expressed SERT may serve as an indicator of
the overall integrity of serotonergic terminals in the CNS.25 The distribution of
SERT in the CNS in healthy human brains has been determined from
postmortem studies26-29 and a summary of relative (high, medium, low) SERT
distributions in different brain regions is given in Table 1.2. The role of SERT in
neuropsychiatric disorders (depression, dependence, bipolar disorder, obsessive
compulsive disorder, among others) and neurological disease (Parkinsons’s
disease, Wilson’s disease, Stroke, Tourette’s syndrome, among others) is still
poorly understood. Studies in postmortem and living brain have demonstrated
significant changes in SERT density (increases and decreases) for these
diseased states, relative to healthy controls.

6
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Table 1.2: Relative SERT densities in discrete brain regions.

Relative amount
of cell surface
expressed SERT

Brain Regions

High

MIDBRAIN AND DIENCEPHALON: Medial and
dorsal raphe, thalamus, hypothalamus, striatum

Medium

LIMBIC SYSTEM: Hippocampus,parahippocampal
gyrus, amygdala and cingulate cortex

Low

Neopallium and cerebellum

Additionally, regional cerebral changes in SERT density have been noted
for age differences (decreased availability with increasing age) and seasonal
variation (decreased in autumn and winter) in healthy patients.

Detailed

summaries of these studies have recently been reported.23, 24 The results from
these studies have provided conflicting correlations.

For example, in two

separate studies of depression, children and adolescents have shown increased
(p < 0.02) SERT in the midbrain regions relative to controls30 while adults
demonstrate significant (p = 0.02) decreases in SERT within the same region.31
Similar

conflicting

correlations

for

other

diseased

states

have

been

documented.23,24 Clearly there are discrepancies observed in the current body
of research that has been devoted to understanding the role of SERT in
neuropsychiatric disorders and neurological disease.

It is suggested that an

enhanced understanding of the SERT role in these disorders will be assisted by
the development of better in vivo pharmacological tools, such as new positron
emission

tomography

(PET)

and/or

single

photon

emission

tomography (SPECT) imaging agents 23

7
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computed

Of the conditions mentioned above, depression, anxiety and OCD have
seen significant therapeutic benefit from serotonin reuptake inhibitors.

These

drugs bind to SERT and competitively inhibit (block) the uptake of 5-HT.

It is

hypothesized that a resultant increase of 5-HT in the synaptic cleft affords
increased transmission of signal and an amelioration of symptoms.32
The earliest SERT inhibitors, introduced in the 1950’s, were the tricyclic
antidepressants (for example 4 and 5, Figure 1.3).

Although these had a

profound effect at reducing depressive conditions, they also promoted adverse
side effects such as cardiotoxicity, sedation and weight gain.1 A new generation
of a SERT inhibitors, the selective serotonin reuptake inhibitors (SSRI’s, for
example 6 - 9 , Figure 1.3), were introduced in the late 1970’s. The most prolific
and well known SSRI, Fluoxetine (Prozac, 6), was the first to receive Food and
Drug Administration (FDA) approval for the treatment of depression in 1987.1, 33
The SSRI’s interact selectively with SERT to provide their therapeutic effect and
have demonstrated a reduction in adverse side effects relative to the tricyclic
antidepressant counterparts.1

8
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NH

4 Imipramine

5 Amoxapine

Cl
7 Sertraline (Zoloft)

6 Fluoxetine (Prozac)

O

CF3
8 Fluvoxamine (Avoxin)

9 Paroxetine (Paxil)

Figure 1.3: A collection of known SERT ligands; the tricyclic antidepressants (4 and 5) and the
modern selective serotonin reuptake inhibitors (SSRI's, 6 - 9).

1.4

Positron Emission Tomography Imaging
Positron Emission Tomography (PET) is a medical imaging technique that

utilizes radioactive probes (tracers, radioligands) to visualize and quantitate
biochemical processes within living tissues.

These tracers possess positron

emitting radionuclides that undergo decay in vivo, thereby providing the
necessary signal for quantifying the biochemical process of interest.34 The most
commonly utilized radionuclides are fluorine-18, carbon-11, nitrogen-13 and
oxygen-15.35 Another radionuclide that is often used with CNS ligand tracers, is
bromine-76.36 These positron radionuclides undergo beta plus (p+) decay and
emit a positron that travels a few millimeters or less before colliding with an
electron.

The annihilation event produces two high-energy photons that are
9
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emitted 180° apart along a line of decay response.

Using precision detection

instrumentation, the origin of the photons in three-dimensional (3D) space can be
determined thereby providing the in vivo location of the decay event. Resultant
3D maps of radionuclide decay can be created that allow for the quantitative
measurement of radiotracer accumulation and/or localization in the tissue or
region of interest. Anatomical correlation of the 3D PET decay images with highresolution nuclear magnetic resonance images (MRI) allows for the discrete
identification of target tissues and the anatomical volume associated with tracer
accumulation.37

Provided that the radiotracers are selective for their in vivo

target, PET imaging allows for the non-invasive measurement of the associated
biochemical processes.34 A sample PET image is shown in Figure 1.4.

Figure 1.4: Sample PET images (bottom) from a study in baboon, displaying the accumulation of
SERT tracer [11C]AFM 14 in the midbrain and thalamus. The corresponding MRI image of the
brain is displayed above the PET images. (Image from ref. 51).

10
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To afford efficacious PET imaging agents for the CNS, prospective PET
ligands must meet certain criteria. These criteria have been recently detailed38"41
and are summarized below.
-Synthetic Criteria - Radioligand planning and synthesis - The position of
radionuclide introduction into a prospective ligand can have profound implications
on tracer development. The modification of a parent compound to accommodate
a radionuclide may grossly change the ligands properties (lipophilicity, binding
affinity for target, metabolic fate), relative to the parent, and affect the tracers
performance.

Target agents should be rigorously characterized, in non

radioactive form, for the appropriate in vitro characteristics (see below).
Radiochemical syntheses are desired where the yield of target ligand at the end
of synthesis (e.g. incorporation of radionuclide, removal of protecting groups,
purification

and

preparation

of injectate)

is usually greater than

1 0 %.

Furthermore, the radiosynthesis should afford the target tracer with specific
activity (amount of radioactivity per mole or gram of ligand) that is sufficient for
adequate

PET

data

acquisition

(usually

>500

Ci/mmol).

Additionally,

radiosynthesis time needs to be minimized so PET experiments can be
completed in the useable lifetime of the radionuclide (usually 4-5 half-lives). For
certain radionuclides, especially carbon-11 (ti/2 = 20.3 min), this criterion is of
timely importance.
-In vitro pharmacological profiles - The competitive binding affinity (Kj) of the
tracer for its target protein in the CNS should typically be at low nanomolar
concentrations or below, so that the target can be adequately quantitated given

11
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the low doses (< 1 mg) of ligand typically administered for PET imaging studies.
The radioligand should display at least a 100 fold preference for its target over
other sites that it may interact with. This selectivity helps minimize complications
that arise from non-specific (non-target) binding interactions during the in vivo
PET experiments. To achieve adequate brain penetration by passage through
the blood-brain barrier (BBB) the lipophilicity of the compounds (partition
coefficient, logP) needs to be considered. More lipophilic (logP > 3.5) qualities
can sometimes lead to increased nonspecific binding in vivo40 and management
of the tracer lipophilic qualities should be considered as additional synthetic
criteria.
-In vivo pharmacological profiles - The uptake of the radioligand into the brain
should occur quickly following injection.

The nonspecific binding interactions

should washout of the tissues rapidly, so target specific binding can be quantified
on a timescale appropriate for the radionuclide.

The target specific binding

interactions should be reversible on the experiment time scale so kinetic tracer
analyses can be performed.

Radioligands should show minimal metabolic

activity in the CNS since radiolabeled metabolites may have distinct in vivo
properties that could complicate the tracer target evaluation.
-Additional considerations - Ligand toxicity is of minimal concern since the
injected mass of radioligand is well below a therapeutic dose; that is usually less
than 10 pg.

The dose of radiation administered in an experiment is also a

concern, yet is minimal based on the low tracer dose as a function of radioligand
specific activity.

12
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Other specific tracer considerations can be made based on the needs of
the system under study. Additional criteria for the in vivo imaging of the SERT
target within the CNS are provided in the next section.

1.5

Imaging of the Serotonin Transporter with SPECT and PET
Studies toward efficacious imaging agents for SERT have been ongoing

now for approximately fifteen years.

The first successful imaging agent

developed for SERT was the cocaine analog (single photon emission computed
tomography (SPECT) agent [123l]p-CIT 10 (Figure 1.5) . 42

10 [1 2 3 l]pCIT

Figure 1.5: First generation SPECT imaging agent for SERT.

Ligand 10 however, is not selective for SERT, and has also found use as
an imaging agent for the dopamine transporter (DAT).

The inability of 10 to

quantify SERT in regions where DAT was coexpressed proved to be a significant
limitation to the efficacy of this tracer, and has limited it’s use in imaging medium
to low density SERT regions.43 The synthesis of novel ligands that are selective
for SERT, relative to the other biogenic am ine transporters (DAT and NET),
remains a ongoing challenge in the development of new SERT imaging agents.

13
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Next generation SERT PET imaging agents have largely been derived
from two structural classes (Figure 1.6, with references); the pyrroloisoquinolines

(11 and 12) derived from (+)-McN5652 26 and the diaryl sulfides (13 - 15).

Cmpd
Cmpd

R

R-,

R2

ref

11 CH3

CN

47

11 CH3

CH2F

47

ref
13DASB

11

11 CH3

44

12

CH218F 48

NH2 14[11C]AFM
15[18F]AFM

CH3

CH218F 52

F ig u re 1.6: Next generation PET imaging agents for SERT.

The first tracer to find use as a selective in vivo imaging agent for human
SERT was 11.44 Although 11 has been utilized successfully in human studies of
depression45 and drug abuse,46 it has been shown to be an inferior tracer to
ligands from the diarylsulfide series (particularly 13 and 14, Figure 1.6) . 47 The
fluorine-18, fluoromethyl analog

12

has demonstrated superior in vivo properties

(40% higher specific binding, reduced metabolism, faster kinetics) relative to
carbon-11 variant 11.48

Additionally, the longer-lived fluorine-18 radionuclide

provides an opportunity for off-site imaging applications.

However, the

successful imaging of brain tissues with low SERT density may fail as a result of
high NSB in non-target regions (i.e. cerebellum) . 49
Of the diaryl sulfides that have been developed, DASB 13 and [11C]AFM

14 have emerged as lead SERT imaging agents (Figure 1.6) . 47 Although 13 has
been one of the most widely used ligands for the in vivo imaging of SERT in
humans,46,

50

it still does not allow for a reliable quantification of low-density
14
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SERT regions.43 It has been suggested that the use of [11C]AFM 14 (with greater
target to non-target ratios) may allow for the quantification of low-density SERT
regions.43,47,51 A recently developed fluorine-18 ligand, [18F]AFM 15, shares the
high specific binding qualities of carbon-11 analog 14 as demonstrated in rat.52
Given the longer lifetime of the fluorine-18 radionuclide, and the possibility for offsite imaging applications, 15 may emerge as a superior ligand to both 13 and 14.
Studies of ligand 15 in non-human primates, to substantiate the early rodent
findings have yet to be put forward. To date, diaryl sulfide ligands 13 and 14
have been established as the most efficacious ligands for the in vivo imaging of
SERT.43, 47,

53

However, there still exists a need for ligands that can quantify

SERT in brain regions displaying low-density expression of the receptor.43
Six

6 -nitroquipazine

analogs have been advanced as plausible SERT

tracers since the early 1990’s (Figure 1.7, with references). These tracers have
all largely failed to provide the in vivo qualities necessary for efficacious SERT
imaging agents.

Compound 16 suffers from metabolic defluorination and an

apparent lack of selectivity for SERT in blocking studies.54

Cmpd R-|
16

NH

R2

ref

H -(CH2)318F 54

17

11 CH3

H

55

18

123l

H

57

19

76Br

H

36

20

18F

H

56

F ig u re 1.7: SERT imaging agents derived from 6-nitroquipazine.
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Compounds 17, 19 and 20 all showed poor thalamus to cerebellum (high to low
SERT density; target to non-target) ratios.36, 55, 56 Compound 17 also displayed
slow binding kinetics (equilibrium not reached at 90 min) that was not amenable
to the lifetime of the carbon-11 radionuclide. SPECT agent 18 has demonstrated
good target to non-target ratios (>

2)

in primate brain but the use of this

compound has been limited due to metabolic dehalogenation generating free
iodine-123 that obscures experimental images.55' 57 PET agent 21 has recently
been described.58 However, in a comparison study with DASB 13, 21 was shown
to be an inferior PET ligand.59 Collectively, these

6 -nitroquipazine

agents have

not proven as efficacious at imaging SERT as diaryl sulfides 13 and 14.

1.6

6-Nitroquipazine Analogs: Previous Work from Our Lab and Others
Our group has been interested in the development of novel SERT tracers

derived from the known SERT inhibitor 6 -nitroquipazine (6 -NQP, 22) (Figure 1.8 ).

4

22

23

3'

Figure 1.8: 6-Nitroquipazine and a description of ring numbering in the quipazine series.

The IUPAC name for 22 is 6-nitro-2-(piperazin-1-yl)quinoline.

However,

the term ‘quipazine’ is typically used when referring to compounds in this series.
The parent compound, quipazine 23, is also shown in Figure 1.8 and the
numbering scheme for the rings is indicated. Substituents on the piperazine ring

16
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are indicated with a ‘prime’ after the position number to differentiate them from
substituents on the quinoline ring.
Compound 22 was first described in the early 1980’s under the trade
name DU 24565 and its selectivity for SERT over the other biogenic amine
transporters (NET and DAT) was high (10 3 fold) . 60 A tritiated ([3 H]) variant of 22
was generated61 and the in vitro and in vivo characterization of [3 H]22 further
demonstrated the potency and selectivity of 22 for SERT .62,63
Our group performed a structure activity relationship (SAR) study to
evaluate the effects of methyl group introduction to quipazine 22 at the 2’- and 3’positions (Figure 1 .Q) . 64

Figure 1.9: Investigational compounds from our initial SAR study.64

We observed a marked increase in SERT affinity with 2’-methyl agent 24
(K j

= 0.08 nM) relative to 22 (K j = 0.16 nM) and a competitive binding decrease

with the 3’-methyl analog 25 (K j = 4.56 nM). The selectivity of these compounds
for SERT has not yet been evaluated through comparison biding studies at NET
and DAT.

However, it is conjectured to be high, based on the selectivity of

parent compound

22

.

Concurrent with this SAR study, our group was generating an inhibitorbased pharmacophore of the SERT binding site using SERT inhibitors of known

17
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efficacy.6 5 ,66 The training set ligands used in this computational study are shown
in Figure 1.10 with their key structural similarities identified.

NH2

Terminal
Amine

Terminal
Amine

N.

\

\

Terminal
Amine

Central
Carbon

Central
Carbon

7 Sertraline

26 (+)-MCN5652

27 Indatraline

28 (S)-Citalopram

Figure 1.10: Training set ligands utilized in the generation of our SERT pharmacophore.

These computational studies used rigorous conformational searching and
scoring functions to identify conformations of each molecule (7, 26 - 28) that are
most like each other in three-dimensional (3D) space relative to their key
structural similarities. The key points of similarity, the terminal amine group, both
aromatic rings (Ar1, distal to amine group; Ar2 proximal to amine group) and the
X group (Shown in Figure 1.10) were used as points of comparison in this study.
The resultant pharmacophore model is shown in Figure 1.11 as a superposition
overlay of select conformations of the training set ligands. The similarities in the
alignments of the key structural elements are detailed in Figure 1.11 where the
regions are indicated with arrows.
When 2’-methyl quipazine analog 24 was fit into the pharmacophore, it
was observed that the methyl group provided a contact into the Ar2 region of the
model. It is thought that this simple alkyl group may be a suitable replacement

18
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for the Ar2 moiety.

The 3’-methyl analog 25 fit less optimally into this region,

placing the methyl group into a region of the 3D model that was undefined. The
decreased affinity of 25 might result from steric interactions that occur within this
undefined region of our model.

Het
Terminal
Amine
\

X Group

Connecting
Carbon

A h -a x is
View

Terminal
’ Amine
(1 S,4S)-(+)-c/s-Sertraline
(1 R3S)-(+)-fra/?s-lndatraline
(1 S)-(+)-Citalopram

Top View

Het

|

(6S,10bR)-(+)-McN-5652

Figure 1.11: Our derived SERT pharmacophore model, illustrated as a superposition overlay of
select conformations of training set ligands. (Image from ref. 6 6 ).

With quipazine 24 identified as a new lead agent, subsequent studies
sought to refine the SAR of this initial lead.

Our computational efforts

corroborated our initial SAR findings and suggested the abandonment of the 3’substituted-6 -nitroquipazine analogs (like 25).

Former group member Mark

Walker initiated these studies with his synthesis of 2’-methoxymethyl-6nitroquipazine (MOM-NQP, 35, Figure 1.12 ) . 67

Briefly, the Walker synthesis

began from known dibenzylpiperzine ester 2968 that was reduced to alcohol 30
19
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with UAIH 4 in ether.

Alkylation of 30 with NaH and CH 3 I in THF, followed by

dihydrochloride formation gave 31. Hydrogenolysis of the benzyl groups with PdC in ethanol gave piperazine 32 that was protected with trityl chloride in DCM to
give 33.

B nN / N ' i

Et02 C '4 % /NBn
H

L1AIH 4

ether

29
Rondu, 1997

30

31

32

2-CI-quinoline
NH
Et3N

H
33

H
34

H
35

Figure 1.12: Walker's synthesis of 2'-methoxymethyl-6-nitroquipazine (MOM-NQP).67

Compound 33 was coupled to 2-chloroquinoline using the method of
Gilman69 to provide quipazine 34 following deprotection. Nitration of 34 provided
the target, MOM-NQP 35 .67
Compound 35 displayed very high binding affinity for SERT, and is one of
the most potent SERT inhibitors known to date .70 It displayed a 65-fold increase
in potency over parent compound 22 and a 32-fold increase over our initial lead
agent 24. The MOM-NQP ligand 35, like the 2’-methyl analog 24, still needs to
be evaluated for its SERT selectivity relative to DAT and NET. A summary of the
initial SAR data is detailed in Table 1.3, in comparison to parent compound

6-

NQP 22. The radioligand displacement binding assay used to acquire the SERT
binding data is detailed in Chapter 5.
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Table 1.3: Preliminary SAR data from the Gerdes laboratory.

Compound

Structure

Binding affinity (Kj± sd) nM

22m

0.163 ± 0 .0 5 3

0.081±0.061

4.56 ± 2.4

0.0025 ± 0.0003

N
H

Other structure activity studies of

6 -NQP

analogs at SERT have been

ongoing by other researchers and their work has focused primarily on quinoline
ring substituted analogs.54,71' 73 A few representative targets from their work are
shown in Figure 1.13. Many of the compounds produced by Chi and coworkers
have displayed good SERT affinity in the low to sub-nanomolar concentration
range (i.e. compounds 36, 38 and 40 and others).

Additionally, they have

successfully demonstrated that groups of moderate size are well tolerated at the
3- and 4- positions of the quinoline ring (i.e. 37, 38 and 40).
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Cl
F

N

N' ^ 1
k^NH

3672
SERT K = 0.03 +/- 0.01 nM

N

l^ N H

l^ N H

3772
SERT Ki = 5.23 +/- 0.53 nM

38s4
SERT K| = 0.31 +/- 0.01 nM

Cl

Cl

Br
N

N ^ i

N

N'''X |

k^NH
3973
SERT K = 17.28 +/- 2.33 nM

4073
SERT K, = 2.70 +/- 0.32 nM

k^NH
4171
SERT Ki = 12.62+/-1.44 nM

F ig u re 1.13: Example ligands from the SAR studies performed by Chi et al. The Kj values are
determined with rat brain homogenate2 and fHlcitalopram.

The addition of a methyl group to the terminal amine was not well
tolerated, and a 570 fold decrease in SERT affinity was demonstrated for the
conversion of 36 to 39.
To date, compound 38 is the only ligand from Chi and co-workers that has
been advanced as a PET imaging tracer.

This agent however displayed

significant in vivo metabolic defluorination as evidenced by the accumulation of
radioactivity in bone. Additionally, the in vivo challenge of [18F]38 with selective
SERT blocking agents (fluoxetine and paroxetine) only reduced the binding of
[18F]39 by 11-31% in the frontal cortex signifying that in vivo nonspecific binding
of this tracer is high.54 These results suggest that [18F]38 may not be a suitable
tracer for imaging SERT.
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1.7

Focus of the Investigation
Following the successes of our initial SAR investigations, attention was

turned toward the development of
imaging agents.

6 -nitroquipazine

analogs as new SERT PET

As discussed earlier, recent reports of new PET agents for

SERT have suggested that a need still exists for tracers that can quantitatively
measure SERT in brain regions with medium to low SERT density.43,47 A tracer
that can meet these demands must demonstrate the in vivo properties that
promote accurate in vivo SERT measurements; including, the disappearance of
nonspecific binding within a timeframe that is within four half-lives of the
radionuclide and appropriate signal-to-noise ratios that permit reproducible
quantification of moderate to low SERT density regions.

Given the very high

affinity of our new 2’-substituted-6-nitroquipazine analogs (compounds 24 and

35, as per Table 1.3) and the known SERT selectivity of 6 -nitroquipazine 22,60
we felt that select analogs may offer significant improvements in tracer
performance relative to the established

6 -NQP

SERT imaging agents (Figure

1.7).
With the new goal of obtaining novel PET imaging agents that could
reproducibly image brain regions with moderate and low densities of SERT, we
set out to establish synthetic protocols for obtaining these agents from our initial
lead agents MOM-NQP 35 and 2’-methyl-NQP 24. The investigation described
within, details our discovery of new SERT PET imaging agents, with an emphasis
on the synthetic methods utilized to obtain our targets in non-racemic form.
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Chapter Two of this dissertation discusses the initial racemic syntheses of
our new targets and the preliminary radiochemical studies that produced our
target fluorine-18 and carbon-11 SERT PET tracers. The asymmetric synthetic
methods developed to obtain our non-racemic targets will be discussed in
Chapter Three.

The discussion of the asymmetric method is extended in

Chapter Four, as it is applied to the synthesis of novel 2’-aryl-6-nitroquipazine
analogs.

The biological evaluation of our new SERT ligands is provided in

chapter five, and a summary of the study closes out this work in chapter six.
Finally, full experimental details are afforded in Chapter Seven.
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CHAPTER 2

SYNTHESIS OF RACEMIC TARGETS

2.1

Introduction
Preliminary studies from our laboratory aimed at acquiring a SERT PET

imaging agent have been focused on the generation of a fluorinated target ligand
derived from the initial lead agent 2’-methyl-6-nitroquipazine 24. The fluorinated
target ligand 42 was never synthesized, even in non-radioactive ‘cold’ form and
efforts to acquire it were abandoned (Figure 2.1).

Failed

BnN

''i

PAST
PAST

BnN""''N|

H° ^ 4 ^ NBn CH2Cl2
FH2C.4 — NBn
l2CI2 FH2c

H2, Pd/C

H N '^

Et3N

EtOH

FH2C

c h 2ci2

H

30

Trityl-CI

43

44

45

Figure 2.1: Attempted route toward the generation of 2 ’-fluoromethyl-6-nitroquipazine.

These synthetic failures resulted largely from the instability of the fluorine
atom to the alkyllithium coupling conditions (discussed later) used to form 42
from piperazine 45 and 2-chloroquinoline. A control reaction confirmed that the
fluorine atom was undergoing elimination (HF) since an analysis of the product
mixture by GC/MS showed a decrease in mass (m/z A20) of the trityl protected
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material 45 consistent with the loss of HF. This was unfortunate since piperazine
45 could be synthesized easily from the dibenzyl alcohol substituted 30 (Figure
2.1).

Additionally, attempts at generating a tosylate leaving group from the

alcohol 30 and another alcohol intermediate 58 (HOM-BOC, shown later) failed.
Thus, a radiochemical precursor could not be generated. The introductions of
other sulfonate leaving groups (mesylate, triflate) were never attempted since our
radiochemical collaborators preferred to have the tosylate leaving group
chromophore as an experimental tool for observing its displacement by
radioactive [18F]fluoride ion.
Given these failures at generating fluoromethyl agent 42, our group next
sought to extend the piperazine side chain to 3-fluoropropyl in the hope that a
fluorinated agent might be generated.

These efforts were successful, and the

formation of compound 50 was partially the focus of another research group
member, Brian Kusche.74

The synthesis of target ProF-NQP 50 is briefly

summarized below (Figure 2.2).

F ig u re 2.2: Summary of the route used by Kusche74 to obtain ProF-NQP. For 4 9 , the protecting
group (PG) was N-formyl or N-ferf-butoxycarbonyl (N-Boc).
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The

side

chain

extension

was

accomplished

through

a

Swern-

oxidation/Horner-Emmons homologation sequence using alcohol 30, to afford
unsaturated ester 46.

The conversion of 46 to protected piperazine 47 was

accomplished in five steps and the coupling of 47 to 2-chloroquinoline afforded
2’-(3-methoxy-1-propyl)-6-nitroquipazine (PrOM-NQP) 48 following deprotection
and nitration.

With the extended side chain, the introduction of the tosylate

leaving group proceeded smoothly and precursor 49 for radiolabelling was
generated in 3 steps from 48. Depending on the method of synthesis, an U-tertbutoxycarbonyl (N-Boc) or N-Formyl protecting group (PG) was utilized.

The

conversion of 49 to 2’-(3-fluoro-1-propyl)-6-nitroquipazine (ProF-NQP) 50 was
accomplished using nucleophilic fluoride ion from tetrabutylammonium fluoride
(TBAF) in THF. Radiochemical studies with the compound are ongoing and an
optimization of the synthesis to obtain a fluorine-18 radiotracer is forthcoming.74
The synthetic studies described herein detail the efforts to generate SERT
PET agents from our refined lead agent MOM-NQP 35.

2.2

Generation of N-Boc-2’-Hydroxymethyl-6-Nitroquipazine
To afford plausible radiotracers, the synthetic plans must meet certain

criteria.

Mainly, because of the short half-life of the carbon-11 and fluorine-18

atoms, the radionuclide group must be introduced very late in the synthesis,
ideally as a last step. This is a necessary criterion since the short half-lives of
the radionuclides ([18F] tm = 1 1 0 min; [11C] tm = 20.4 min) require that the
formation of the radioactive atom, synthesis of the radiochemical tracer and PET
27
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experiment all be accomplished in a short period of time ( 4 - 5 half-lives of the
respective radionuclide).

The subsequent removal of any protecting groups

should also be fast and the purifications uncomplicated so reaction times can be
minimized.

To fulfill these criteria, an alkylation strategy was considered

whereby a [11C]-methyl group could be introduced on the side chain using routine
synthetic protocols, followed by removal of an appropriate nitrogen protecting
group (PG) to afford the desired radiotracer [11C]35 (Figure 2.3).

°2 Nv

V

\

I T ]

[11C]CH3-X

deprotection

o 2nl

H3- 0 0 _ 4 J nH
51

H

11

[11 C]35

H

Figure 2.3: Synthetic strategy devised for the synthesis of [11C]MOM-NQP.

Initial studies from our laboratory aimed at generating a protected
hydroxymethyl-nitroquinoline 51 met with only mediocre success. For example,
attempts at generating ethyl 2’-carboxylate-6-nitroquipazine 53 that could be
reduced to alcohol 51 were unsuccessful (Figure 2.4, unpublished results).
Thus, alternate methods were investigated that began from lead compound 35
and necessitated O-dealkylation technologies.

~xx

Trit

52

Et02C‘^ v ^ ' NH

.~!'ccx
2. protection

H0^ ^ ^ N' PG

53

51

Figure 2.4: Failed, previously attempted route for acquiring an alcohol intermediate.
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Trimethylsilyl iodide (TM S -I) is a reagent well characterized in its ability to
afford O-dealkylation under generally mild conditions.7 5 ,76 T M S -I is commercial
ly available, but it can also be generated in situ through the reaction of TMS-CI
with Nal in toluene.77

In our hands however, this reagent gave unsatisfactory

results (yields < 20%) with unnitrated quipazine 34 yielding only a poor yield of
alcohol 54 (Figure 2.5 ) . 67 In hindsight, the poor yields may have resulted from
the lack of a protecting group on the secondary nitrogen. However, this notion
has yet to be fully investigated and alternate methods have been considered.

Toluene
34

54

Figure 2.5: TMS-I promoted dealkylation reaction attempted by Walker .67

Boron tribromide (BBr3) is another common O-dealkylation reagent and it
is most commonly utilized for the demethylation of phenols.7 8 ,79 However, there
are reports in the literature of BBr3 use for the demethylation of aliphatic ethers,
which provided good yields of target alcohols.80

A BBr3 dealkylation was

attempted with MOM-NQP 35 using 400 mol% of BBr3 (1 M in CH 2CI2) in CH 2 CI2
(DCM) at -78 °C. Excess BBr3 was used so that coordination of the reagent to
the other electron donors would not inhibit reactivity with the methyl ether.78
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B B f3, C H 2C I2
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N^X |
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-78 °C

.

H

ho^

60%

55

N ^ j

4 ^ nh
H

xHCI

Scheme 2.1: Boron tribromide mediated demethylation of MOM-NQP.

These conditions resulted in good conversion to alcohol 55 and the
product was isolated as a hydrochloride salt through a forced crystallization from
EtOH/HCI(g)

with ether.

Product identity was assigned

based

on the

disappearance of the methyl singlet and a TLC profile that showed a more polar
material (as the free base) relative to starting material (Rf of 0.04 vs. 0.15;
MeOH:DCM, 1:9). With the alcohol in hand, it was now necessary to choose a
nitrogen protecting group that could easily be removed and would withstand the
conditions necessary for O-alkylation (base and electrophile, CH 3-X).
The triphenylmethyl (trityl) protecting group was chosen initially because it
met these general criteria and was a reagent with which we were familiar from
previous work in our lab (e.g. Figure 1.12) . 67

The nitrogen protection was

attempted using the method of Rondu68 which employed trityl chloride in DCM
with triethylamine at 0 °C. These reaction conditions provided a poor yield of the
desired N-trityl protected alcohol 56 because of a competing reaction with the
primary alcohol to provide di-protected product 57 (Scheme 2.2).

Products 56

and 57 were easily separated (column chromatography) and their 1H NMR
spectra clearly indicated the presence of a single protecting group and two
protecting groups, respectively.
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NH

2. Trityl chloride

55

0 °C

56 31%

5 7 24%

-7 8 ° C

50%

20%

Scheme 2.2: Formation of N-trityl protected alcohol.

An attempt to minimize the alcohol reactivity by lowering the temperature
to -78 °C only improved the yield of desired product slightly, providing milligram
quantities of 56 in 50% yield.
With N-trityl alcohol 56 generated, it was time to attempt our cold
radiosynthetic strategy (Figure 2.3) to reintroduce the methyl group and remove
the trityl protecting group.

The alkylation of 56 was first attempted in

tetrahydrofuran (THF) with NaH as the base followed by the addition of methyl
iodide at 35 °C. Although conversion to the methyl ether occurred, the reaction
was slow and required an overnight stir to reach completion. Another attempt
was made using DMF as a solvent with excess NaH (3000 mol%) and methyl
iodide (800 mol%) (Scheme 2.3 ) . 81

NH
65%

Scheme 2.3: 'Cold' radiochemical synthesis of MOM-NQP from the N-trityl protected alcohol.
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Following the addition of reagents, the reaction was heated (35 °C) briefly
and a check by TLC after five minutes showed that the starting material had been
consumed, and the alkylated product had formed.

After work-up, the crude

reaction mixture was immediately subjected to deprotection conditions (EtOH,
HCI, 10 min) to remove the trityl group.

Work-up and chromatography provided

lead agent MOM-NQP 35 in 65% yield (Scheme 2.3). The 1H NMR spectrum of
35 was identical to that produced according to Walker as described in Chapter
1 67

This synthesis validated our radiosynthetic strategy for the generation of
[11C]35.

Furthermore, the transformations were accomplished quickly, with

reaction times being

less than ten

minutes.

However,

we were

still

disadvantaged by the lack of regioselectivity in our N-trityl protection that
provided only a modest chemical yield of protected target 56. At this time other
efforts

within

our

laboratory

demonstrated

the

usefulness

of the

tert-

butylcarbamate (Boc) group for the protection of the secondary amine
functionality in our quipazine compounds.

The introduction of this group

proceeded smoothly using di-ferf-butyldicarbonate (B0 C2O) in DCM followed by
concentration of the reaction mixture and chromatography of the residue.82 This
was an attractive alternative sequence to the trityl synthesis since Boc groups
are well known for their tolerance of aqueous environments83 and they could
likely be introduced in the workup of the boron tribromide demethylation reaction.
Additionally, the Boc deprotection products (CO 2 and isobutylene) are gaseous
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and easily removed from the reaction mixture, simplifying the purification process
for target 35.
The initial attempt of this reaction sequence using 500 mol% BBr3 (1 M
solution in DCM) and 180 mol% of di-fe/f-butyldicarbonate provided a modest
yield of N-Boc protected product 58 (Scheme 2.4).

NBoc
35

H

2. Aq. NaHCOo

H

H
58

55
H2S04, THF, 73%

Scheme 2.4: Synthesis of key intermediate 58, HOM-BOC-NQP.

Pure, free-base form, amino alcohol 55 can be isolated by deprotection of
the Boc group with 4 M sulfuric acid in THF. The identity of 58 was confirmed
primarily from LC/TOF-MS data, which provided a molecular weight of 388, that
was consistent target molecule 58. Analysis by 1H NMR was problematic since
the incorporation of the tert-butylcarbamate protecting group had a profound
broadening effect on the piperazine hydrogen signals, and to a lesser extent on
the aromatic signals. However, the absence of a methyl singlet (expected at 3.2
-

3.7 ppm) and the presence of the tert-butyl group singlet (~1.5 ppm)

accompanied with all of the quinoline resonances was enough for us to proceed
with confidence that compound 58 had been formed.
The 1H NMR spectra of 58 in comparison to the deprotected amino
alcohol 55 are shown in Figure 2.6, where line broadening of the Bocintermediate (upper panel) is shown.
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Figure 2.6: 1H NMR spectra of N-Boc protected alcohol 58 (top) and amino alcohol 55 (bottom)
demonstrating the line broadening observed as a result of the introduction of the N-Boc protecting
group. The scale is in 5 ppm.

The differences in the resolution of the piperazine protons is clearly
observed and this broadening has been consistent across all Boc protected
compounds in the quipazine series. This broadening effect is also transferred to

the carbon atoms and a similar comparison can be made with the 13C NMR
spectra of the same compounds (Figure 2.7).
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Figure 2.7: 13C NMR spectra of N-Boc protected alcohol 58 (top) and amino alcohol 55 (bottom)
demonstrating the line broadening observed as a result of the introduction of the N-Boc protecting
group. The scale is in 5 ppm.

Ultimately, the confirmation of product identity came from the independent
synthesis of the methyl ether to form 35 using the same strategy that was
employed for the N-trityl protected alcohol 56. A clean conversion to the methyl
ether was accomplished using 250 mol% NaH, and ~600 mol% CH3-I in DMF

35
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(reduced quantities vs. N-Trityl reaction). The crude Boc protected intermediate
(not shown) was treated with trifluoroacetic acid (TFA in DCM, 111)84 at ambient
temperature until complete conversion to the secondary amine (more polar) was
observed by TLC (~1 h). A basic workup provided the crude material that was
unambiguously identified as desired target 35 by 1H NMR (Scheme 2.5).

NBoc
58

H

2. TFA:CH2CI2

NH
35

120% Crude

H

Scheme 2.5: 'Cold' radiosynthesis of MOM-NQP using the N-Boc protected alcohol.

This experiment was evidence enough that we had developed a
methodology that could be adapted to the synthesis of [11C]35.
quantities

of

radiolabelling

precursor

58 could

be

generated

Adequate
so

that

radiochemical experiments by collaborators at the Lawrence Berkeley National
Laboratory (LBNL) could commence. These experiments are detailed in Section
2.7.

2.3
Synthesis of (rac)-MeProF and a Tosylate Precursor for the
Radiosynthesis of [ 8F](rac)-MeProF
Other concurrent efforts within our laboratory were focused on the
synthesis of the fluorine-18 agent [18F]2’-(3-fluoropropyl)-6-nitroquipazine [18F]50
([18F]ProF-NQP, shown in Figure 2.8a) as per Figure 2.2. However, preliminary
results

from

our

radiochemical

collaborators

at

LBNL

indicated
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some

decomposition and side reaction complications during the radiosynthesis.74
Consequently, avenues toward other fluorine-18 ligands were considered.
We decided to append a fluroroalkyl side chain onto the primary alcohol of
our N-Boc intermediate 58. In this way we had the opportunity to gain multiple
agents 59 - 61 from a common intermediate (Figure 2.8b).

a.

b.

NH

NBoc
H
[18F]50

59 n = 1
60 n = 2
61 n = 3

common
intermediate

H

Figure 2.8: a) [18F]ProF-NQP; b) Alkylation strategy to afford fluoroalkyl ethers.

Thus far, these routes have proven quite unsuccessful.

The Boc

protected fluoromethyl ether (n = 1, 62) was readily formed in a reaction of 58
with FCH 2 CI in DMF with NaH as the base. However, the ether side chain did
not survive the Boc deprotection step under a number of different conditions
(Figure 2.9).

4 M H2S 04

NBoc

NBoc
H
62

NH

H
58

Phenol/

H
55

TMS-CI

Figure 2.9: Attempted Boc deprotection conditions for the formation of fluoromethyl target 59.
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The conditions included; 4 M H2S 0 4 in THF at 50 °C and 0 °C, SnCI4 in
EtOAc 85 and TMS-CI/Phenol 86. Under all of these conditions, the fluoromethyl
ether cleaved in preference to removal of the Boc group to give intermediate 58
and/or amino alcohol 55.

With these results, we abandoned our efforts at

generating fluoromethyl ether 59.

Attempts to alkylate the N-trityl protected

alcohol 56 with bromofluoroethane (n =2) under DMF/NaH and THF/NaH
conditions failed for unknown reasons, resulting with the generation of multiple
side products as observed by TLC. Since these reactions were attempted on a
small scale ( < 1 0 mg), characterizations of the reaction products were not
attempted. Efforts to alkylate Boc alcohol 58 with bromofluoroethane to generate
compound 60 are currently underway at LBNL with our collaborator Dr. Andy
Gibbs.

The reaction of 58 with bromofluoropropane in DMF with NaH failed to

produce the Boc protected fluoropropyl ether (structure not shown), and only
recovered starting material was obtained. Although it was never investigated in
detail, it is suspected that lack of conversion to the propyl ether resulted from the
alkoxide acting as a base rather than a nucleophile.
Since these alkylation attempts were not efficacious, a new synthetic
strategy was devised which would afford the fluoropropyl target,
fluoropropoxymethyl)-6-nitroquipazine (MeProF-NQP, 61).

2’-(3-

Key to this new

approach was the use of allyl bromide in the alkylation step which reduced the
possibility of elimination reactions competing with substitution. Importantly, this
synthesis generated Boc-Tosylate 65 that later served as the precursor for
radiofluorination and the generation of [18F]MeProF-NQP [18F]61 (Scheme 2.6).
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Alkylation of Boc alcohol 58 with allyl bromide provided allyl ether 63 in good to
almost quantitative yields following chromatography.

NBoc
73 - 97%

63

H

68 - 78 %

1. THF, TBAF

CH2CI2, Pyridine
Tosyl-CI
75 - 80%

64

H

2. cold H2S04

NBoc
65

H

70%

NH
61

H

Scheme 2.6: Synthesis of racemic MeProF-NQP.

Hydroboration of the terminal alkene with 9-borabicyclo[3.3.1]nonane (9BBN),87 followed by alkaline peroxide oxidation provided primary alcohol 64.
Conversion of 64 to tosylate 65 was accomplished with tosyl chloride and
pyridine in DCM in good yield.

Displacement of the tosylate with nucleophilic

fluoride ion was accomplished with 150 mol% of tetrabutyiammonium fluoride
(TBAF) in THF at 60 °C.88 After chromatography, the Boc protected fluoroalkyl
intermediate (structure not shown) was deprotected to provide target compound
61 in 70% yield.

Incorporation of the fluorine atom was very efficient, and no

detectible traces of alkene were observed (1H NMR) as a result of fluoride
promoted elimination which has been characterized as a common side reaction
in nucleophilic fluoride transformations.89

Side chain identity was confirmed

based on the 1H NMR spectrum of 61 which shows doublet of triplet and doublet
of pentet hydrogen signals that were split by the fluorine for the geminal and
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vicinal (relative to fluorine) hydrogens, respectively, indicating that the fluorine
atom was at the end of the propyl chain (Figure 2.10).
o 2n.

NH

Figure 2.10: 1H NMR of MeProF-NQP 61, with the fluorine-coupled hydrogen resonances
indicated. The scale is in 5 ppm.

For this new synthetic approach, our target ligand MeProF-NQP 61 was
synthesized in five steps from intermediate Boc alcohol 58.
process on average was 32%.

The yield for this

However, given optimal yields for each step, this

yield can be as high as 45%,
Other alkylation methodologies were attempted to short-cut the approach
of Scheme 2.6 by synthesizing propyl alcohol 64 or tosylate 65 directly from
protected alcohol 58.

As shown in Scheme 2.7, tetrahydropyranyl (THP)

protected 3-bromopropanol 66 and 1,3-propanediol di-p-tosylate 67 were used as
alkylating agents in these reactions. Unfortunately, these attempts provided the
same poor results that were observed with bromofluoropropane (as per Figure
2.8), with no significant product formation seen. To test our hypothesis that we
were seeing a lack of substitution due to competing alkoxide elimination
40
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reactions, control reactions were performed with the more nucleophilic alkoxide,
methoxide ion.

1. NaH, DMF

C X

66

X

NBoc

V o ^ B r

:

2. cat. H+ MeOH

H

! CH2 CI2, Pyridine
♦
Tosyl-CI

NBoc
NaH, DMF
TsO-(CH2)3 -OTs
67

NBoc
65

H

Scheme 2.7: Attempted 'short-cut' alkylations to obtain intermediates in the synthesis of MeProFNQP.

The electrophiles 66 and 67 were added to NaOCH3 in DMF in an
identical manner to the alkylation strategies employed for 58 (as per Scheme 2.7)
and the crude reaction mixtures were analyzed by 1H NMR (Scheme 2.8).

Br NaOCH

68

66

major products

69
not observed

TsO-(CH2)3 -OTs
NaOCH3

70

71

Scheme 2.8: Control reactions to evaluate the ability of methoxide ion to evoke SN2 substitution
on our 'short-cut' electrophiles.

In both cases, the predominate product formed was the alkene (68 or 70)
and little substitution product (69 or 71) was observed, as evidenced by a lack of
a strong singlet at 3.0 - 3.5 ppm in the 1H NMR spectra of the crude reaction
mixtures. Based on these results, our original synthetic plan (Scheme 2.6) was
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maintained to produce our target, MeProF-NQP 61. Additionally, intermediate
tosylate 65 proved to be an excellent radiochemical precursor for the
radiofluorination reactions performed at LBNL.

The successes in forming

[18F]MeProF as well as its preliminary in vivo performance in rat will be detailed in
Section 2.7 and Chapter 5, respectively.

2.4

Synthesis of 2’-(2-Methoxyethyl)-6-nitroquipazine: EtOMe-NQP
The synthesis of the methoxyethyl side-chain analog of 6-nitroquipazine

was desired as an alternative route to additional PET imaging agents. However,
ethyl analog 78 was also desired as a part of a larger structure activity
relationship (SAR) study to explore the size of the Ar2 SERT binding region (as
per Figure 1.11). The Ar2 region is presumed to accommodate our piperazine
side chains (Figure 2.11).74

35

78

48

Figure 2.11: Methyl, ethyl and propyl side chain quipazines to study the Ar2 region SAR.

Since the Ar2 region of the SERT pharmacophore is represented by
aromatic ring groups in a majority of commercial and non-commercial ligands (as
per discussions in Chapter 1), we had hoped to better understand the limits of
the Ar2 binding region as our alkyl side chains extend beyond the volume
occupied by the more common, aromatic side chains. Additionally, we sought to
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better understand the role of the side chain oxygen heteroatom for modulating
the binding affinity of our ligands at SERT. The ethyl side chain compound 78
would place the oxygen one atom further away from the piperazine headgroup
relative to 35 and may provide us with insight into the subtle SERT binding
characteristics of this ligand region.
The synthesis of 78 was modeled on the chemistry utilized to synthesize
lead compound 35, with only minimal changes made to the previous procedure
(Scheme 2.9).67
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Scheme 2.9: Synthesis of EtOMe-NQP that w as modeled after W alker’s67 synthesis of
M O M -N Q P 3 5 (Figure 1.12).

An

intermediate

in

the

synthesis

of

35,

1,4-dibenzyl-2-

hydroxymethylpiperazine 30,90 was the chosen starting material for this
sequence, and the addition of a carbon to the side chain was accomplished
through an oxidation-homologation sequence. Compound 30 was subjected to
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Swern oxidation conditions, according to Kusche,74 to generate the intermediate
aldehyde (not shown). Following the workup and evaporation of the extraction
solvent, the crude aldehyde material was pumped under high vacuum for ~10
minutes then immediately used in a Wittig reaction with 200 mol% of ylide to give
alkene 72 in a 76% combined yield.

The alkene 72 underwent hydroboration

with 9-BBN, and oxidation with alkaline hydrogen peroxide afforded primary
alcohol 73 in excellent yield.

From here forward, the synthesis parallels the

methods used by Walker to form lead agent 35.67 The alkylation of alcohol 73 to
provide methyl ether 74 was performed with DMF as a solvent rather than THF
as had been utilized previously for the synthesis of 35.

The more polar DMF

solvent greatly increased the reaction rate (1 h vs. 16 h) and simplified the work
up. DMF could easily be removed by flooding with two volumes each of water
and saturated NaHC 0 3 , then and extracting the product with ether.

Following

chromatography, free base form 74 was dissolved in ether and the solution
saturated with HCI(g) to produce dihydrochloride 74.
The benzyl groups were removed by catalytic hydrogenolysis using 5%
Pd/C in MeOH, with balloon pressure of hydrogen to afford 75. The trityl group
was selectively introduced to the 4-position of the piperazine to provide 76 by the
reaction of trityl chloride in DCM with Et3 N.68 In general, the crude material from
the tritylation reactions was usually of sufficient purity for the subsequent
quinoline

coupling

step.

However,

should

these

intermediates

require

purification, the stationary phase must be something other than silica gel, or
deprotection of the trityl group will result. Our lab has discovered that using basic
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alumina as a stationary phase, with mixtures of chloroform and ethyl acetate as
eluent is a suitable replacement, and provides efficient separations of N-trityl
protected piperazines.
The coupling of compound 76 to 2-chloroquinoline was performed
according to the method of Gilman, who in the 1940’s, described an efficient
coupling of simple lithium di-alkylamides to 2-chloroquinoline.69
discussion of this reaction follows (Section 2.5).

A detailed

Briefly, a solution of 2-

chloroquinoline (100 mol%) in ether was added to an etheral solution of 150
mol% each of piperazine 76 and n-butyllithium at 0 °C. Following the work-up,
chromatography, and removal of the trityl protecting group, compound 77 was
isolated in 92 % yield.

Nitration of this material provided the target quipazine

EtOMe-NQP 78 in excellent yield. The overall synthesis of 78 was accomplished
in eight steps with an overall yield of 38%.
The protocol used for the removal of the trityl group to form 77 was
significantly improved relative to earlier work in our laboratory.67 The previous
procedure utilized 6 M HCI in ethanol, followed by a base quench and extraction
to give the crude product that contained trityl left-overs and required column
chromatography for purification.
around 80%.

This method worked well, providing yields

However, the polarity of the deprotected secondary amine made

normal phase purification of desired product 77 difficult. Very polar MeOH:DCM
solvent mixtures were required to elute the product and excessive tailing of
material 77 was observed. The improved procedure used 6 M HCI (6 ml_) added
to a solution of trityl protected quipazine (structure not shown) in a minimal
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amount of acetone ( 3 - 4 mL). The mixture was swirled or stirred for only a few
minutes, then diluted with 20 - 30 mL of 1 M HCI. Washing the acidic, aqueous
mixture with DCM removed all traces of the trityl side products and upon
returning the aqueous layer to basic pH with 4 N NaOH and saturated NaHCC>3 ,
the pure, deprotected quipazine 77 could be extracted with DCM.
With the synthesis of our ethyl homolog 78 complete, we turned our
attention again to the preparation of potential radiolabelling precursors that might
afford us new fluorine-18 or carbon-11 PET agents.

Compound 78 was

converted to the Boc-protected alcohol 79 using the same dealkylation strategy
developed for key intermediate 58 and the demethylation reaction with BBr3
provided an efficient conversion of ether 78 to the primary alcohol (Scheme
2 . 10).

1. BBr3, DCM
-78 °C; NaHCO;

H O ' ^ W NBOC
63%

79

BocO ' ^ 4 - - NB“

f MeOH, K2 CQ3i 60 °C |

80

Scheme 2.10: Synthesis of N-Boc protected ethyl alcohol.

However, unlike the formation of methyl alcohol 58, the N-Boc protection
of the crude ethyl alcohol (structure not shown) was not regioselective for the
nitrogen and, in addition to desired target 79, a di-Boc protected product 80 was

also formed. This reactivity is also observed for longer alkyl chains (3 carbons
and more).74 Presumably the ethyl side chain provides reduced steric influences
that hinder attack for the methyl alcohol side chain and limit the formation of a di46
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Boc derivative.

Both Boc protected compounds (79 and 80) were collected

together following chromatography and treated with excess K2 C O 3 in MeOH at
60 °C. These conditions resulted in the selective deprotection of the carbonate
after ~3 h and provided 79 in 63% yield.
The alkylation of 79 to generate parent methyl ether 78 using the non
radioactive (cold) methods described in Scheme 2.5 has not yet been attempted.
Furthermore, no radiochemical studies have been planned with this material to
generate a carbon-11 agent. Interestingly, two separate experiments to convert
the alcohol into a tosylate-leaving group for fluorination attempts have failed,
using the same conditions that readily formed tosylate 65. No product was ever
identified and the starting material was not recovered in any significant quantity.
This curious reactivity is still under investigation within our laboratory, and
opportunities for undesired intramolecular reactivities are being considered.

2.5

Gilman Quinoline Coupling Mechanistic Considerations
Earlier work in our laboratory67 has demonstrated that the Gilman coupling

reaction69 is highly sensitive to the ratios of reactants.

Deviations from the

reported ratios (150 mol% each of amine and n-BuLi to 100 mol% 2chloroquinoline 81) significantly reduced the yield of coupled product.

A

mechanism was suggested that sought to explain this sensitivity, that also
incorporated the formation of a reactive, aryne intermediate specie (Figure

2.12)67
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Figure 2.12: The elimination-addition Gilman coupling mechanism proposed by Walker,67
demonstrated with a general N-trityl protected piperazine.

The proposed mechanism begins with the removal of the 3-position
hydrogen of 81 by lithium amide 82 to eliminate the chlorine atom and form aryne
intermediate 83. Intermediate 83 then undergoes protonation from amine 84 to
form charged intermediates 82 and 85 that combine to form the coupled product

86. Although the mechanism seems plausible, there is nothing to suggest the
need for an extra 50 mol% of lithium amide 82 to afford efficient conversion to 86
(as suggested by the strict adherence to reagent ratios).

Additionally, it is

believed that nucleophilic attack on arynes (like 83) precedes the protonation
step in elimination-addition type mechanisms.91
An alternate mechanistic explanation (Figure 2.13) addresses these
concerns by suggesting a need for excess amide 82 to act as a proton transfer
agent in the reaction.

Furthermore, the mechanism also provides for a

nucleophilic attack on aryne 83 by am ide 82.
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Extra
50 mol%

Proton Transfer
, Process

82

F ig u re 2.13: Alternate mechanistic explanation for the extra 50 mol% of lithium amide.

For this mechanism, excess amide 82 (extra 50 mol%, top-center) serves
as a proton acceptor-donor, initially generating aryne 83, then protonating (as
conjugate acid 84, step 2) the 3-position of the quinoline ring following
nucleophilic attack of amide 82 at the 2-position (step 1). The proposed proton
transfer process ensures that a nucleophilic specie will attack aryne 83 and also
suggests an explanation for the need of excess 82.
Although the above mechanism may provide a better explanation than
Walker’s67 for the sensitivity of the Gilman coupling to the stoichiometry of the
reactants, it does not account for the explicit regioselectivity for substitution at the
2-position of quinoline 81.

It is known that nucleophilic attacks on arynes

typically produce two or more regioisomeric products as a result of reactivity at
both ends of the triple bond.92 This was in fact how the benzyne intermediate
was discovered, when attempts at doing nucleophilic substitution reactions on
aromatic halides produced multiple regioisomeric products.93 Furthermore, it has

49

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

been shown that substituent effects can influence the preferred side of
nucleophilic attack. However, the regioselectivity is rarely shown to be high.94
Connon

and

Hagarty

have suggested that 2,3-pyridynes 87

may

experience bond polarization as the result of the electron withdrawing effect of
the ring nitrogen to generate the dipolar specie 87a (Figure 2.14).95 Provided this
opportunity, it is reasonable to suggest that a nucleophilic attack on 83 would
favor substitution at the 2-position as a result of the dipolar character of 83a
(Figure 2.14). However, the degree to which this may be favored is not clear.

87

87a

83

82

83a

Figure 2.14: Proposed dipolar character of 2,3-pyridynes as an explantion for Gilman coupling
regioselectivity for substitution at the 2-position of quinoline.

Another, recent observation from our laboratory was the conversion of 1chloroisoquinoline 88 and lithium amide 89 to coupled material 90 in excellent
yield using the same Gilman conditions as described above (Scheme 2.11).

Trit

Scheme 2.11: Another coupling, facilitated by the Gilman conditions, that is unable to proceed
under benzyne-type conditions.
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Since 88 cannot react in a benzyne-type mechanism, a different
mechanism must be operating. Simple nucleophilic aromatic substitution (SnAr)
may be the mechanism operating, and this is also a very plausible mechanism
for our Gilman coupling using quinoline 81 (Figure 2.15).

R

F ig u re 2 .15: Nucleophilic aromatic substitution (SnAr) mechanism for the Gilman coupling

reaction.

However, the SNAr mechanism still does not explain why the Gilman
coupling is highly sensitive to reactant stoichiometry.

Clearly, more detailed

experiments aimed at discovering the actual mechanistic details are required.
Benzynes are known to undergo [4 + 2] cycloadditions92, 95 and trapping
experiments with furan or other dienes could be performed to detect the
formation of aryne intermediate 83.

2.6
The Boron Tribromide Dealkylation: Reaction Complications and
Inconsistencies
The boron tribromide dealkylation reaction (Scheme 2.4 and Scheme
2.10) has led to frustration on a number of occasions because the reaction
outcome is not consistent. The conversion has been attempted with a methoxy
methyl side chain a total of eighteen times with an average yield of 48% for Boc
alcohol 58. However, across all of these synthetic attempts the range of yields
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extends from 0 - 70%. The conditions for this reaction had 500 - 600 mol% of
BBr3 added to a -7 8 °C solution of ether 35 in DCM.

The mixture was

maintained at -7 8 °C for 3 - 4 h then warmed to ambient temperature and stirred
overnight. The reaction was quenched with saturated NH4CI solution and made
basic with 4 M NaOH. The alcohol was extracted and the Boc group installed to
provide 58 (as per Scheme 2.4).

This methodology was utilized on eight

instances with an average yield of 46% (range, 34 - 58%).

Then, for still

unknown reasons, yields dropped in two attempts to 0% and 11%.

The same

trend was observed by another group member, who had similar poor results
(yields < 30%) with similar reactions on propyl side chain quipazine analogs.74
At this time the reaction quench was changed to saturated NaHC 0 3 so
that any acid generated as a result of BBr3 reacting with water would be
neutralized.
range.

Following this change, product yields increased to the mid 60%

Ultimately, the most consistent results were observed when the ether

starting materials (e.g. 35 or 48)

were purified prior to use using a Biotage

purification system with amine-based silica gel.
mixtures of

The amine silica allowed for

EtOAc:Hexanes to be used as eluent rather than the very polar

MeOH:DCM or MeOHiCHCh mixtures that had been employed previously.
When the Biotage purification method was used in combination with a NaHCC>3
quench, Boc protected product 58 was obtained in an average yield of 60% (49 70%, n = 5). The average yield for all uses of NaHCOs in the quench was 58%
(31 - 70%, n = 8), and this is marked improvement over the 38% (0 - 58%, n =
10) average yield for all NH4CI quenched reactions. It is recommended that the

52

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Biotage Purification-NaHC03 quench conditions be utilized until a more
promising set of conditions emerges.

2.7

Radiochemical synthesis of [11C]MOM-NQP and [18F]MeProF-NQP
The radiochemical syntheses of our PET ligands was accomplished at

LBNL in collaboration with scientists specializing
development.

in radiopharmaceutical

Dr. James P. O’Neil is the lead radiochemist in charge of the

Cyclotron facility and has been our key liaison for these studies. The Biomedical
Isotope Facility at LBNL houses a CTI RDS-111 cyclotron that is used to
generate the positron emitting radionuclides.
The synthesis of [11C](rac)-MOM-NQP [11C]35 followed the general
alkylation approach described earlier for the cold radiochemical synthesis of 35
(Scheme 2.5). Carbon-11 methy liodide is synthesized from [11C]C02 in a gas
phase procedure adapted from published methods.96,97 Briefly, carbon-11 CO 2
is generated through the 14N(p,a)11C nuclear reaction using a 10 MeV proton
beam. The [11C]C02 is then transferred to a flow reactor where it is reduced to
[11C]CH 4 then subjected to a thermal free-radical halogenation reaction with
gaseous iodine (I2) to generate [11C]CH 3-I that is cryogenically (-78 °C) trapped
for subsequent reactions.
The two-step alkylation sequence begins with the deprotonation of N-Boc
precursor 58 with NaH in DMF (Scheme 2.12). The mixture was cooled to - 5 °C
and gaseous [11C]CH 3-I was bubbled into the solution.

The mixture was then

heated at 100 °C for 2-3 min and cooled. The crude reaction mixture was loaded
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onto a C-18 Sep-Pak cartridge and the crude intermediate (structure not shown)
eluted with DCM. Trifluoroacetic acid (TFA) was added in a 1:9 ratio and the
solvent was concentrated at 100 °C to provide the crude product [11C]35 that was
purified by reversed phase HPLC (radioactivity detection) to afford the target
radioligand [11C]35 in 9 - 16% (n = 4) decay corrected (dc) end-of-bombardment
(EOB) yield.

NaH, DMF; [11 C]CH3 1,100 °C, 2-3 min;
NBoc

Scheme 2.12: Radiochemical synthesis of [11C](rac)-MOM-NQP.

Recent

literature

evidence55 has

demonstrated

that

the

in

vivo

equilibration point of binding of 6-NQP derived SERT PET lignds is not achieved
until 2-3 hours. Consequently, we have not pursued any in vivo studies with this
ligand since the experiments could not be performed in the useable lifetime (4 5 half-lives) of the radionuclide ([11C] ti /2 = 20.4 min).

However, radioligand

[11C]35 may be of use for examining SERT density in cerebral slice preparations
employing in vitro autoradiographic techniques.98
The synthesis of [18F]MeProF-NQP [18F]61 followed the general procedure
developed for the cold synthesis of 61 (Scheme 2.6) but with modifications
necessary for radiochemical synthesis (Scheme 2.13).
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1. [18 F]TBAF, ACN, 100 °C 10 min;
then silica cartridge
NBoc
H
65

NH

2. H2 SO4 20 °C, 10 min; NaOH
3. 0 1 8 SepPac; RP-HPLC; SepPak

H
[18F]61

Scheme 2.13: Radiochemical synthesis of [18F](rac)-MeProF-NQP.

Briefly, radioactive fluoride ion was generated by irradiating oxygen-18
enriched water (> 94%) with a 10 MeV proton beam in a silver coated target
chamber. Following irradiation, the water (containing Ag[18F]F, 175 pL) and dry
acetonitrile (ACN, 300 pL) were added to 2 pL of tetra-n-butyl-ammonium
hydroxide (TBAOH) in a siliconized vacutainer. The water was removed through
azeotropic evaporation of the water/ACN mixture at 100 °C (3 cycles) to afford
[18F]TBAF in > 90% radiochemical yield (rcy).

The [18F]TBAF was then

transferred with ACN to a reaction vial containing tosylate 65.

The vial was

sealed and heated at 100 °C for 10 min. The crude mixture was pushed through
a silica gel cartridge with ACN and evaporation of the solvent at 100 °C provided
the crude Boc-protected fluoride (structure not shown) in > 50% dc RCY. The
crude material was treated with conc. H2 SO 4 for 10 min at 20 °C to remove the
Boc group. After diluting with 0.1 N NaOH, the solution was loaded onto a C-18
Sep-Pak cartridge and rinsed with water.

The crude target radiotracer [18F]61

was eluted by flushing the cartridge with MeOH.

The methanol solution was

diluted with water (1 mL) and purified by semi-preparative HPLC (radioactivity
detection), and the product fraction was diluted with water and loaded onto a C18 Sep-Pak cartridge. The purified, [18F](rac)-MeProF [18F]61 was obtained in
17.8% dc radiochemical yield by eluting with ethanol.

The radiochemical
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synthesis takes 90 minutes to complete. Tracer [i8F]61 has undergone initial
vivo evaluations in rat and these studies will be discussed further in Chapter 5.
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CHAPTER 3
ASYMMETRIC SYNTHESES

3.1

Introduction
The enantiomers of a wide range of chemical compounds are well known

to elicit different biological responses. The enantiomers of the terpene carvone
(Figure 3.1) have very distinct fragrances and flavors and are the major
components of the essential oils from common spices and herbs.

('S>(+)-Carvone
Caraway smell

('Rj-(-)-Carvone
Spearmint smell

fSJ-Thalidomide
Teratogen

('flj-Thalidomide
Sedative

Figure 3.1: Examples of enantiomers that elicit different biological responses.

For carvone, the olfactory receptors in our bodies are able to distinguish
between the stereoisomers and the biological effect is a different ‘smell’ signal
that is transmitted to our brains." Another well-known example is Thalidomide
(Figure 3.1). The racemic mixture of this compound was utilized in the 1960’s as
a sleep-aid and anti-nausea medication for pregnant women.

Thalidomides’s

teratogenic effects at that time were unknown, and unfortunately, around 15,000
pregnancies were affected by the drugs use. The birth defects that resulted left
the children deformed and often lead to death in the first years of life. Later, it
was found that only the (S)-stereoisomer provided these teratogenic effects and
the (Rj-antipode was shown to be an effective sedative. Unfortunately, even if
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the ‘safe’ (RJ-isomer is administered, the compound is metabolically racemized in
vivo and the teratogenic qualities will still be afforded.100
The naturally occuring benzomorphan compounds that exert strong painrelieving qualities through interactions with the opioid receptors (e.g. morphine)
are all the levorotatory form. The dextrorotatory isomers (e.g. dextromethorphan)
do not show activity at the opioid receptors and often possess activities at other
CNS receptors such as NMDA.101 The differences in biological activity are a
result of optically active compounds interacting with the optically active bio
molecules.
This relationship can be explained simply, although somewhat crudely, as
shown in Figure 3.2 for a hypothetical ligand-receptor interaction involving the
enantiomers of 35.

The general receptor biding site is shown (panel a.) and

consists of amine, aromatic and side chain binding regions.

The side chain

binding region extends above the other two regions (as indicated by the
darkened lines). When (R)-Z5 is bound to the receptor, the molecule contacts
these point nicely with the methoxymethyl side chain extending up into the
appropriate side chain binding region (panel b.).

However, when (S)- 35 is

bound with the side chain in the correct ‘up-position’ it is on the wrong side of the
piperazine ring to reach into the side chain binding region (panel c.).

If the

piperazine ring is rotated 180° around the quinoline bond to move the substituent
into the correct position, it will not be extending up into the binding region (panel
d.).

Instead, it will be positioned significantly below that region, and provide a

different binding profile relative to the (R)-isomer.
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(ftj-enantiomer
good site fit

Aromatic

Amine

HNv ^ k ^ O

Side
Chain

(Sfenantiomer
poorer site fit

rotation

F ig u re 3.2: Hypothetical ligand-receptor model to demonstrate a plausible enantiomeric
discrimination of a ligand. The general receptor binding site consists of amine, aromatic and side
chain binding regions (panel a). When (RJ-MOM-NQP binds to the receptor (panel b), ligand
contact with each receptor binding region is made. When (SJ-MOM-NQP binds (panels c and d),
ligand contact with each binding region cannot be made since the side chain is positioned far
from the binding region (panel c) or extends well below that region (panel d).

Given this hypothetical example, the enantiomeric binding differential
could result in a variety of biological outcomes.

These include: 1) The (S)-

enantiomer may show no activity at this receptor at all; 2) The molecule may
have a reduction in activity as a result of less optimal binding and 3)

The

molecule may show an inverse in activity relative to the (R)-isomer (i.e. its
antagonist-agonist properties).
The inherent chirality of bio-macromolecules enables the stereochemical
discrimination of stereoisomers, and pharmaceutical researchers are trying to
take advantage of these differences in their drug design strategies. The use of
stereochemically pure pharmaceuticals can improve the therapeutic effect of an
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active ingredient, enhancing product marketability.

Furthermore, researchers

may find that they can extend the profit-life of a molecule by patenting a pure
stereoisomer for a ‘new’ inventive use.102
Given the diverse differences that exist between enantiomers within some
biological systems, it was desirable for us to isolate and biologically characterize
each enantiomer of our final synthetic targets. Additionally, we desired to acquire
the radiolabeiling precursors so we could also evaluate the enantiomers of our
PET agents in vivo. The differences in biological activity for the enantiomers of
our 6-NQP analogs could result in the identification of a non-racemic radioligand
with increased in vivo efficacy relative to the racemate, providing a more
efficacious candidate PET tracer.
Our laboratory performed an initial SAR study with the enantiomers of 2’methyl quipazine 24.103 The synthesis of the (RJ-enantiomer (R)-24 is shown in
Figure 3.3.

Hn - ^ N
I
1
h 3C

Trityl-CI
FtQN

bX3lV

CHoCU

(R)-92

nn^

i

N

2 ’
’
2-CI-quinoline

I

H'J^NTrit

---------------- -

HgC

2. HCI
3. HN03, H2 S0 4

N

(R)-93

Figure 3.3: Synthesis of (R)-2'-methyl-6-nitroquipazine. The (Sj-isomer is similarly prepared.

The synthesis was accomplished in four steps from commercially available
(R)-

and

fSj-methylpiperazines,

according

to

the

method

of Walker.67

Unfortunately, when the enantiomers were individually evaluated for their binding
affinity at SERT, a significant difference in the affinities was not observed.103 We
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cautiously attribute the lack of difference to the relatively short methyl side chain,
which may not be large enough to evoke stereochemical differences in SERT
binding affinity (additional discussion can be found in Chapter 5).
Unfortunately, for our more complex piperazine side chains (for example,
with

MOM-NQP

35

and

MeProF-NQP

61),

commercially

available,

stereochemically pure piperazine starting materials are either too costly or
unavailable.

Thus, our initial strategy was to resolve the stereoisomers from

racemic intermediates.
Traditional attempts of resolving the stereoisomers through diastereomeric
salt formation and fractional crystallization were unsuccessful mainly because
crystals never formed.74 This methodology was attempted on the two racemic
compounds 31 and 32 in their free base forms (Figure 3.4).
(Sy 35 and 61
tartaric

/

fractjonal

mid salts V crystalization

(R)- 35 and 61

Figure 3.4: Failed resolution strategy attempted by Kusche to isolate stereochemically pure
piperazine intermediates.

Compounds 31 and 32 can be easily synthesized in quantities (gram
scale) amenable to the resolution technique (as per Figure 1.12, Walker, 2001).
Multiple attempts to form crystals from tartaric and benzoyl tartaric acid using
different solvents and solvent mixtures all resulted in the formation of oils.
Additionally, semi-preparative chiral HPLC columns were used in an attempt to
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isolate final compounds in quantities sufficient for bio-assay ( 1 - 2 mg). These
attempts also failed to generate satisfactory results.

Rather than belaboring the

resolution methods, alternate chiral synthetic approaches were investigated.
Because of their widespread use in biologically active molecules,
piperazine rings have received significant attention in medicinal chemistry
literature.
since

The modification of the nitrogen atoms is relatively straightforward,

general

amine

chemistry

is typically

employed.

However,

the

functionalization of the ring carbon atoms is more synthetically challenging. The
most common way to accomplish this is through synthesis from a-amino acids.
Recently, routes that utilize direct alkylating methods have been developed.35
There is also a considerable quantity of literature devoted to the isolation and
synthesis of non-racemic piperazine compounds. These syntheses encompass
a wide range of methods including enzymatic kinetic resolution, 104 traditional
fractional crystallization105 and a myriad of synthetic strategies. 106"110

Of the

literature we reviewed, the work of Naylor111 caught our attention because of the
ease of synthesis of alcohol (S)-9A (Figure 3.5).

(SH* 1

H

(sy35 H

Figure 3.5: Key intermediate alcohol described by Naylor as a precursor for the enantiomers of
MOM-NQP and MeProF-NQP.

The features of this intermediate that appealed to us were, 1) the
hydroxymethyl side chain that provided a direct handle for the synthesis of non
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racemic MOM-NQP 35 and MeProF-NQP 61; 2) the benzyl group was installed
as a protecting group, in the correct position for us to accomplish our Gilman
quinoline coupling reaction and 3) the chiral center seemed stable to most
chemical transformations and did not easily racemize.

Indeed, the authors

elaborated (S)-9A in five additional synthetic steps and the final product still
showed an enantiomeric excess (ee) of >99% (HPLC).

The transformations

included a Swern oxidation that introduced an aldehyde on the side chain, and
this afforded an acidic a-hydrogen on the chiral carbon. It was critical to use Nmethylmorpholine as the base, in place of the usual E^N, which resulted in
preservation of the stereochemical center.

The convenience of this method,

coupled with the apparent robustness of the chiral center, encouraged us to
abandon our efforts to achieve resolution through the more tedious crystallization
or chromatographic techniques and proceed with our asymmetric synthesis.

Note:

for all of the schemes shown in this chapter, only one stereoisomer is

indicated. However, bear in mind that these routes were usually run in parallel,
employing both enantiomers.

The results for the stereoisomer not shown were

usually consistent with the results provided for the other.

The range of yields

reported below the

observed for both

synthetic steps

are

the range

stereoisomers.
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3.2

Synthesis of the Enantiomers of MOM-NQP

Since the method described by Naylor111 suited our needs we adapted the
method directly toward our synthetic goals (Scheme 3.1).
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EDC.HCI, PFP

HCI H

CH2 CI2

95
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THF
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H O ^ k . N . Bn
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Et3 N, CH2 CI2

2. NH4 OH

> 90% (65%)
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H H
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V HCI

EDC.HCL

=

91% (91%)

C 02Me

Bn

1. MeOH
SOCI
SOCI22

V

fy

PFP=

V

F

M

(5>94

Scheme 3.1: Our synthesis of key amino alcohol (S>94 using D-serine. Naylor’s reported yields
are in parentheses.

The carboxyl group of protected, N-Boc-N-Bn glycine 95 was activated by
the conversion to the pentafluorophenolic ester with 1-[3-(dimethylamino)propyl]3-ethylcarbodiimide hydrochloride (EDC.HCI) and pentafluorophenol (PFP). The
activated ester (structure not shown) was then coupled to D-serine methyl ester
hydrochloride in CH 2CI2 (DCM) to provide dipeptide (R)-96.

Naylor and co

workers reported only modest (~65%) yields for this transformation but in our
hands the coupling provided excellent results with yields consistently in the mid
nineties. We also found that the coupling reaction could be run in reagent grade
DCM, without concern for maintaining dry conditions, with no change in chemical
yield.
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The piperazinedione (R)-97 was generated in a two-step process.

The

Boc protecting group was removed in the first step using thionyl chloride in
MeOH to form the secondary amine hydrochloride salt (not shown). The isolated
intermediate was then dissolved in methanol and treated with ammonium
hydroxide to generate the amine free-base that cyclized with the ester to form

(R)-97. Naylor’s workup involved the removal of all volatile components followed
by column chromatography with the very polar mixture of DCM:MeOH:NH4OH
(75:10:2). We found this to be tedious and problematic since the crude material
included NH4 CI that was not soluble in the organic solvent and therefore made
loading a column difficult. We found that a simple aqueous work-up (saturated
NaHC 0 3 ; extracting with 4:1 CHCh.isopropyl alcohol) following the evaporation
(in vacuo) of the methanol provided (R)-97 with the same purity and with
increased yield.

The reduction of diamide (R)-97 proceeded smoothly with

UAIH 4 in THF to give the benzyl protected aminoalcohol fSJ-94 in excellent yield.
The di-protected glycine 95 was synthesized according to literature
procedures that detailed the formation of monobenzylglycine hydrochloride
100 112 and the final product 95 83 (Scheme 3.2).

r\

Bn

I

N

HOAc
98

80%

H

99

.HCI

MeOH, HCI

H2 0:Dioxane

H2, Pd/C

NaOH, Boc20

96%

100

76%

Scheme 3.2: Synthesis of N-Boc-N-Benzyl glycine.
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Bn'

Boc
I
N

95

Briefly, dibenzyl glycine 99 was generated through the base promoted
alkylation of 98 with benzyl bromide.

Catalytic hydrogenolysis with Pd/C in

MeOH with 150 mol% of HCI provided an excellent yield of 100, that was readily
converted to product 95 with B0 C2 O in watendioxane. This sequence was easily
accomplished, and 95 was typically produced in 15-18 g batches.
With benzyl protected alcohol intermediate (S>94, it was necessary to
convert the alcohol to a methyl ether so that the Gilman coupling to the quinoline
could be accomplished. To eliminate reactivity of the amine, our initial strategy
was to protect it with a Boc group and perform our usual alkylation with DMF,
NaH and CH3-I (Scheme 3.3).
NaH, DMF 71%

.

O

|

CH2CI2

H0 \ , 4 v / N . b

BocaO

H
(R).94

q

NaH, DMrF

H0 \ . 4 v /N

CH3-I

H
93%

|

Not Observed

B ocN ^

X" ’i ^ N'Bn
H

(R)-101

(R)-102

H
<7?>103

Scheme 3.3: Attempted O-methylation sequence using N-Boc as the protecting group.

The preliminary chemistry was performed with the (R)-enantiomer and the
protection of the amine (R)-94 went smoothly, with the B0 C2O in DCM producing
(iRJ-101 in excellent yield. However, when the alkylation was attempted to form
ether (7?)-103, the crude 1H NMR did not show an -O C H 3 singlet, indicating the
alkylation failed.

The N M R also did not show a f-butyl singlet from the Boc

protecting group, indicating that this group had reacted. Our assumption was the
alkoxide reacted intramolecularly with the carbamate to displace the f-butoxy
group and form the five-membered cyclic carbamate (R)-102. A control reaction,
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in the absence of CH3I, produced the same result and cyclized product (R)- 102
was isolated. Product identity was confirmed by NMR and GC/MS.
Another method needed to be identified to introduce the methyl group.
We hoped initially that a selective O-alkylation (in the presence of an amide -NH)
of diamide (S)-97 would afford ether (S)-104 that could then be reduced with
LiAlhU to provide our desired piperazine (Scheme 3.4).

Bn

rNY°
H H ^

Bn

Bn

NaH-dmf rny °
CHg-l "

0

H Y ^ ° 'C H

rNr°
0 ^ n 4 - ° H

3

ch3

fS>97

fS>104

1 : 3 5

fS>105

Scheme 3.4: Failed attempt to selectively introduce a methyl group to the alcohol.

Unfortunately, the pKa differential between the amide -NH and the alcohol
(both ~16 - 17) afforded a majority of the undesired N-alkylated product (SJ-105
in a ratio of 3.5:1 relative to the desired methyl ether fSJ-104. This determination
was made by integrating the methyl singlets in the crude 1H NMR spectrum (NCH 3 at 2.96 ppm; -OCH 3 at 3.30 ppm). Another attempt at selective O-alkylation
involved the use of Ag30 and CH3-I in acetonitrile according to the method of
Andurkar.113 This method was extremely slow (4 day reaction time), did not
produce satisfactory yields of (SJ-104 and required large amounts (> 1000 mol%)
of CH 3-I. With the poor results of these two attempts, we decided to abandon
selective alkylation in favor of alternate protecting group strategies.
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We

decided

to

try

another

protection-alkylation

sequence

from

intermediate (S>94, employing N-formamide as the protecting group (Scheme
3.5).
0
HCQ2H
HO ^X^NBn
H

fS>94

AcaO
8 7 0 /0

h^

o
N ^ ,

H° ^ k ^ NBn
H

fS>106

NaH, DMF

HaSOf

CH3-I ^ O ^ J ^ N B n

THF

HN^
/O ^ k ^ N B n
H

8 3 0 /0

(S)-107

84%

rs>ios

Scheme 3.5: Successful alkylation strategy using N-formamide as a protecting group.

Since DMF (an N-formamide) as the reaction solvent does not interfere
with O-alkylation, we figured the N-formyl protecting group would be a good
alternative to N-Boc.

Working on

a 45 mg scale, the formamide group was

introduced with acetic anhydride in formic acid according to Sheehan114 providing
an excellent yield of N-formyl alcohol (^ -1 0 6 .

The product was subsequently

alkylated under our standard conditions (DMF, NaH and CH3-I) to afford methy
ether (SJ-107 in 83% yield. Deprotection of the formyl group with H2SO 4 in THF
at 60 °C afforded the sought after amine-ether (SJ-108 that was ready for Gilman
coupling.
Given the success of this method on small scale we adapted it to our
normal quantities (> 600 mg) of aminoalcohol (SJ-94 and found that the amineether fS>108 could be generated with comparable yields. At this point it seemed
that the conversion to our targets, (R)- and (SJ-MOM-NQP 35, would be
straightforward.

The Gilman coupling was effective, giving good to excellent

yields of the coupled benzyl protected quipazine (SJ-109 (Scheme 3.6).
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H N ^

Problematic

Et 2 0 , n-BuLi;
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----------- _ - -te -

N^|

2-CI-quinoline
H

70 - 98%

(sy34

(S>109

Scheme 3.6: Formation of N-Bn-MOM-quipazine with the Gilman coupling.

However, the removal of the benzyl group, initially thought to be a trivial
step, proved to be a challenge. The initial de-benzylation attempt with fS>109
using 5% Pd/C (15% by weight) and H2 in MeOH with 300 mol% HCI went very
well.

The conversion to product was clean, although very slow, requiring an

overnight reaction time.

During the course of the reaction, an additional

equivalent of acid was added to protonate the quinoline ring, thinking that it may
be poisoning the catalyst and slowing the reaction. Additional catalyst (25% by
weight) was also added and the reaction allowed to proceed and additional 4 h.
Following work-up, (SJ-34 was isolated in 96% yield with a minimal amount of
impurities. The 1H NMR was a match to a sample prepared according to our
racemic strategy 67 validating our asymmetric synthetic methodology.
When this reaction was attempted on (R)-109 however, a very different
result was obtained.

Under virtually identical conditions and after stirring

overnight, two products were formed as observed by TLC and 1H NMR.

The

product mixture was nitrated and the compounds protected with a Boc group to
facilitate

a

more

straightforward

chromatographic

separation.

chromatography, the compounds were immediately deprotected.

Following

Interestingly,

the proportion of side product (determined by 1H NMR) was greatly reduced upon
nitration, possibly as a result of its degradation in the strong acid.
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One of the

products was our target (R)-MOM-NQP (R)-ZS.

The other product was a

compound showing only three aromatic proton signals in the 1H NMR, indicating
that quinoline ring reduction had occurred, possibly giving (R)-110 (Scheme 3.7).
Reductions of the quinoline ring are known under these conditions and reduction
usually occurs on the nitrogen containing ring.115

Pd/C, H 2
M eO H

Product
mixture

(Ry35

<7?>109

(Ry 1 1 0

Scheme 3.7: Debenzylation reaction giving side product formation from ring-reduction.

Concurrent with this study, the synthesis of (R)- and (S)- MeProF 61
(discussed later) was encountering the same benzyl group removal problems. In
this series, Rainey-Ni was used as a catalyst and provided similar poor results.
In this case, the removal would not go to completion (3 days, 40 psi of Ffe) and
side products were again forming as observed by TLC.

Based on the lack of

consistency for the debenzylation transformation, and the possibility that side
products could be formed in significant quantities, catalytic hydrogenolysis of the
benzyl groups was abandoned.
We next considered the use of 1-chloroethyl chloroformate (ACE-CI, 111)
for the debenzylation transformation.116 This reagent is well known for its ability

to dealkylate tertiary amines to provide good yields of secondary amine products.
When cyclic amines are reacted with this reagent, there also occurs a preference
towards the dealkylation of the noncyclic alkyl group. The use of this reagent for
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the removal of benzyl groups from cyclic tertiary amines

(piperazines,

piperadines) is well documented.117,118
The mechanism of the dealkylation is shown in Figure 3.6 for the
debenzylation of N-benzylmorpholine 112.

The amine is heated with 111 in

refluxing dichloroethane (DCE) to afford the dealkylated chloroethyl carbamate
intermediate 113 and benzyl chloride 114. To complete the transformation all
volatiles are removed (in vacuo) and the residue is treated with methanol and
heated at 50 - 60 °C. The methanol reacts with the chloroethyl side chain to give
intermediate 115 that decomposes to dimethylacetal 116 and N-morpholine
carboxylic acid 117 that further decomposes to CO 2 and the product morpholine

118; the later picks up the HCI generated in the reaction.

M eO H A
116

118

115

Figure 3.6: The mechanism of ACE-CI dealkylation.
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©Cl

The first attempts at effecting this transformation provided confusing
results. The reported conditions (~100 mol% ACE-CI in DCE, reflux 1 h; then
MeOH hydrolysis at 50 - 60 °C, 1 h) seemed to provide a complete conversion of
the benzyl amine to the secondary amine product based on TLC analysis
(product R f = ~0.15 vs. starting material Rf = 0.70 MeOH:DCM 1:9); where the
analysis showed no starting material and a large product spot. However, when
the crude reaction mixture was analyzed the next day by 1H NMR it appeared
there were three products present and the benzyl group still appeared to be
partially intact.
After considering this result, a follow-up TLC analysis was performed and
this distinctly showed the presence of the N-Benzyl starting material (Rf = 0.70;
MeOH:DCM 1:9).

We figured that this had just been missed on the previous

analysis and thought initially that the reaction had not gone to completion.
Consequently, our next attempts at dealkylation utilized increased amounts of
ACE-CI reagent (400 mol%) and increased reaction times (reflux 4-5 h; then
MeOH hydrolysis). Following this sequence, the material was chromatographed
immediately and product yields in the 75 - 80 % range were afforded.

Given

these improved yields with the more rigorous conditions, we attempted a larger
scale reaction for our coupled tertiary amine (SJ-109.
reaction were exactly as described immediately above.

The conditions of this
However, the crude

material was not chromatographed immediately following the work-up and was
kept under high vacuum overnight. The crude weight the next morning was very
high (150%) and a TLC showed that a significant quantity of starting material
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remained. Following chromatography, we obtained product (S)-34 and starting
material (SJ-109 in yields of 51% and 43% respectively (Scheme 3.8).

1. ACE-CI (200 mol%) DCE, A 2.5 h

^

N

/ S ,

N^^|

/° v ^ k ^ N B n
H

2. MeOH, 60 °C, 1 h
Acidic work-up

1. ACE-CI (400 mol%)
DCE,
reflux,
L
/W I- , K
7 I I U A , x5
J h
II

--------------------- 2. MeOH, 60 °C, 2 h
Basic work-up
Pumped overnight

^

N "^|
^O ^k^N H

~90%

N

N "^|

/O ^ k ^ N B n

H
(S>34 51%

H
(S>109 43%

Scheme 3.8: Refinement of the ACE-CI mediated debenzylation reaction.

Since the yields of products from immediate chromatography (75 - 80%)
varied greatly from the materials that pumped overnight (-50% ) we concluded
that something was reacting within the crude material as it sat on the pump. It
became obvious after considering the literature117, 118 and the reaction
mechanism (discussed above) that we were simply alkylating our amine with the
benzyl chloride 114 that was formed as a reaction side product (See mechanism,
Figure 3.5).

Our work-up conditions after the methanol hydrolysis, were to

evaporate the reaction solvent then dilute the residue with saturated NaHC 0 3
and DCM. The basic (pH ~9) aqueous layer was extracted with DCM to afford
the crude product.

Unfortunately, this also extracted 114 and any ACE-CI

reagent 111 that wasn’t destroyed in the workup.

When these reagents were

concentrated and allowed to sit for 16 h overnight, the alkylation reaction took
place.
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The recovered benzyl amine fSJ-109 was subjected again to the
debenzylation reaction conditions (Scheme 3.8).

This time less rigorous

conditions were used (ACE-CI 200 mol%, reflux 2.5 h), and the work-up was
changed.

Following the hydrolysis step with methanol, the crude residue was

dissolved in 1 N HCI and washed with a few portions of DCM. A check of these
washes by TLC showed that a UV active non-polar material had been removed
(probably benzyl chloride).

The aqueous phase was then made basic and

extracted with DCM to afford (S)-34 in ~90% yield. This material did not show
reactivity once it had been concentrated and allowed to stand for extended
periods of time. Furthermore, the purity of the isolated product was high enough
so that column chromatography was not required. For the last transformation, the
nitration of (S)-34 was achieved in > 90% yield in all cases to afford the final
target (S)-35.
The complete synthesis for (S)-35 is shown above and the yields below
each step represents the range obtained for both isomers (Scheme 3.9). The
asymmetric syntheses of the enantiomers of MOM-NQP were accomplished in
nine steps from inexpensive amino acid starting materials. Given the typical
yields for each of these transformations, the final compounds are routinely be
obtained in ~40% overall yield. Given optimal yields for each step, this overall
yield could go as high as 60%.
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Scheme 3.9: The complete synthesis of fSJ-MOM-NQP; the (R)- stereoisomer was similarly
prepared.

3.3

Synthesis of the Enantiomers of MeProF-NQP
The synthesis of (R)- and (S)- MeProF-NQP 61 utilized the same

asymmetric peptide 96 that was used in the synthesis of (R)- and (S)- MOM-NQP
35. However, there were two criteria that we wanted to meet so that we could
avoid synthetic complications.
synthesis of (R)-

Firstly, we wanted to avoid performing the

and (S)- 61 from 35 as was done for (rac)-61, so the BBr3

demethylation step could be avoided (see Chapter 2, Scheme 2.6). Secondly,
we understood that we could not have a fluorinated side chain present during the
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Gilman coupling step since the halogen lacked stability under the alkyllithium
coupling conditions (as per Chapter 2, Figure 2.1). Consequently, we desired to
discover a protecting group for the alcohol of diamide 97 that could withstand the
transformations (diamide reduction and Gilman69 coupling) to the coupled
quipazine and then be easily removed.

This strategy would allow us the

convenience of obtaining the alcohol side chain without the need for the
inconsistent BBr3 demethylation reaction. Furthermore, it would allow us to use
the same side chain extension chemistry that we had developed for (rac)MeProF 61 (as per Scheme 2.6).
Because of its stability to basic reaction conditions and the ease with
which it is introduced and removed 79, our first choice of a new alcohol protecting
group was the tetrahydropyranyl ether (-OTHP). Given the general lack of
nucleophilicity of amides we felt that a selective protection of the alcohol (R)-96
could be accomplished in the presence of the secondary amide. Our choice of
the THP protecting group happened to be a correct one, as demonstrated by the
facile synthesis of the benzyl protected quipazine alcohol (S)-122 shown below
(Scheme 3.10). The introduction of the THP group was accomplished according
to the method of Bernady119 and utilized excess dihydropyran (460 mol%) in
DCM with p-toluenesulfonic acid as the catalyst ( 3 - 5 mol%). The reaction was
complete after 30 min, and following chromatography, an excellent yield of (R)119 was obtained as a ~6:4 mixture of diastereomers (C-2 of the THP ring). The
reduction of (R )-M 9 went easily with UAIH4 in refluxing THF to give protected
piperazine fSJ-120 in excellent yields.
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Scheme 3.10: Facile production of benzyl protected quipazine alcohol fSJ-122 using the OTHP
group for alcohol protection.

Compound fSJ-120 underwent Gilman69 quinoline coupling to provide (S)121, however, the yields were inconsistent. The best yield (93%) was obtained
with a piperazine that had not been column purified following the UAIH4
reduction. As such, this is explained simply as a lingering anomaly. The removal
of the THP group was consistent, giving excellent yields of (S)-122. Conversion
to alcohol fS>122 was accomplished very cleanly, in high yield by stirring in
MeOH with 220 mol% of HCI overnight.
Given the ease of synthesis of alcohol (S)-122, it is worthwhile to discuss
the option of abandoning the previously described synthesis of (R)- and (S)MOM-NQP

(Scheme 3.9) in favor of adopting the new THP

protected

methodology (Figure 3.7). Simply alkylating (S) - 122 with DMF, NaH and CH 3-I
would provide M O M -N Q P intermediate fSJ-109 in an equal number of steps

(seven) from the amino acid starting materials.

For future studies, if large

quantities of the enantiomers of MOM and MeProF are required, it may be
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desirable to generate bulk quantities of (R)- and (S) - 122 so two synthetic routes
will not be required to acquire all of the targets.

OoN

N N ^ i
HCX^-v^NBn

N

N

N

(S>122

fS>35

Figure 3.7: Intermediate benzyl alcohol fSJ-122 to generate both asymmetric targets.

The conversion of the alcohol side chain of (SJ-122 to the fluorinated
propyl side chain followed the same basic methodology (as per Scheme 2.6) that
was utilized for the conversion of N-Boc alcohol 58 to (rac)-MeProF 61 (Scheme
3.11).
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Scheme 3.11: Synthesis of the fluoropropyl side chain from the key alcohol intermediate fSj-122
using two distinct fluorination stragies.

The reaction conditions were identical in all cases, with the exception of
the alkylation step ((SJ-122 -*■ (S>123) where care was taken to use s 5 mol%
excess of allyl bromide to avoid quaternization of the tertiary amine. This change
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in concentration did not effect the conversion to ether (S J -1 2 3 and excellent
yields of product were obtained.

The hydroboration-oxidation sequence went

smoothly producing alcohol (S J -1 2 4 in high yield. Interestingly, the conversion of
(S)- 1 2 4 to tosylate (S J -1 2 5 could only be achieved in modest yields of 40-52%
(yields with the Boc protecting group were consistently > 70%). This range of
tosylate yields was maintained with 100, 200, and 400 mol% of tosyl chloride.
This conversion was not investigated in detail.

However it is suggested that

future attempts utilize dimethylaminopyridine (DMAP) as a catalyst with only 100
- 150 mol% of tosyl chloride. The formation of very polar material was observed
with reactions involving 400 mol% of tosyl chloride and it may result from amine
quaternization. Fluorination of (S J -1 2 5 using 150 mol% of TBAF in THF initially
gave very poor results with yields of (S J -1 2 6 being < 50%. Later attempts, using
1500 mol% of TBAF, afforded yields > 80% and (S )-1 2 6 was easily separated
from the remaining TBAF with column chromatography. The combined yield for
the tosylation-fluorination sequence was, at best, 47 %.
An alternate fluorination method was investigated to enhance the chemical
yield of the fluorinated product (S )-1 2 6 .

Diethyl aminosulfurtrifluoride (DAST) is

well known for its ability to convert alcohols to alkyl fluorides.120 The DAST
reagent was effectively used in DCM at -78 °C to convert alcohol (S)A2A directly
to the fluoride (S )-1 2 6 in yields of ~60%. Although not a large improvement from
the two-step process, this alternative synthetic transformation does provide a
modest increase in yield and shorten synthetic time. Benzyl tosylate (S )-1 2 5 , is
not an

appropriate

radiochemical

precursor since two

lengthy chemical
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transformations would be required following the fluorination to generate the target
tracer. Consequently, it is not necessary to generate this intermediate, and the
DAST route can be routinely used.
The final conversion of the benzyl protected fluoride (SJ-126 to MeProF
product fSJ-61 follows the same ACE-CI and nitration sequence that was used
for (R)- and (S)- MOM-NQP.
provided

consistent good

chromatographed

The ACE-CI promoted debenzylation reactions

results since the

crude material was

always

immediately following the work-up so that subsequent

alkylation was avoided.

The acidic work up has not yet been utilized in this

series, however, it is recommended that it be the standard method for obtaining
the crude products from ACE-CI reactions.

The usual nitration of (SJ-127 to

provide target material (S)-61 completed the synthesis.
The complete synthetic scheme for the formation of (R)- and (S)- MeProF
61 is shown below and is completed in 11 - 12 steps from the amino acid starting
materials with the best overall yield being 32% (Scheme 3.12).
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Scheme 3.12: The complete synthesis of (SJ-MeProF-NQP; the (R)- stereoisomer was similarly
prepared.
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3.4

The Synthesis of Enantiomeric Radiolabelling Precursors
The precursors for radiochemical synthesis studies were synthesized

initially in an identical manner to the racemic targets (Scheme 3.13).

The

enantiomers of 35 were treated with boron tribromide to remove the methyl group
and the Boc group was introduced to generate the key N-Boc protected alcohol
(SJ-58. This radiochemical precursor for (R)- and (S)- [11C]35 has not yet been
utilized in any radiosyntheses based on the presumed poor in vivo properties
(e.g. long equilibration time), discussed earlier in Chapter 2 (Sandell, 2002), that
would not afford a useful carbon-11 imaging agent.
The MeProF tosylate precursor (S)-65 was again synthesized from Boc
intermediate (S)-58 in an identical manner to the racemic variant.

These

approaches are summarized again below and the radiochemical precursors are
boxed (Scheme 3.13).

(R)-or(S)-

NaH, DMF ° 2 N

1■BBr3,
CH2 CI2

Scheme 3.9
35

N

N
HO^Jx^NBoe

MOM-NQP 2 . Boc20

N

O ^J^N B oc
73 - 97%

0 - 70%

OoN
CH2 CI2, Pyridine

1. THF, 9-BBN
N

Tosyl-CI

2. H2 0 2> -OH

75 - 82%

62 - 78 %

Scheme 3.13: Synthesis of enantiomeric radiolabelling precursors (boxed).
intermediates are shown.
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Only the (S)-

Since this pathway involves the inconsistent BBr3 demethylation reaction,
an alternate synthesis was desired, particularly one that began from the key
asymmetric intermediate, N-benzyl alcohol (S)- 122. It has been shown already
how this compound can afford both cold asymmetric agents (35 and 61), and an
efficient conversion of (SJ-122 to Boc alcohol (S)- 58 would provide a GRAND
UNIFICATION of the asymmetric pathway by affording all targets, from a
common intermediate (Figure 3.8).

0?N

N

N '^ 'j

N

N

? CAN TH S BE

N
3

NXVs|
H

N

N

ACCOMPLISHED ?

N

N

H0^ T ^ ' NBoc

O ^v^NH
H

[18F]rS>61

[11 CtfS>35

Figure 3.8: Intermediate N-benzyl alcohol fS>122 as a plausible precursor for all assymetric
targets.

To achieve this transformation a relatively simple synthetic strategy hs
been developed using only the ('RJ-stereoisomer, (R)- 122 (Scheme 3.14). A key
feature of this synthesis was the need for an acid stable protecting group for the
alcohol so the nitration could be accomplished.
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3. MeOH
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N
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N ^ |

HO\..''[v^NBoc

50%
(3 steps)

H
fff>58

Scheme 3.14: Synthesis of Boc alcohol radiochemical precursor (R)-58 from the key intermediate
N-benzyl alcohol fRj-122.

When the alcohol is subjected to cold H2 SO 4 and HNO 3 a reaction occurs
(perhaps an oxidation) to form a water soluble product that does not extract into
organic solvents under basic (pH 9) conditions.

This result suggests that a

carboxylate anion may be present. The acetate group was chosen as the alcohol
protecting group since it shows a general stability to rather acidic conditions.79
The introduction of the acetate protecting group was accomplished using typical
conditions (AC2O, Pyr, cat. DMAP in DCM) to afford acetate (R) - 128 in 95% yield.
In one experiment, this material was nitrated with 300 mol% HNO 3 to afford
dinitro product (iRJ-131 that surprisingly would not debenzylate under our usual
ACE-CI reaction conditions (Scheme 3.15).

1. ACE-CI
DCE
2. MeOH
H
(R)-131

H
(fl>132

Scheme 3.15: Attempted debenzylation of the nitrobenzyl intermediate.
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The alternate approach performed the debenzylation first to afford (R)-129
in a yield of 95% (Scheme 3.14). In the work-up, care was taken to ensure that
the aqueous layer did not become to basic and cause acetate hydrolysis by using
only saturated NaHC 0 3 to bring the mixture to basic pH. The secondary amine
acetate (R )A 29 was then nitrated under our standard conditions and protected
with B 0 C2 O in the work-up to afford the crude intermediate N-Boc acetate (R)130. Following the evaporation of the extraction solvent, selective hydrolysis of
the acetate was accomplished using K2 C O 3 in methanol at room temperature to
afford the key radiolabelling precursor intermediate (R)-58 in an overall yield of
45% from N-Benzyl alcohol (R)A22.
This synthetic route has demonstrated that the conversion of (R) - 122 to
key Boc intermediate (R)-58 is a reality, and can be accomplished with moderate
yields.

The low yield of the final nitration step likely occurred because of

conditions that caused acetate deprotection and subsequent reactivity of the
alcohol to form the water-soluble product mentioned above. Less acidic nitration
conditions may be employed that will minimize this side-reactivity and
subsequent

reduction

in

chemical

yield.121

This

synthesis

of

(R)-58

demonstrates the ability of N-Benzyl alcohol (R)A22 to act as a key intermediate
for the generation of all asymmetric targets detailed in this chapter.
The pairs of enantiomers that were generated from this work all
demonstrated equal and opposite optical rotations in polarimetry experiments.
The differences in the optical rotations for a pair of enantiomers was typically less
than 5%.

More quantitative determinations of optical purity (enantiomeric
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excess, ee) need to be established, and experiments to provide these
determinations are being planned. W e hope to utilize gas chromatography with a
chiral stationary phase to quantity the enantiomeric excess of our final
compounds.

Should these chromatographic separations fail to adequately

resolve the enantiomers, the %ee determinations will be made using the NMR
method of Mosher.122
Mosher’s method reacts an enantiomerically pure acid chloride (R)-133
with an optically active molecule (for example (S)-61) to form a compound with 2
or more stereocenters 134 (Figure 3.9). The trifluoromethyl group (circled) will
be diastereotopic as a result of the (S)- and (R)- configurations at the other chiral
center. An analysis of product 134 with 19F NMR allows for the determination of
enantiomeric excess by the integration of trifluoromethyl signals.

(S>«1

134

(R)-133

ffl>only

(S)- and (R)-

Figure 3.9: Reaction of (SJ-MeProF with Mosher's reagent.
analyzed by 19F NMR to quantify enantiomeric excess.

The trifluoromethyl group can be
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CHAPTER 4
OTHER ASYMMETRIC-LIKE SYNTHESES

4.1

Introduction for the 2’-Aryl-6-Nitroquipazines
Given the success of the asymmetric synthesis for generating the

enantiomers of 35 and 61, we thought that this technology might be useful for
generating other 2’-substituted-6-nitroquipazine analogs using different amino
acids.
Of particular interest was the generation of 2’-aryl-6-nitroquipazine
analogs containing phenyl and benzyl substituents (135 and 136, Figure 4.1).
These ligands will someday serve as test agents for the hypothesis that 6-NQP
analogs containing dual aromatic ring motifs (quinoline ring and pheny or benzyl
substituent) may allosterically modulate ligand transport and binding at the
substrate (5-HT) binding site of SERT because of their prospective steroid like
qualities.

OoN

NH

NH

136

135

Figure 4.1: Our 2'-aryl target ligands: 2'-phenyl- and 2 '-benzyl-6 -nitroquipazine.

This hypothesis was developed from a collection of evidence from several
researchers, that indicates certain steroids and steroid-like molecules, as well as
commercial SSRI’s, can allosterically influence the binding characteristics and
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transport properties of ligands at the substrate (endogenous 5-HT) binding site of
SERT.

A common structural motif to these ligands (steroids excluded) is the

presence of two aromatic ring functional groups. We hypothesize that this ligand
structural feature may promote select influences on SERT function.
Plenge demonstrated that the dissociation rates of [3H]imipramine 4 and
[3H]paroxetine 9 from SERT could be modulated in a dose-dependent manner by
the addition of micromolar concentrations of non-radiolabelled paroxetine 9 or
citalopram 28 (Figure 4.2 for structures).

4 Imipramine

9 Paroxetine

28 Citalopram

Figure 4.2: Compound structures from the study of Plenge, 1985, 1991.123,124

The addition of 28 caused a decrease in the rate of dissociation from
SERT for both radioligands (increased affinity). Compound 9 caused an increase
in the dissociation rate for [3H]4 (decreased affinity) and a decrease in
dissociation for [3H]9 (increased affinity).

Since these experiments were run

under non-competitive conditions ([3H]4 was diluted ~50 fold at the time of 9 or
28 addition), the modulatory effect had to arise from a ligand-protein interaction
at a different or allosteric binding site on SERT.123,124 Recent affinity modulation
(Af-M) studies on SERT mutants have provided additional evidence that the
allosteric site is independent from the

reuptake inhibitor binding site.14
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Interestingly, the SSRI

sertraline 7

has shown Af-M

properties at the

norepinephrine transporter (NET) by decreasing the dissociation rate of the NET
selective ligand, [3H]nisoxetine 137.

The results suggest that the allosteric

binding site may be a common feature of the biogenic amine transporters (Figure

NH

ci
7 Sertraline

137 Nisoxetine

8 Fluvoxamine X = CF3
138 Clovoxamine X = CI

139 Indalpine

Figure 4.3: Compound structures from the study of Plenge, 1997.125

What was most intriguing from the work of Plenge, were the results of an
experiment that evaluated the Af-M properties of around 10 SSRI’s under the
same

assay conditions.125

The

experiments demonstrated

that SSRI’s

possessing two aromatic rings in their structure show enhanced ability to
allosterically modulate ligand affinity at the substrate binding site of SERT. The
study showed that the SSRI’s Fluvoxamine 8, Clovoxamine 138 and Indalpine
139 (Figure 4.3), that do not have two aromatic rings, were the least potent Af-M
ligands.

This subtle structural observation is key for the developm ent of our

hypothesis, that may also involve Af-M ligand confomational flexabilty.

In that,

ligands that have decreased structural rigidity seem to demonstrate diminished
Af-M activity.
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Chang demonstrated a similar Af-M phenomenon at SERT when
examining transport velocities of [3H]5-HT 1 and the binding characteristics of the
cocaine analaog [3H]CFT 140. The observations were made using the steroids
p-estradiol 141 and estriol 142 and the steroid analog tamoxifen 143 (Figure

COOCH;

140 CFT

141 p-estradiol R = H
142 estratriol
R = OH

143 Tamoxifen

Figure 4.4: Compound structures from the study of Chang, 1999.126

Similar to Plenge, Chang observed a dose-dependent decrease in [3H]1
uptake, and also observed a decrease in [3H]140 dissociation from the SERT
substrate site, in the presence of micromolar concentrations of 141. Drugs 142
and 143 also displayed the ability to inhibit [3H]1 uptake, but with decreased
potency. The similarities of the results to the work of Plenge are notable and
they may suggest a relationship between steroid qualities, dual aromatic ring
structural motifs, ligand flexibility and affinity modulation properties.
Our laboratory has

identified two flavonoids,

144

and

145,

that

demonstrate Af-M properties towards the dissociation rate of [3H]paroxetine 9
from the reuptake site on SERT.127 These flavonoid compounds also possess
dual aromatic ring motifs and are conformationally limited (Figure 4.5).
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OH
.OH

HO

OH
144 Genistein

O
145

F ig u re 4 .5 : Compound structures from the study of Weller, 2 0 0 2 .127

Furthermore, flavonoids have been shown to possess steroidal qualities128
and our experiments provide additional evidence that rigid, steroid-like molecules
demonstrate affinity modulation properties at SERT.
Other evidence that may further link steroids and SSRI’s possessing two
aromatic functional groups comes from the work of Griffin (Figure 4.6).129

6

Fluoxetine

7 Sertraline

9 Paroxetine

F ig u re 4.6: Compound structures from the study of Griffin, 1999.129

Griffin demonstrated that the SSRI’s fluoxetine 6, sertraline 7 and
paroxetine 9 (all with two aromatic rings) interact with neurosteroid enzymes
within the CNS, and affect the oxidative and reductive pathways of their
respective steroid enzymatic substrates. The results present additional evidence
that SSRI’s having two aromatic rings may posses some “steroid-like” qualities
that afford these overlapped properties with steroids and steroid analogs.
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Yet another possible correlation exists with the sexual dysfunction (SD)
that results from SSRI therapy.130 Many patients (occurrence may be as high as
80%) experience SD as a result of SSRI administration and this effect is thought
to be highly dose-dependent.131

Although the exact mechanisms of SSRI

induced SD remain less clear, correlations of SD to low levels of estradiol 141 in
females have been observed.132

Studies have demonstrated that in some

instances switching to a different SSRI medication can ameliorate these side
effects. Interestingly, two medications that have shown decreased incidence of
SD side effects both possess only a single aromatic ring; Bupropion 146133 and
Fluvoxamine 8 (Figure 4.7).134

146 Bupropion

8

Fluvoxamine

Figure 4.7: Two pharmaceutical agents with reduced incidence of sexual dysfunction side effects.

The reductions in SD for 146 have been observed in double blind studies
where direct comparisons to SSRI’s with two aromatic functional groups were
made, and a statistically significant difference was noted.135

Provided that

S S R I’s have been shown to interact with steroid enzym es, 129and that changes in

endogenous hormone levels can lead to sexual dysfunction,132 it is reasonable to
hypothesize that SSRI’s induce SD side effects though interactions with various
sites associated with the neuroendocrine system.

By switching to medications
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that have only one aromatic functional group (rather than two, like 6, 7, 9, and
28), one could eliminate the interactions with steroid receptors since the single
aromatic moiety compounds structurally less like steroids.

Hence, we suggest

that SSRI’s that have two aromatic ring moieties provide the binding affinity
modulation and promote sexual dysfunction qualities as a result of their steroid
mimic qualities.
Given the potential use of our 6-NQP analogs in SSRI therapies, we
focused to minimize these potential sexual side effects by designing ligands
devoid of the two aromatic functional group structural motif.

Towards the

generation of novel PET imaging agents and to provide a handle for radionuclide
introduction, our ligand design strategy has utilized an alkyl side chain
replacement for one of the aromatic rings (similar to fluvoxamine 8). Preliminary
biochemical studies in our lab, following the techniques of Plenge,125 have shown
that MOM-NQP 35 does not display affinity modulation properties at SERT.127
To an extent, this supports our initial hypothesis that ligands devoid of two
aromatic moieties are with minimal Af-M qualities.

To further test the dual

aromatic functional group - steroid mimic hypothesis, we sought to purposely
alter our 6-NQP analogs by introducing the dual aromatic ring structural motif
through the synthesis of quipazine analogs Phen-NQP 135 and Ben-NQP 136
(Figure 4.8).
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o 2n

o 2n

o 2n

NH
H
35 MOM-NQP

135 Phen-NQP

136 Ben-NQP

Figure 4.8: Refined lead agent MOM-NQP, and new dual aromatic ring ligands Phen-NQP and
Ben-NQP.

With ligands 135 and 136, we would now be able to test our hypothesis
that 6-NQP analogs containing dual aromatic functional groups may allosterically
modulate ligand transport and binding at SERT because of their steroid qualities.
Doing so, would allow us to compare, within the same chemical family, changes
in the affinity modulation properties as a result of the introduction of a second
aromatic group.

The ligands could be further tested at steroid receptors to truly

evaluate their steroid qualities. With this goal in mind we began our syntheses of
the 2’-aryl-6-nitroqupazines 135 and 136.

4.2

Synthesis of 2’-Aryl-6-nitroquipazines
The first attempts at generating a 2’-aryl agent focused on the synthesis of

a 2-phenyl substituted piperazine.

There are several literature accounts of

piperazine syntheses related to our target and many of them begin from ethyl
bromophenyl acetate 147 or a similar alpha bromo ester.136,137 Roderick utilized

147 in a reaction with ethylene diamine to generate 2-phenyl piperazineone 148
and we hoped to utilize a similar procedure, with N,N-dibenzylethylene diamine
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(DBEDA) as the nucleophile, in an analogous manner to Rondu’s method for the
generation of piperazine ester 150 (Figure 4.9 ) . 68

Br
OEt

H N "^

(H2NCH2)2

NH

147
Br

Roderick, 1966136

148
(BnNHCH2) 2
Rondu, 199768

Et0 2 C 'x^ / B r

toluene, Et3l
Et3N

Et02u

149

150

(BnNHCH2) 2

Our design

147

151

(BnNHCH2) 2
Naylor, 1993111

O
152

153

Figure 4.9: Various strategies for piperazine synthesis and our design for obtaining a phenyl
piperazine.

Our first attempts to generate 151 from bromo ester 147138 and DBEDA
utilized conditions analogous to those of Rondu, with —1:1 ratio of 147 and
DBEDA with 110 mol% EtaN in toluene at 80 °C. A TLC (EtOAc:Hexanes, 2:3)
showed a non-polar (Rf = 0.63) ninhydrin active and UV active spot that
appeared to be the desired target.

However, following chromatography, a 1H

NMR spectrum clearly showed that this material was not desired product 151.
However, while sitting for two days, the chromatography column had leaked and
an oil had been deposited on the counter top. This material was analyzed by
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TLC (EtOAc:Hexanes, 2:3) and was considerably more polar (Rf = 0.29), showed
minimal UV activity and was only very slightly active to ninhydrin staining (faint
pink).

This material however, was very clearly product 151 by 1H NMR.

The

column fractions were analyzed again and a 58% yield of 151 was obtained. We
were pleased with this result but given the side products that were generated via
this route, we felt that alternate synthetic conditions could be found to increase
the product yield.
Naylor had cyclized diethyl bromomalonate 152 with 200 mol% DBEDA in
refluxing acetonitrile and obtained good yields of piperazinone 153 (Figure
4.9 ) . 111

Attempting this strategy with bromo ester 147 resulted in a good

conversion to product 151 with a yield of 77%.

Satisfied with this result we

proceeded further with our synthesis (Scheme 4.1).

M eO H, Pd/C,

(BnNHCH2)2

1. Et2 0 , n-BuLi,
2-CI-quinoline
Trityl chloride

153

154

155

Scheme 4.1: Initial synthesis of 2'-phenylquipiazine.

The cyclized material 151 was reduced to piperazine 152 with LiAIFU in
THF and removal of the benzyl groups by catalytic hydrogenolysis provided 153
in excellent yields. The less hindered amine was protected with a trityl group and
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protected

piperazine

154

was

coupled

to

2-chloroquinoline.

Following

deprotection, 2’-phenylquipazine 155 was obtained in 90% yield.
Unfortunately, we naively thought that a regioselective nitration of the
quinoline ring might be possible since it was activated by the piperazine nitrogen.
However, this was not the case.
dinitrated products was formed.

Using 400 mol% of HNO3, a mixture of

Reducing the HNO3 to 100 mol% provided a

mixture of unnitrated starting material 155, dinitrated mixture 156 and what
appeared to be desired product 135 (Scheme 4.2).

OoN
N

N '^ 'j
155

NH

NH

155

NH

156

135

S c h e m e 4.2: Nitration attem pt with 100 mol% o f nitric acid form ing a com plex product
mixture.

Attempts

to

isolate

135

through

various

protection-purification-

deprotection cycles with N-Boc and N-formyl protecting groups all failed to
generate a pure sample of 135 so an alternate synthetic route was pursued.
The obvious solution was to avoid the nitration step altogether, by
coupling protected piperazine 154 to an already nitrated quinoline ring.

A

literature search demonstrated that the strategy could be accomplished, in that
researchers working with quipazines had already established the utility of
chloro-6 -nitroquinoline 159 for these purposes (as per Figure 4.10 ) . 139
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2-

The

nitroquinoline can could be synthesized easily from commercially available
hydrocarbostyril 157 in two steps (Scheme 4.3).

DD Q , PO CI 3
N
H

O

°2 N

Cl

H2 S 0 4
H
98%

158

159

Scheme 4.3: Synthesis of 2-chloro-6-nitroquinoline.

Nitration of 157 provided a mixture of

6-

and

8 -nitrostyrils.

The

6 -nitro

regioisomer 158 could easily be isolated through recrystallization from EtOAc or
rinsing the crude solids with cold EtOAc.

Chloro nitroquinoline 159 was

generated through a one-pot, chlorination-oxidation reaction of amide 158 with
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and POCI3 .
With nitrated quinoline 159 in hand, Gilman coupling reactions (similar to
those described previously) with trityl protected methylpiperazine 89 were
attempted and these all proved unsuccessful (Scheme 4.4).

Et 2 0 , n-BuLi;

no product observed
159, Et20

TH F , n-BuLi;

no product observed

159, T H F
159

89
Et2 0 , n-BuLi;

159, D M F
160

Scheme 4.4: Gilman coupling attempts with 2-chloro-6-nitroquinoline.
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Quinoline 159 was exceptionally insoluble in ether, relative to the 2chloroquinoline, and the usual Gilman conditions did not lead to product
formation. The more polar etheral solvent, THF was utilized and this resulted in
similar poor results. Using DMF as the solvent for 159, provided a small amount
of a product-like (yellow colored) material by TLC. However, after isolation, the
material was shown to be 2 -dimethylamino-6 -nitroquinoline 160, that was formed
upon displacement of the dimethylamide ion from the DMF solvent.
Although discouraged by these results, we were encouraged by literature
accounts detailing piperazine couplings to 159, and related quinolines, using
excess amine in DMF at elevated temperatures (as shown in Figure 4.10).54,72,73,
139

We proceeded to study the thermal coupling reaction with benzyl and phenyl

piperazines, using three different nitrogen protecting groups; N-trityl, N-formyl
and N-benzyl. The protected piperazines were coupled to 159 under a variety of
conditions (solvent, temperature, concentrations, ratios) and the discussion of
these coupling attempts follows below. First, we’ll discuss the application of the
asymmetric synthesis to acquire our aryl piperazines and then the synthetic
transformations necessary for the introduction of our protecting groups
The peptide coupling was performed according to the method of Naylor, 111
using phenylglycine or phenylalanine methyl ester hydrochlorides 161 and 165,
respectively.

The starting materials were synthesized from the commercially

available amino acids using SOCI2 in MeOH .140 Both couplings went smoothly,
providing excellent yields of dipeptides 162 and 166 that were routinely cyclized
to the piperazindiones 163 and 167 (Scheme 4.5).
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Boc

i

Boc

I

Bn
0

EDC.HCI, PFP

X

OH

CH2 CI2

95

Et3 N, CH2 CI2

Bn'N>

C 02Me

C 02Me

O ^N^Ar

hq r
H2NX^Ar
H

Bn

1. MeOH
SOCI2

N ^O
X

2. NH„OH

O

T
fjX * '

H H

161 Ar = Ph

96% 162 Ar = Ph

90% 163 Ar = Ph

96% 166 Ar = Bn

93% 167 Ar = Bn

165 Ar= Bn
LiAIH,

OH

HN^

THF

Ar

" V ' hci

R
F.

EDC.HCL =

F

■ S./-' PFP=f

^v^,N B n

H
74% 164 Ar = Ph
77% 168 Ar = Bn

Scheme 4.5: Synthesis of the N-benzyl aryl piperazines using the 'assymetric' methodology
described in Chapter 3.

The reduction of the diamides with LiAlhU in THF provided our N-benzyl
protected aryl piperazines 164 and 168 in good yields. The synthesis of these
piperazines, again, demonstrated the ease to which the non-racemic compounds
could be generated from the commercially available D or L amino acid starting
materials.
The N-formyl protected piperazines 170 and 171 were selectively formed
from dihydrochlorides 153 and 169 using methyl formate in DCM or DME with
Et3 N as a base (Scheme 4.6 ) . 141
CH2CI2, Et3N

HN^
Ar^ ^ N B n
H
164 Ar= Ph
168 Ar= Bn

MeOH, Pd/C,

HN^,

HCI, H2

A r X - NH
H

Methyl formate

HN^
a,

X -

H

no ho

62% 170 Ar= Ph

.2HCI

DME, Et3N

99% 153 Ar = Ph

Methyl formate

94% 169 Ar = Bn

HN' ''j

A rX " " 0
76% 171 Ar = Bn

Scheme 4.6: Synthesis of N-formyl protected aryl piperazines.
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Since these reactions were run under heterogenous conditions, it was
important at the outset that the hydrochlorides be fine powders to ensure
adequate mixing.

The piperazine hydrochlorides 1 5 3 and 1 6 9 were easily

formed from 1 6 4 and 1 6 8 using standard hydrogenolysis conditions. The phenyl
dihydrochloride 1 5 3 was also generated from dibenzyl piperazine 1 5 2 under the
same catalytic conditions, according to Scheme 4.1 above.
The synthesis of the trityl protected phenylpiperazine 1 5 4 was described
above (Scheme 4.1).

The benzyl analog 1 7 2 was synthesized in an identical

manner from 1 7 1 in excellent yield (Scheme 4.7).

CH2CI2, Et3 N;
Trityl chloride
H .2HCI
171

H
172

98%

Scheme 4.7: Synthesis of N-benzyi protected benzyl piperazine.

Our thermal coupling studies were adapted from those of Lee 139 who
utilized 500 mol% of N-formyl piperazine 1 7 3 with 1 5 9 in DMF to generate

6-

nitroquipazine 2 2 in 95% yield following deprotection (Figure 4.10).

HN^
+
159 100 mol%

^

ny °
H
173 500 mol%

95%

22

Figure 4.10: Lee's reported thermal coupling to form 6 -nitroquipazine.

However, we decided to use a maximum of 200 mol% of amine since our
piperazine fragments were synthetically valuable to us, in contrast to the
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inexpensive and commercially available 1 7 3 . Our thermal synthesis trials (Table
4.1) began with the N-trityl protected phenyl and benzyl piperazines ( 1 5 4 and
172,

respectively, Entry 1 and 2).

These fragments were reacted with 1 5 9 in

DMF at 110 °C and we were pleased that the coupling reaction occured as
observed

by the formation of a non-polar spot by TLC

( R f = >0.55,

EtOAc:Hexanes, 2:3) that had the distinctive yellow nitroquipazine color.

The

new spots were distinct from the 2-dimethyl-aminoquinoline 1 6 0 ( R f = 0.29,
EtOAc:Hexanes, 2:3) observed with the Gilman coupling attempts in DMF. Thus,
we were confident that the desired transformation was occuring. However, when
the products were isolated and the trityl groups removed, very poor yields of the
products (1 3 5 and 1 3 6 ) were obtained (< 20%) in both cases.
Interestingly, there was also a very polar (R f = 0.0, EtOAc:Hexanes, 2:3;
Rf

= ~0.4, MeOH:CH 2Cl2 , 1:9) material observed by TLC that had the same

distinctive yellow color as the product.

We suspected that the material was

coupled product that had deprotected under the conditions of the coupling
reaction and we investigated this further for the phenyl case (Entry 1).

After

flushing the material from a column we attempted to isolate it from the rest of the
polar side products by treating the mixture with excess B0 C2 O in DCM.
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T a b le 4.1: Summary of the thermal coupling experiments. For the amine substrate, A r denotes
the side chain aromatic functionality and P G denotes the nitrogen protecting group used for that

entry. Mol% indicates amount of amine substrate relative to quinoline 159 (100 mol%). For trityl
and formyl protecting groups, standard acidic deprotection conditions were used as described
earlier in Chapters 2 and 3.
Solvent, Heat
N

Cl

X

N'P f;

I-,
Deprotection
(CHO, Trit)

159

A m in e
Ar

E n try

#

1

154

2

° 2N
i
J,
A r " ^ N'H/Bn

C o n d itio n s
S o lve n t T e m p

O u tc o m e
Tim e(h) P roduct Y ie ld

PG

Mol°/o

Ph

trityl

200

DMF

110 °C

20

135

15%

172

Bn

trityl

200

DMF

110 °C

6

136

18%

3

170

Ph

formyl

200

DMF

130 °C

20

135

54%

4

171

Bn

formyl

200

DMF

120 °C

44

136

46%

5

168

Bn

Bn

200

DMF

155 °C

24

175

37% a

6

168

Bn

Bn

200

Cl-Ben

155 °C

44

175

43%

7

164

Ph

Bn

200

Cl-Ben

130 °C

40

174

29% a

8

171

Bn

formyl

200

Cl-Ben

135 °C

39

136

<25% b

9

168

Bn

Bn

200

DMSO

120 °C

20

175

74%

10

171

Bn

formyl

200

DMSO

120 °C

44

136

45%

11

164

Ph

Bn

200

DMSO

120 °C

24

174

76%

12

164

Ph

Bn

200

DMSO

80 °C

44

174

63%

13

168

Bn

Bn

100
200

DMSO

120 °C

20

175

46%

100
200

DMSO
(.35 M)

120 °C

29

174

59%

100
200

DMSO
(.91 M)

115 °C

40

174

53%

w / Hunig's Base

14

Ph

164

Bn

w / 2,4,6-collidine

15

Ph

164

Bn

w / 2,4,6-collidine

N
135

^

N ^ I
^ |^ N H
H

174

\

136/ —\ Ht X ' N H
\ —/
0

i

XX

N ^ I

I

Hunig's Base
CH;3

2N
—

I

L

J-L<X

H3 C ^ N ^

175^ ~ / 1H / ^ NBn

2,4,6-collidine

a) yield off the column in question, other material present; b) estimated, not isolated
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CH3

The yellow spot showed a distinct change in polarity (Rf = 0.29,
EtOAc:Hexanes, 2:3) suggesting that the Boc protecting group had been
introduced.

After isolating the product 176 by column chromatography and

removing the protecting group we found that we had isolated the 3’-phenyl
isomer 177 of our desired product 135 (Scheme 4.8).

Polar column
CH2 CI2
fraction from
--------- •
Entry 1 (Table 4.1) Boc20

N ^ Ph
L^NB oc
176

177

Scheme 4.8: Isolation of 3'-phenyl-6-nitroquipazine.

The yield of 177 (29%) was nearly double the yield of the target 135
(15%).

The results clearly suggested that N-trityl was not a good protecting

group for this transformation. It also suggested that the 3’-isomer 177 is readily
formed.

An observation that is not surprising, since the phenyl substituent

provides steric hindrance towards the formation of the 2 ’-isomer.
Following these initial encouraging results, our attention turned to the use
of the formamide and benzyl protected piperazine coupling fragments.

The

reactions involving the N-formyl protected phenyl and benzyl piperazines (170
and 171 respectively, Entries 3 and 4) gave improved yields (54% and 46%,
respectively) of their respective products and this is attributed to the increased
stability of the N-formyl protecting group.

A side product observed in these

transformations was 2-dimethylamino-6-nitroquinoline 160.

Clearly, the DMF

solvent is again contributing to the formation of 160, by a displacement of the
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dimethylamine group under the coupling reaction conditions.

Compound 160

was also a side product from a Gilman coupling attempt using DMF as per
Scheme 4.4. It should also be noted that doubling the reaction time (Entry 4 vs.
3) did not improve the overall yield of the reaction. In all attampts involving DMF
as a solvent, the reactions never went to completion, as 159 was still clearly
visible by TLC.
Our next experiments utilized N-benzyl protected benzyl piperazine 168
with DMF and chlorobenzene (Cl-Ben) as reaction solvents (Entries 5 and

6 ).

Again, using DMF, we observed the same formation of 160 as a result of solvent
participation in the reaction.

The N-benzyl product 175 was formed with

decreased yield and the purity of 175 isolated from column purification was low
because a range of unidentifiable side products coeluted with the product. The
use of chlorobenzene as the reaction solvent inhibited the reaction, as observed
(TLC) by the slow disappearance of quinoline 159.

However, the formation of

side product 160 was eliminated and the product 175 isolated from the column
was of much higher purity than that from the DMF reaction. Interestingly, when
the benzyl protected phenyl piperazine 164 was reacted under similar conditions
in chlorobenzene (Entry 7), poor conversion to the product 174 was observed
and the product isolated from the column was contaminated with unidentifiable
side products. The use of N-formyl benzyl piperazine 171 in chlorobenzene was
remarkably slow (Entry

8 ).

After 39 h very little product formation was observed

by TLC and no attempt to isolate the product was made.
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Of the experiments that had been completed (Entries 1 - 8 ) , the best
coupling results were demonstrated with N-formyl piperazines and DMF as the
reaction solvent.

However, these conditions were hampered by the unwanted

formation of 160 as a result of solvent participation in the reaction. Additionally,
with the poor results observed in chlorobenzene, we were compelled to believe
that the polarity of DMF played an important role in assisting the transformation;
very likely through the stabilization of charged intermediates and/or transition
states. Consequently, we decided to try DMSO as a reaction solvent and entries
9 - 1 5 summarize these transformations.
For the first time, we observed the consumption of our quinoline starting
material 159 by TLC. The initial trial (Entry 9) produced an excellent 74% yield of
175 from our benzyl protected benzyl piperazine 168 at a relatively low
temperature (120 °C) in 20 h.

Although DMSO if often difficult to remove

following a reaction, the crude coupled product can easily be isolated by flooding
the reaction contents with water and extracting the aqueous mixture twice with
ether. The combined extracts are then washed with five portions of water and
two portions of brine to provide the crude material that is virtually free from
DMSO and can be chromatographed immediately. The Entry 9 transformation
was also much cleaner than the all reactions performed in DMF. The reduced
formation of unidentifiable side products resulted in simpler chromatographic
separation and increased product purity.
Another intriguing observation was the general lack of reactivity of the Nformyl protected benzyl piperazine 171 to the DMSO conditions. The reaction
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was exceptionally slow and after 2 days only a 45% conversion to product was
observed (Entry 10). This decreased reactivity could be explained by a reduction
in the nucleophilicity of the amine lone pair of electrons as a result of the electron
withdrawing influence of the formamide protecting group.

The inductive effect

resulting from the formal positive charge in resonance structures 179 and 180 is
thought to lessen the availability of the lone-pair electrons for nucleophilic attack
(Figure 4.11).

178 °

179

180

Figure 4.11: Reduction in amine nucleophilicity as a result of inductive effects from the formyl
protecting group.

Given the poor DMSO coupling result with the N-formyl piperazine 171 we
returned our attention to N-benzyl protected phenyl piperazine 164. When 164
was coupled to 158 in DMSO, coupling results were obtained that were similar to
those for 168 (Entry 11).

A clean reaction and a good conversion to product

afforded 174 in yield of 76%. This reaction was repeated at a lower temperature
(80 °C, Entry 12) and although slower (reaction time of 44 h, 159 was not
consumed), a good yield of 174 was still obtained. We felt that we had finally
established reaction conditions that provided consistent, satisfactory results with
both piperazine substrates.

What was even more pleasing was the ability to

achieve yields > 70% with only 200 mol% of our piperazine fragments.
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Pragmatically, we were still throwing away half of our amine starting
material in every coupling reaction, and the yields based on our piperazine
starting materials were only -38% .

In an attempt to reduce our amine starting

material utilization, we experimented with some non-nucleophilic amine bases as
additives to act as a sponge for the HCI that is generated in the coupling reaction
(Entries 13-15). The amine bases we chose were Hunig’s base (diisopropylethyl
amine) and 2,4,6-collidine (Table 4.1). The bases were utilized as 200 mmol%
additives in a 1:1 mixture of 159 and benzyl protected piperazine (164 or 168).
When Hunig’s base was utilized with piperazine 168 (Entry 13), the overall
conversion was low and it was evident by TLC that additional side products were
forming.

Still, the yield of product relative to the piperazine (46%) showed a

-1 0 % increase over the prior DMSO conditions that utilized 200 mol% of amine
(e.g. Entry 12 vs. Entry 13). Collidine was used twice with two different amounts
of solvent and provided a marked improvement over the Hunig’s base conditions,
giving a much cleaner conversion and yields that approached 60%. The yields
relative to the piperazine were now - 2 0 % greater than those observed with

200

%

mol% of piperazine and no additive base (e.g. Entry 12 vs. Entry 14). Increasing
the concentration of the reactants by reducing the amount of solvent didn’t seem
to have much of an effect on the overall transformation (Entry 15).
We had now established a simple and relatively efficient method of
generating

our

methodology.

2

’-aryl-6 -nitroquipazine

agents with the thermal

coupling

Furthermore, the reactions are simple to perform: place the

starting materials in an

8

ml_ vial, add stirbar and solvent, seal under argon and
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place in an oil bath at a temperature of 120 °C.
chromatography

are

straightforward

giving

The reaction workup and

products

with

high

purity.

Additionally, the best results were obtained with the N-benzyl protected
piperazines (164 and 168) that could easily be generated using the ‘asymmetric’
methodology adapted from Naylor (Scheme 4.5). We had earlier established
good benzyl deprotection conditions using ACE-CI, so the final products (135 and

136) can be obtained in good overall yields.
The complete syntheses of our 2’-aryl-6-nitroquipazine analogs are
detailed in Scheme 4.9 and are accomplished in five steps with > 40% yields
from the amino acid starting materials 161 and 165. The nitroquinoline coupling
fragment 159, is easily synthesized from a commercially available starting
material 157 in 8 6 % yield.
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Boc

i

Boc

i

Bn

>

EDC.HCI, PFP

Et3 N, CH2 CI2

CH2CI2

G0 2 Mg
HCI I

O^OH

Bn"N''i

O ^N^Ar

161 Ar = Ph
165 Ar = Bn

N^O

XX.

2. NH4OH

H H

H2N ^A r
95

C 02Me

Bn

1. MeOH
SOCI2

O'

N 'T 'A r
H H

96% 162 Ar = Ph

90% 163 Ar = Ph

96% 166 Ar = Bn

93% 167 Ar= Bn

OoN

LiAIH,

DMSO, A

HN^
A r A NBn

THF

H

U' 'N'^X |
OoN

A r 4 ~ NH

N
74% 164 Ar = Ph

H
76% 174 Ar = Ph

Cl

159

1. ACE-CL, DCE
2. MeOH,
Acidic work-up

74% 175 Ar = Bn

77% 168 Ar = Bn

COUPLING STEP OPTIMIZED IN TABLE 4.1
OoN

N' 'N ^ |

A r 4 ~ NH

EDC.HCL =

H

N HCI

S
U

N -/
c

PFP =

OH
F^A^F
T
fV >

78-91% 135 Ar = Ph
75 - 85% 136 Ar = Bn

Scheme 4.9: Complete, optimized synthesis of the 2'-aryl-6-nitroquipazine targets. The thermal
coupling step was optimized as detailed in Table 4.1.

4.3

The Alternate Assymetric-Like synthesis of 2’-EtOMe-NQP
Given the potential need for the enantiomers of the ethyl side chain analog

78, it was undertaken to see if Naylor’s synthesis111 could be applied to these
targets. The obvious choice for an amino acid building block was aspartic acid
since the R group contained a 2-carbon ester that could be reduced to the
alcohol and afford the methoxyethyl ether.
The racemic acid 181 was utilized since proof of concept was all that was
desired and the aspartate dimethyl ester hydrochloride 182 was generated with
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excess SOCb in refluxing methanol. 140

Diester 182 underwent the Naylor

peptide coupling under the reported conditions to provide dipeptide 183 in
excellent yields (Scheme 4.10).

H2N

I

C 02H

SOCI2

C 02H

MeOH

181

1. 95, EDC.HCL
PFP, CH2 CI2

H2 N ^ . C 0 2Me

Bn

I

Boc"

>

C 02Me

c r vNx^ ' ' C° 2Me
H H

93%

> 90%

182

183

Scheme 4.10: Synthesis of the racemic aspartyl dipeptide.

When considering the cyclization step though, we realized that we may
encounter a problem.

Our dipeptide 183 presented two opportunities for ring-

closing amide formation

1)

with the amino-acid ester and

2)

with the side chain

ester (Figure 4.12) to provide six and seven membered ring products 184 and
185, respectively.

Given the relative stabilities of the ring sizes, we were

concerned about the formation of isomeric product mixtures. Indeed, these ring
closures, being

6

-exo-trig and 7-exo-trig, are both ‘favored’ according to

Baldwin92 so a mixture of cyclized products was expected.
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HN

HN

HN-Bn
O-Me

-

NBn

Ht i .
G02Me

C 02Me
Boc

184

I

B n'N>

C 02Me

0 ^ N^
H

only product

I.MeOH, SOCI2

C° 2Me 2. MeOH, NH4OH
4

183

HN

,

HN-Bn
P-M e

HN

NBn

Me02C

°
185

Figure 4.12: The peptide cyclization step showing the opportunities for two isomeric products.

Interestingly, when the crude reaction product was analyzed by 1H and 13C
NMR it was clearly shown to contain a single, major isomeric product.

More

careful inspection of the 1H NMR spectra indicated the presence of another
product, but this made up < 2% of the total material. The major product was later
proven to be the desired 6-membered piperazine dione 184, once the synthesis
had been carried through to product 78. The selectivity for this single product is
curious since both ring sizes are known to be relatively stable.
With the fortunate formation of a single major cyclized product, we
proceeded with our synthesis (Scheme 4.11) and reduction of dione 184 with
LiAIH4 in THF provided the crude piperazine alcohol 186 in 97% yield. Since this
alcohol is a homolog of the alcohol 94 from the asymmetric MOM-NQP synthesis
(Scheme 3.9, Chapter 3) we used the same synthetic strategy to generate target
quipazine 78.
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OoN
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NBn

61%
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N
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F ^X F
Y

F 'V ^ F

96%

Scheme 4.11: Complete synthesis of 2'-methoxyethyl-6-nitroquipazine using dimethyl aspartate
amenable for asymmetric preparations.

The crude alcohol 186 was converted to N-formyl alcohol 187 that was
alkylated with CH 3-I to provide 188. After removal of the formyl group, 189 was
coupled to 2-chloroquinoline to provide benzyl-protected quipazine 190.

The

removal of the benzyl group with ACE-CI, followed by the acidic work-up,
provided unnitrated quipazine 77 in an excellent 97% yield. The 1H NMR spectra
of 77 was identical to the material generated via the previously described route
(Chapter 2, Scheme 2.9) confirming that 6-membered ring dione 184 had been
generated upon cyclization of peptide 183. The nitration of 77 provided target
EtOMe-NQP 78. The alternate synthesis of 78 established proof of concept for
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the future asymmetric synthesis of 78, provided that racemization does not occur
at some point.

The racemic EtOMe-NQP 78 generated via this route was

synthesized in nine steps with a 40% overall yield from the amino acid starting
materials.
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CHAPTER 5

BIOLOGICAL DATA

5.1

Serotonin Transporter Binding Affinity of Target Ligands
The initial evaluation of our new ligands is performed though a standard

radioligand displacement binding assay. The method utilizes the procedure of
Habert142 as described by Mathis143 and it is summarized below. The assay is
used to determine the binding affinty (K i) of the ligands at SERT. Lower Kj values
(more dillute concentrations) represent higher affinity ligands.

Tissue Preparation - The cerebral cortex from commercially available (PelFreeze Biologicals, Inc.) frozen male rat brains is suspended in twenty volumes
of 50 mM Tris-HCI buffer (pH 7.4 at ambient temperature) and homogenized.
The brain mixture is centrifuged and the supernatant decanted. The tissue pellet
was suspended in the same volume of Tris-HCI buffer and heated at 37 °C for 10
min before centrifuging and decanting the supernatant.

The final tissue

suspension is generated by adding 50 mM Tris-HCI buffer (~ 1 mL for every
milligram of wet tissue) containing 5 mM KCI and 120 mM NaCI to the pellet and
mixing. The brain prep suspension is used immediately in the assay.

Radioligand Displacement Binding A s s a y - To the tissue preparation suspension
(0.8 mL) is added a solution of [3H]Paroxetine ([3H]Px) in Tris-HCI buffer (0.1 mL,
2 - 3

nM, final concentration of 0.2 -

0.3 nM) followed by decreasing
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concentrations of challenge ligand (0.1 mL, 10'5 - 10'10 M; final concentrations of
10"6 — 10"11 M) to give a total assay volume of 1.0 mL. Three assay solutions
were prepared for each concentration of challenge ligand. Total binding (defined
below) was determined by adding 0.1 mL of [3H]Px solution and 0.1 mL of TrisHCI buffer (no challenge ligand) to 0.8 mL of tissue solution.

Non-specific

binding was determined by adding a solution of 6-Nitroquipazine 22 in Tris-HCI
buffer (0.1 mL, 10 pM, final concentration 1 pM) to 0.1 mL of [3H]Px solution 0.8
mL of tissue solution. The mixtures were incubated at 25 °C for 3 hours then
diluted with 5 mL of cold (4 °C) Tris-HCI buffer. These solutions were rapidly
filtered through Schleicher and Schuell #32 glass fiber filters (presoaked with
0.5% polyethyleneamine solution) using a Brandel cell harvester (protein is
collected on the filter, unbound [3H]Px is washed away). The filters were washed
twice with 5 mL of cold Tris-HCI buffer, transferred to scintillation vials and
scintillation fluid was added. The radioactivity remaining on the filters ([3H]Px still
bound to protein) was determined using a Packard 1500 Tri-Carb liquid
scintillation counter.

Data Analysis - The total specific binding of [3H]Px to SERT is defined as the
difference between total binding and nonspecific binding.

Total binding is the

total amount of [3H]Px that was bound to protein, including specific and
nonspecific interactions.

Nonspecific binding is determined using a high

concentration (1 pM) of the non-radioactive, selective SERT ligand 6-NQP 22.
Since the high concentration (4000 fold or greater) of 22 results in nearly all of
the available SERT being bound by 22, the radioactivity present after filtration
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represents the [3H]Px that was bound to other macromolecules in the assay
matrix.
The [3H]Px binding observed for test agent samples is reported as a
percentage of the total specific binding.

When this data is plotted, a binding

curve like that shown in Figure 5.1 will result.

100

o>
c

80
CO

2o

40

#

20

H
•s

-12

8

-10

4

6

log [te s t ligand] (m o la r)
Figure 5.1: Sample binding curve from a radioligand displacement binding assay. No error bars
are indicated. The dotted lines demonstrate an estimation of the IC50 value.

For

our

experiments,

each

data

point

is an

average

of three

determinations from the same assay. Since the figure above is an example, no
error bars are indicated. Using GraphPad Prism software IC50, (inhibitor
concentration that blocks 50% of [3H]Px binding) values w ere determined.

On

the above graph this value can be estimated as a concentration slightly less than
10'8 M. The inhibition binding constant (Kj) is determined from the IC50 values
using the following equation: Kj = IC50/(1 + [L]/Kd).144 Where [L] = concentration
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of [3H]Px used in the assay (0.2 - 0.3 nM) and KD = 0.15 nM (known constant142).
Final Kj values are reported as an average of at least three different assay
determinations on different days. A standard ligand, 6-NQP 22 (known Kj = 0.16
nM), was analyzed in each assay to evaluate assay performance.

Table 5.1: Comprehensive SERT binding affinity data for all racemic compounds from our lab that
have been tested. The entries above the dotted line were also shown in Table 1.3.
0 2N

R a c e m ic T a rg e ts
r2

Cm pd.

Ri

r2

K| ( p M )

R e f.

22
24

H

163 ± 53
81 ± 61

64
64

ch3

H
H

25

H

ch3

4 5 6 0 ± 2400

64

35

CH2OCH3

H

2 .4 8 ± 0 .2 8

70

55

CH2OH

H

12.7 ± 3.0

a

61

c h 2o c h 2c h 2c h 2f

H

3 .9 6 ± 0 .8 8

a

48

c h 2c h 2c h 2o c h 3

H

2 .1 2 ± 1.13

74

50

c h 2c h 2c h 2f

H

2 .4 8 ± 0 .1 9

74

191

c h 2c h 2c h 3

H

4 1 .5 ± 19.9

74

192

c h 2c h 2c h 2c h 2c h 2f

H

7 9 .6 ± 21.2

74

aPresent stu d y

A comprehensive summary of our SERT binding data for racemic targets
is presented in Table 5.1 (Data above the dashed line was also shown in Table
1.3). From our initial SAR studies, discussed in Chapter 1, we demonstrated a
56 fold decrease in SERT binding affinity with the 3’-methyl positional isomer 25
relative to the 2’-isomer 24. As a result, we maintained the alkyl substituents at
the 2’-position for all of our quipazine targets. This ligand design strategy has
proven successful, as all new racemic targets (55 and 61, present study; 48, 50,
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191, 192, Kusche, 2006) have demonstrated sub-nanomolar binding affinity at
SERT that remains improved relative to parent ligand 6-NQP 22.
An interesting trend from the SAR data suggests an oxygen heteroatom in
the side chain provides an enhancement SERT binding affinity. This trend can
be observed by comparing side chains of similar length (excluding hydrogens).
For example, MOM-NQP 35 and Prop-NQP 191 both have three atoms in the
side chain (MOM, C-O-C; Prom, C-C-C) and 35 demonstrates a 17-fold increase
in binding affinity relative to 191. A similar trend is observed with MeProF-NQP
61 (C-O-C-C-C) and PentF-NQP 192 (C-C-C-C-C) where 61 demonstrates a 20fold increase in binding affinity relative to 192.

It is plausible that the oxygen

atom enhances SERT binding affinity by acting as a hydrogen bond acceptor in
the Ar2 binding domain at SERT or as an electronegative contact for positively
charged amino acid residues or ions (salt-bridge interactions). Interestingly, the
alcohol side chain ligand 55 shows a slight decrease in SERT binding affinity
relative to the methyl ether side chain analogs (35 and 48). This decrease in
affinity may result from the OH group being a hydrogen bond donor, rather than
an acceptor (like the methyl ethers).

Additionally, moving the oxygen atom

further from the piperazine ring does not seem to alter the enhanced binding
affinity observed with oxygenated side chains, as evidenced by the low binding
affinity of propyl analog 48.
A fluorine atom might also provide a similar contact, as evidenced by a
comparison of ProF-NQP 50 and Prop-NQP 191, where a fluorine-for-hydrogen
replacement is made at the end of the side chain. The fluorinated variant 50,
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displays a 17-fold increase in potency over 191, a difference identical to that
observed between 35 and 191.
The non-racemic 6-NQP analogs that have been evaluated by our group
are shown in Table 5.2.

Table 5.2: SERT binding data for the non-racemic ligands.

N o n -R a c e m ic T a r g e ts

N '^ j

RV" l ^ NH
r2

Cm pd.

Ri

r2

K, (p M )

R e f.

(R )2 4

H

ch3

91 ± 16

103

(S )2 4

ch3

H

68 ± 21

103

(S )3 5

H

CH2OCH3

1*

a

(R ) 35

CH2OCH3

H

47*

a

aPresent s tu d y ; *P re lim in a ry value

The enantiomers of 2’-methyl-NQP 24 did not demonstrate significant
differences in SERT binding affinity, as evidenced by the overlap of their error
bars.

It is plausible the methyl side chain may be too short for a significant

change in biological activity to be observed, as a result of stereoselective
interactions at SERT. The enantiomers of the longer side chain MOM-NQP 35,
have demonstrated more pronounced differences in their biding affinities, but
reliable values have yet to be confirmed. The preliminary results indicate that an
approximate 47-fold difference in affinity exits between the isomers, with the (S)isomer (S>35 being the more potent form.

The increased binding affinity

observed for (SJ-35, relative to the racemate may result from a more optimal
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contact of the methoxymethyl side chain with the Ar2 binding region (see
pharmacophore model Chapter 1, Figure 1.11).

Likewise, the converse

argument can be made for the decreased affinity of (R)-35. Efforts to establish
more accurate Kj values for these targets are presently underway and we hope to
confirm these values through determinations at an independent laboratory.
To date, the only compound from our work that has been tested for SERT
selectivity is [3H]Prop-NQP 191.74 Since [3H]191 was not significantly displaced
by the NET and DAT selective ligands, Nisoxetine and GBR12935 respectively,
the interaction of [3H]191 with NET and DAT is presumed to be minimal.145
Although the selectivity of [3H]191 suggests that collectively our family of 2’substituted quipazines may demonstrate significant SERT selectivity, these
results can not serve as a definitive measure of SERT selectivity for all new
target ligands.
The target compounds from this study that remain to be tested for their
binding affinity (K j) at SERT are shown in Figure 1.2.

78

(fl)-61

135

(S)-61

136

Figure 5.2: New ligands from this study that remain to be tested for activity at SERT. The 2'-aryl
agents also need to be evaluated for affinity moduation properties.
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More rigorous biochemical studies with the 2’-aryl-6-nitroquipazine ligands

135 and 136 will serve to evaluate their affinity modulation properties at SERT as
per the discussions in Chapter 4.

The methods utilized for these studies will

mirror those of Plenge124 that have been adapted for experiments in our
laboratory.127

5.2

Preliminary in vivo Evaluation of Racemic PET Agent [18F]MeProFNQP

The new SERT PET radioligand [18F]MeProF [18F]61 has undergone
preliminary in vivo evaluation in rats to determine whole body organ tracer
distribution.

Within the brain, these studies were expanded to include the

quantification of radioligand presence in discrete brain regions. This study also
involved a preliminary evaluation of the in vivo metabolism of [18F]61 in blood
plasma and brain. Our primary investigator, Dr. John Gerdes, performed these
studies in collaboration with Dr’s Jim O’Neil, Scott Taylor and Jamie Eberling at
the Lawrence Berkeley National Laboratory (LBNL). The scientists and facilities
at this institution provide the necessary knowledge and resources for this study,
including

instrumentation

dedicated

to

radiochemical

experiments,

a

radiochemical synthesis lab and an on-site cyclotron for the preparation of the
fluorine-18 tracer.
For all data collected in these studies, the following general procedure
was used for the administration of tracer [18F]61 and sacrifice of the animals:
Radiotracer [18F]61 was synthesized according to the synthetic protocols detailed
122
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in Chapter 2, Section 2.7.

Male Sprague-Dawley rats were anesthetized and

received a 35 - 50 pCi tail vein injection of radioligand [18F]61 in a saline matrix.
Following a set period of time (15, 30, 60, 120 or 240 min), the animal was
sacrificed with a large dose of anesthetic followed by exsanguination. The
subsequent data collection protocols are summarized below.

Blood Metabolism - Radioligand metabolism in blood was determined at 15 and
60 minutes post injection.

Blood was collected from the sacrificed animal and

centrifuged. The supernatant blood plasma was decanted, extracted with MeOH
and the mixture centrifuged to separate the layers. The methanolic extracts were
first analyzed by UV/radioactive TLC and for both the 15 and 60 minute extracts
the major radioactive product had an Rf that matched an unlabelled, standard
sample of 61 . The methanolic extract was further analyzed by reversed phase
HPLC (UV and radioactivity detection) using a coinjection of unlabelled standard

61. The major (> 95%) radioactive fraction had a retention time identical to that
of unlabelled 61.

These results were consistent at 15 and 60 minutes and

suggest that tracer [18F]61 is relatively inert to metabolic degradation in the blood
or the metabolites are not detected by this method.

Brain Metabolism - Radioligand metabolism in the brain was determined at 60
and 240 minutes post injection.

Following sacrifice, the brain was carefully

removed, placed in buffer and homogenized.

The brain homogenate was

extracted with methanol and the mixture centrifuged to separate the layers.
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The

analysis of the brain extracts was identical to those from the blood, and again the
major (> 95%) radioactive fractions for both time points (60 and 240 minutes)
was parent radioligand [18F]61.

Whole Body Tracer Distribution - Organ tracer distribution measurements were
collected at 15, 30, 60, 120 and 240 minutes.

Following sacrifice, the organs

were carefully excised and the tissues analyzed for radioactivity (counted). The
data for each time point represent an average of three replicate measurements
from separate animals and the results are decay corrected.

The whole body

tracer distribution data is presented in Figure 5.3.

Figure 5.3: Whole body rat tracer distribution data with [18 F]MeProF. Data is reported as an
average of three measurements. The brain study (boxed) was expanded to include brain subregions (Figure 5.4)
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The distribution data demonstrate adequate brain penetration of the
radioligand. The penetration was rapid (maximal radioactivity after 15 min) and
tracer washout was observed over the experiment time course (gradual decline
in radioactivity from 30 - 240 minutes).

The gradual increase in radioactivity

observed in bone (femur) suggests that ionic fluorine-18 is being generated as a
result of some metabolic defluorination.
The tracer distribution study was extended to sub-regions of the brain to
evaluate regional brain uptake as function of relative SERT distributions.
Following animal sacrifice, the brains were carefully removed and the discrete
brain regions were meticulously dissected and the radioactivity counted.

The

data for each time point represent an average of three replicate measurements
and the results are decay corrected. The regional brain tracer distribution data is
presented in Figure 5.4.

C e re b e llu m

H yp o th a la m u s

Cort m

.

H ip p o c a m p u s

B lood

Brain Tissues and Blood

Figure 5.4: Rat tracer distribution data for discrete brain regions. Data is reported as an average
of three measurements.
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The greatest radiotracer uptake was observed in the SERT rich hypothalamus,
and the moderate density cortex, and hippocampus. Radioligand uptake in the
cerebellum, known to have low SERT densities, was reduced relative to the other
regions and washout of the tracer was observed over the experiment time
course.

The radioactivity in the cerebellum after 240 minutes was almost

equivalent to the amount in blood suggesting that minimal nonspecific binding is
observed. At 240 minutes, the target (hypothalamus, cortex, hippocampus) to
non-target (cerebellum) ratios of radiotracer accumulation were greater-than or
equal to two.

The preliminary results demonstrate that [18F]61 may provide

quantitative determination of SERT densities within moderate and low density
target regions. Furthermore, the metabolic analyses suggest that [18F]61 does
not succumb to measureable metabolic degradation, with the exception of some
in vivo defluorination as evidence by the accumulation of radioactivity in bone.
Additional studies to evaluate the performance of [18F]61 in rats and non
human primates are underway at LBNL.

Currently, a rat micro-PET study is

being planned to compare racemic [18F]61 with both (R)- and (S)- forms of the
tracer. Following this study, a non-racemic [18F]61 PET agent may be identified
that possesses superior rodent in vivo qualities over its enantiomer and the
racemate.

Non-human primate studies in macaque monkeys with racemic

[18F]61 have also begun.

These studies will be invaluable for determining if

[18F]61 possesses the necessary in vivo characteristics to advance it as PET
agent for human imaging studies.

The quantification of target to non-target

binding ratios in primates is a critical determinant for ligand advancement.

126

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Additional primate study components will involve a more rigorous treatment of
metabolite formation including the identification of metabolic products with
tandem liquid chromatography-mass spectroscopy.
At the close of these studies, we hope to have identified a non-racemic
[18F]61 lead agent that we will advance for imaging human SERT.

Follow up

studies will compare our lead agent to the current standard SERT PET agents
[11C]DASB 13 and [11C]AFM 14.

Following these studies, the efficacy of our

tracer to target the SERT shall be established.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK

This study has successfully identified [18F](rac)-MeProF-NQP [18F]61 as a
new candidate SERT PET imaging agent (Figure 6.1).

[18F]61

13

14

Figure 6.1: New SERT PET agent [18 F](rac)-MeProF-NQP and current standard ligands DASB 15
and [11C]AFM 16.

The in vivo properties, demonstrated thus far in rat, provide compelling
evidence that [18F]61 may emerge as new standard SERT agent. What remains
to be seen, is will [18F]61 meet the necessary in vivo performance requirements
in non-human primates? Will [18F]61 or one of the non-racemic variants, provide
the signal to noise ratios necessary for the reliable quantification of medium and
low density SERT regions? Importantly, will [18F]61 outperform the current
standard SERT PET agents DASB 13 and [11C]AFM 14 in comparison studies?
The answers to these questions are currently being sought in collaboration with
researchers at LBNL.
This dissertation has also demonstrated relatively simple routefs) to nonracemic 6-nitroquipazine analogs using an efficient asymmetric synthesis
methodology adapted from the method of Naylor.111 For the syntheses of (R)-
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and (S)- MOM-NQP 35 and MeProF-NQP 61, a key intermediate 122 was
identified that would provide all of the target compounds in the series (Figure

6 .2).

N

N '^ -

N

H O ^L^N B n
(S )-3 5

NH

H

H

H

(S )-1 2 2

(S)-61

N

HO' ^ \ ^ NBoc

H

H
[ 1 1 C ](S )-3 5

[18F](S)-61

(S )-5 8

Figure 6.2: Intermediate N-benzyl alcohol fS>122 as a precursor for all asymmetric targets.

Intermediate (S) - 122 provides the unradiolabelled targets ((S)-35 and (S)61) and the key radiolabelling precursor intermediate (S)- 58 that affords both
target radioligands [^CJfSj-SS and [18F](S>61.
We have also demonstrated that the method of Naylor can readily be
adapted to other amino acids starting materials.

Chapter Four of the present

study was dedicated to a discussion of these efforts as they related to the
synthesis of our 2’-aryl-6-nitroquipazine analogs 135 and 136 and an alternate
synthesis of EtOMe-NQP 78 (Figure 6.3a). Brian Kusche has adapted Naylor’s
method to perform asymmetric syntheses of 6-NQP analogs with three, four and
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five carbon side chains (48, 195 and 196), beginning with both isomers of
glutamic acid 193 (Figure 6.3b). 74
a) Present study

O
H2Nv^ C 0 2Me

HN^^
N

161 Ar = Ph
1 65 Ar = Bn

163 Ar = Ph
1 6 7 A r = Bn

135 Ar = Ph
1 3 6 A r = Bn

u
H 2 N ^ C 0 2M e

H N "N
M e 0 2C

H\

C 0 2M e

Hhr
^ / ^

NBn

NH

O

18 2

78

184

b) Kusche, 2006

H^^COaH
’H

N

HN

N

NBn

COgH

Me° 2 0 '

193

C H ,0 (C H 2)n' ^

' NH

48 n = 3
195 n = 4
196 n = 5

194

Figure 6.3: Summary new SERT agents synthesized using the methodology of Naylor, with
different amino acid starting materials.
materials, Although not indicated, the compounds from Kusche74
were synthesized in non-racemic form.

We have now successfully utilized five different amino acid starting
materials for the synthesis of novel 6-NQP analogs. The potential to discover
additional SERT ligands using this methodology is obvious and the utilization of
unnatural

or

synthetic

a-amino

acids

provide

endless

opportunity

for

diversification at the 2’-position of quipazine. The incorporation of heteroatoms
other than oxygen, particularly sulfur and nitrogen, would provide additional SAR
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data for the Ar2 biding region of SERT and also a handle for the introduction of
radionuclides.
What is most lacking from this work is a complete set of biological data.
Unfortunately, technical issues have limited the amount of SERT binding data
that has been collected. The determinations of the Kj values for all of the ligands
developed here are in progress. However, new compounds that have been
rigorously tested have demonstrated very high affinity for SERT with Kj values in
the low picomolar range (Figure 6.4).

H
55
K| = 12.7 + /- 3 .0 pM

F ig u re 6.4:

H
61
Kj = 3 .9 6 + /- 0 .8 8 pM

New SERT ligands from this study and their determined SERT binding affinity.

The selectivity of new compounds for SERT relative to the other biogenic
amine transporters, NET and DAT, still needs to be evaluated.

Despite the

promising preliminary in vivo PET data accumulated for [18F](rac)-MeProF-NQP,
it is still possible that a lack of selectivity for SERT may limit its use as an
effective SERT tracer.
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CHAPTER 7
EXPERIMENTAL

7.1

General Methods
All reagents and solvents were purchased from commercial suppliers

(Aldrich, Acros, Alfa Aesar, Fisher Scientific, VWR, Lancaster) and used without
further purification unless otherwise stated.

Anhydrous dichloromethane

(CH 2CI2 , DCM) was distilled from calcium hydride (CaH 2) or purchased from a
chemical supplier.

Anhydrous tetrahydrofuran (THF) and diethyl ether (ether,

Et20) were distilled from Na/benzophenone or purchased from a chemical
supplier. Anhydrous N,N-dimethylformamide (DMF), 1,2-dichloroethane (DCE),
1,2-dimethoxyethane (DME),

carbon tetrachloride (CCU),

dimethylsulfoxide

(DMSO), pyridine, triethylamine (TEA, EtaN), benzene and chlorobenzene (ClBen) were purchased from commercial suppliers. Dihydropyran (DHP) was
distilled prior to use.

Recrystallization of p-toluenesulfonyl chloride (tosyl

chloride, Ts-CI) was according to the method of Armarego.146 Solutions of nbutyllithium were titrated prior to use.147 Methyltriphenylphosphonium iodide was
synthesized according to the method of McCortney.148
All non-aqueous reactions were carried out in oven-dried glassware and
magnetically stirred unless otherwise stated.

Reactions requiring anhydrous

conditions were run under an atmosphere of argon. Brine, refers to a saturated
aqueous solution of non-iodized salt, available at a grocery store. Water refers to
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deionized water.

All aqueous solutions were prepared using deionized water.

For all reactions, the dried (K2CO 3 , MgS (>4 or Na2 SC>4 as indicated) organic
phases were filtered (fluted filter paper or cotton plug) prior to evaporation. All
solvent evaporations and/or extract concentrations were performed with a Buchii
rotary evaporator under reduced pressure.

Thin-layer chromatography was

performed with EM Science, Silica gel 60 F254 aluminum-backed plates.
Visualization of TLC plates was facilitated with UV light (254 and 365 nm) and/or
ninhydrin-staining (11 mM in EtOH).

Column chromatography was performed

with EM Science, Silica gel 60 (230-400 mesh ASTM). Chromatography solvent
mixtures are reported as volume:volume ratios.
Nuclear magnetic resonance (NMR) spectra were obtained on a Varian
Unity Plus 400 spectrometer. Proton NMR (1H NMR) spectra were recorded at
400 MHz and the chemical shifts are reported in parts per million (ppm, 5)
relative to residual protonated solvent signal (CDCI3 , 7.26 ppm; D20 , 4.63 ppm;
DMSO-cfe, 2.49 ppm).

Carbon NMR (13C NMR) spectra were recorded at 100

MHz and the chemical shifts are reported in parts per million (ppm, 6) relative to
solvent signal (CDCI3 , 77 ppm; DMSO-cfe, 39.5 ppm) or with 1,4-dioxane as an
internal standard (for D2O; 67.4 ppm).
follows:

Proton NMR spectra are reported as

chemical shift (multiplicity, coupling constant^ in Hertz, number of

protons). Optical rotations were obtained on a Perkin-Elmer 241 Polarimeter at
ambient, room temperature using a 10 cm (1 dm) cell. The concentration of the
solutions analyzed is reported as; c = (grams of solute)/(solution volume in mL).
Optical rotations were calculated using the relationship [a]*5 = a/Lc; where a is
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the instrument reading, L is the length of the sample cell (1 dm) and c is the
concentration

of

solute

(described

immediately

above).

Gas

chromatography/mass spectroscopy (GC/MS) data was collected on an Agilent
Technologies electron

impact (El)

5973Network mass selective detector

connected to an Agilent Technologies 6890N Gas Chromatography system
equipped with an Agilient HP-5MS crosslinked 5% PH ME Siloxane column (30m
x 0.25 mm; 0.25 micron). High-resolution mass spectra (HRMS) were obtained
with a Micromass LCT electrospray ionization (ESI) spectrometer connected to a
Waters 2790 Separations Module. A chromatography column was not used in
these analyses.

Biotage purifications were run on a Biotage Horizon Flash

Collector connected to a Biotage Horizon Pump and Horizon Detector.

7.2

Experimentals
The synthetic procedures detailed in this section are organized by

compound number in ascending order.

1. ACE-CI, DCE
reflux

N

N

2. MeOH, A
H

(7?J-(+)-2-[2-(Methoxymethyl)piperazin-1-yl]quinoline (R)-Z4.

To a 0 °C

solution of methyl ether (RJ-109 (0.119 g, 0.34 mmol) in dry dichloroethane (8
ml_) under argon was added 1-chloroethyl chloroformate (0.093 g, 0.65 mmol).
After stirring at 0 °C for 10 min the flask was heated at reflux for 2.5 h. The
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solution was cooled slightly and the volatile components were evaporated. The
residue was dissolved in methanol (10 ml_), heated at 60 - 70 °C for 1 h, and
then the solvent was evaporated. The residue was dissolved in 15 ml_ 1 M HCI
and washed with CH 2CI2 ( 4 x 1 5 mL). The aqueous phase was made basic with
4 M NaOH, diluted with saturated NaHC 0 3 (20 mL) and extracted with CH 2 Cl2 ( 4
x 10 mL). The combined extracts were dried (K2 CO 3) and concentrated to give
(R)-34 as a pale colored oil (0.081 g, 92%). TLC F?,0.1 (MeOH:CH 2CI2, 1:9). 1H
NMR (400 MHz, CDCI3): 5 1.93 (bs, NH, 1H), 2.87 (m, 1H), 2.98 (dd, J = 4.0 Hz
and 12.5 Hz, 1H), 3.11-3.20 (m, 2H), 3.29-3.37 (m, 4H, overlapped singlet at
3.36, OCH 3), 3.48 (dd, J = 4.8 and 9.2 Hz, 1H), 3.86 (m,

1 H),

4.36 (bd,

1 H),

4.57

(bm, 1H), 6.97 (d, J = 9.2 Hz, 1H), 7.21 (m, 1H), 7.52 (m, 1H), 7.59 (m, 1H), 7.68
(d, J =

8 .8

Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 41.4,

46.0, 46.2, 50.7, 59.0, 69.7, 109.1, 122.1, 126.5, 127.1, 129.4, 137.3, 147.8,
156.9;

(R) - [ a f +103.4 (c 0.0086, CHCI3); HRMS (ESI-TOF) m/z (M + H)+

calcd. for C 15H20N 3O 258.1606 found 258.1610.

H

(,S>)-(-)-2-[2-(Methoxymethyl)piperazin-1-yl]quinoline

fS)-34.

The

title

compound was similarly prepared and provided identical spectroscopic data. (S)
- [a]“ -1 02.2 (c 0.0101, CHCI3).
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o 2n

1. DMF, NaH
CH
U
l 133-I,
I, 35 °C
w

^

N
N
]
H O ^^^N B oc
H

0 2N

:-----2. CH2CI2, TFA
H

2-[2-(Methoxymethyl)piperazin-1-yl]-6-nitroquinoline 35. To a solution of NBoc alcohol 58 (0.0077 g, 0.02 mmol) in dry DMF (1 mL) under argon was added
sodium hydride (0.012 g, 0.5 mmol) producing a dark red mixture, lodomethane
(8

pL, 0.13 mmol) was added and the reaction flask placed in an oil bath at 35

°C. An immediate color change to orange occurred and a TLC confirmed that the
starting material had been consumed. The excess hydride was destroyed with a
few drops of methanol and the reaction contents were partitioned between water
and ether (10 mL each).

The organic phase was separated and the aqueous

phase extracted with two additional portions of ether (15 mL).

The combined

extracts were dried (K2CO 3) and concentrated to give the crude product.

The

residue was dissolved in CH 2CI2 and trifluoroacetic acid (5 mL each).

After

stirring 1.5 h the solution was made basic with 1:5 K2C 0 3 .water solution. The
aqueous phase was extracted with two 20 mL portions of CH 2CI2 . The extracts
were dried (K2CO 3) and concentrated to afford 35 as a yellow film (0.007 g,
120%). TLC Rf 0.14 (MeOH:CH 2CI2, 1:9). The product’s 1H NMR spectrum was
consistent to the known spectra.67 1H NMR (400 MHz, CDCI3):

8

1.77 (bs, 1H),

2.87 (td, J = 3.3, 11.7 Hz, 1H), 2.98 (dd, J = 4.4, 12.5 Hz, 1H), 3.15 - 3.28 (m,
2H), 3.32 (m, 1H), 3.37 (s, 3H), 3.60 (dd, J= 5.5, 9.2, 1H), 3.85 (dd, J = 7.7, 9.2
Hz, 1H), 4.50 (bm, 1H), 4.66 (bm, 1H), 7.08 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 9.2
Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 8.29 (dd, J = 2.6, 9.2 Hz, 1H), 8.54 (d, J = 2.6
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Hz, 1H);

13C NMR (100 MHz, CDCI3): 5 45.9, 46.3, 50.9, 59.1, 70.2, 110.9,

121.0, 123.5, 124.2, 127.0, 138.5, 141.7, 151.4, 158.5; HRMS (ESI-TOF) m/z (M
+ H)+ calcd. for C 15H 19N4 O 3 303.1457 found 303.1448.

h 2 s o 4, h n o 3

N

N
H

H

fiR)-(+)-2-[2-(Methoxymethyl)piperazin-1-yl]-6-nitroquinoline (R)-Z5.

To a 0

°C solution of (R)-ZA (0.038 g, 0.15 mmol) in conc. H2SO 4 (2 mL) was added
HNO 3 (15.4 M, 0.038 mL, 0.59 mmol).

The reaction was stirred 17 min then

quenched by pipetting onto ice. The solution was basified with 4 M NaOH then
diluted with saturated NaHC 0 3 (10 mL). The bright yellow aqueous mixture was
extracted with CH 2CI2 ( 3 x 1 0 mL) and the combined extracts dried (K2CO 3) and
concentrated to provide (R)-35 as a bright yellow-orange oily solid (0.040 g,
91%). TLC R f 0.14 (MeOH:CH2Cl2 , 1:9). The spectroscopic data for (R)-Z5 was
identical to that for the racemic material. (R ) - [a]“ +138.8 (c 0.0016, CHCI3).

H

S)-(-)-2-[2-(Methoxymethyl)piperazin-1-yl]-6-nitroquinoline (S)-35.

The title

compound was similarly prepared and provided identical spectroscopic data. (S )
- [a]“ -1 37.8 (c 0.0023, CHCI3).
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o 2n

o 2n

HOv, A - ' NH
2-[2-(Hydroxymethyl)piperzin-1-yl]-6-nitroquinoline 55. To 58 (0.035 g, 0.090
mmol) dissolved in THF (2 mL) was added H2 S 0 4 (4 M, 5 mL) and the solution
stirred at ambient temperature until a TLC showed consumption of starting
material (~2 h).

The solution was pipetted into cold 4 M NaOH

diluted with saturated NaHC 0 3 (10 mL).

(8

mL) then

The aqueous mixture was extracted

with CH 2 CI2 ( 4 x 8 mL) and the combined extracts were dried (K2 CO 3) and
concentrated to provide 55 as an oily bright yellow solid (0.019 g, 73%). TLC Rf
0.04 (MeOH:CH 2CI2, 1:9).

1H NMR (400 MHz, CDCI3): 5 2.70 - 3.10 (bs, 2H)

overlapped with 2.92 (td, J = 3.3, 11.7 Hz, 1H), 3.07 (dd, J = 4.0, 11.7 Hz, 1H),
3.21 (bd, J = 11 Hz, 1H), 3.36 (bd, J = 12.1 Hz, 1H), 3.56 (td, J = 3.3, 12.5 Hz,
1H), 4.02 (dd, J = 4.4, 11 Hz, 1H), 4.15 (dd, J = 5.5, 11 Hz, 1H), 4.26 (bd, J =
12.5 Hz, 1H), 4.83 (bs, 1H), 7.08 (d, J = 9.5 Hz, 1H), 7.61 (d, J = 9.5, 1H), 7.96
(d, J = 9.5 Hz, 1H), 8.28 (dd, J = 2.6, 9.5 Hz, 1H), 8.52 (d, J = 2.6 Hz, 1H); 13C
NMR (100 MHz, CDCI3): 5 42.7, 46.0, 48.2, 52.0, 64.7, 111.2, 121.1, 123.7,
124.2, 127.0, 138.7 141.9, 151.1, 159.1; HRMS (ESI-TOF) m/z (M + H)+ calcd.
for C 14H 17N4 O 3 289.1301 found 289.1304.
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o 2n

1. BBr3, CH 2 CI2
-78 °C

0 2N

N ^|
u

M3O

2 . Boc20 , CH2CI2

^

H° ^ rrPk ^ N B°c

2-[4-(ferf-Butoxycarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline
58. To a -78 °C stirring solution of MOM-NQP 35 (0.143 g, 0.474 mmol) in dry
CH 2CI2 (75 mL) under argon was added (dropwise) borontribromide solution (1 M
in CH2 CI2, 2.37 mL, 2.37 mmol). The addition turned the mixture black initially
and then faded to a turbid orange.

The reaction was maintained at -78 °C for 3

h then warmed to ambient temperature and stirred 18 h.

The reaction was

quenched with saturated NaHC 0 3 (20 mL), transferred to a separatory funnel
and shaken vigorously.

The organic phase was separated and the aqueous

layer extracted with CH 2CI2 (30 mL) and CHCl3 :isopropyl alcohol, 4:1 (3 x 30
mL).

The combined organic phases were dried (K2CO 3), and concentrated to

give a crude residue. The crude residue was dissolved in about

20

mL of CH 2CI2

and to this was added a solution of di-ferf-butyldicarbonate (0.124 g, 0.569 mmol)
in CH 2CI2 (5 mL).

The solution was stirred for 5 min, concentrated and the

residue purified by column chromatography (silica gel, EtOAc:Hexanes, 3:2) to
afford 58 as a bright yellow foam (0.129 g, 70%). TLC Rf 0.11 (EtOAc:Hexanes,
2:3). 1H NMR (400 MHz, CDCI3): 5 1.47 (s, 9H), 3.09 - 3.62 (bm, 4H), 3.66 3.96 (bm, 2H), 3 .9 8 -4 .4 3 (bm, 3H), 4.82 (bm, 1H), 7.07 (d, J = 9.2 Hz, 1H), 7.61
(d, J = 9.2 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 8.25 (dd, J = 2.6, 9.2 Hz, 1H), 8.47
(d, J = 2.6 Hz, 1H);

13C NMR (100 MHz, CDCI3): 5 28.2, 40.2 (broad), 42.5

(broad), 43.9 (broad), 53.9, 59.8 (broad), 61.2 (broad), 80.5, 111.0 (broad),
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121.1, 123.5, 124.0, 126.7, 138.7, 141.8, 150.6, 155.5 (broad), 158.8 (broad);
HRMS (ESI-TOF) m/z (M + H)+ calcd. for C i9H25N40 5 389.1825 found 389.1810.

o 2n

N ^|
H O ^ jk ^ N B o c

HO\ o' K ^ NBoc
(R)-58
-58

H

(S>58

H

(R)-{+)- and (rS)-(-)-2-[4-(fert-Butoxycarbonyl)-2-(hydroxymethyl)piperazin-1 -

yl]-6-nitroquinoline (R)-5S and (S)-58.

The title compounds were similarly

prepared and provided identical spectroscopic data. (R)- 58 - [a]“ +93.3 (c 0.012,
CHCIs); (S)- 58 - [ a ] * -9 1 .4 (c 0.013, CHCI3).

2.

B o c20

3. K0 CO 0 , MeOH

(7?)-2-[4-(tert-butoxycarbonyl)-2-(Hydroxymethyl)piperazin-1-yl]-6nitroquinoline (R)-58. To a 0 °C solution of acetate (R)-129 (0.108 g, 0.378
mmol) in conc. H 2 S O 4 (7 mL) was added (dropwise) H N O 3 (15.4 M, 0.1 mL, 1.54
mmol). After stirring 15 min at 0 °C the reaction mixture was carefully pipetted
into 200 mL of cold saturated N a H C C >3 in a separatory funnel containing ice. The
bright yellow aqueous mixture was extracted with C H 2 C I 2 (3 x 40 mL) and the
combined extracts were dried (K 2 C O 3 ) and treated with di-fe/f-butyldicarbonate
(0.20 g, 0.917 mmol). When a TLC showed that amine protection was complete,
the solvent was decanted from the drying agent and evaporated.

The residue

was dissolved in methanol (10 mL) treated with K 2 C O 3 and stirred at ambient
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temperature for ~ 1 h. A TLC showed consumption of starting material and the
methanol was evaporated and the residue partitioned between 20 mL each of
saturated NaHC 0 3 and CH 2CI2 .

The organic phase was separated and the

aqueous phase extracted with CH 2CI2 ( 2 x 1 0 mL). The combined extracts were
dried (K2CO 3) and concentrated to provide the crude material that was purified by
column chromatography (silica gel, EtOAc:Hexanes, 2:3 - 3:2) to provide (R)-58
as a yellow foam (0.074 g, 50%). This product was spectroscopically identical to
the 58 generated via the alternate BBr3 deprotection route.

1. THF, TBAF
NBoc
H

H

2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline 61.

To a

solution of tosylate 65 (0.0238 g, 0.040 mmol) in dry THF (400 pL) was added a
solution of TBAF in THF (1 M, 0.06 mL, 0.06 mmol). The reaction was sealed
under argon and heated at 55 - 60 °C for 3 h.

After cooling, the THF was

evaporated and the residue was purified by column chromatography (silica gel,
EtOAc:Hexanes, 1:3) to afford the N-Boc protected intermediate as a yellow film
(0.0137 g, 77%). TLC Rf 0.27 (EtOAc:Hexanes, 2:3). To the intermediate N-Boc
fluoride (0.0217 g, 0.048 mmol) in a flask at 0 °C was added cold (-10 °C) conc.
H2 SO 4 (3 mL).

Immediate bubbling was observed as the N-Boc group

deprotected and the flask was swirled to clear the sides of material. After 5 min
the contents were pipetted onto ice, made basic with 4 M NaOH and further
diluted with saturated NaHCOs. The yellow aqueous mixture was extracted with
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CH 2CI2 ( 3 x 1 0 mL) and the combined extracts dried (K2CO 3) and concentrated to
give the crude material that was purified by column chromatography (silica gel,
MeOH:CH 2Cl2 , 1:39 - 1:19) to afford 61 as a yellow film (0.013 g, 80%). TLC Rf
0.16 (MeOH:CH 2CI2, 1:9).

1H NMR (400 MHz, CDCI3): 5 1.80 - 2.00 (m, 3H,

overlapped bs of NH and dp, Jf-h = 26.0 Hz, FCH 2CH 2-, Jh-h = 6.2 Hz), 2.87 (m,
1H), 2.99 (m, 1H), 3 .1 2 -3 .3 6 (m, 3H), 3.58 (t, J = 6.2 Hz, 2H), 3.68 (dd, J = 5.5,
9.5 Hz, 1H), 3.88 (dd, J = 7.3, 9.5 Hz,

1 H),

4.44 (dt, J F.h = 47.2, FCH2-, Jh-h = 5.9

Hz, 2H, overlapped with a bs at 4.50, 1H), 4.66 (bs, 1H), 7.08 (d, J = 9.2 Hz, 1H),
7.63 (d, J = 9.2, 1H), 7.95 (d, J = 9.2, 1H), 8.28 (dd, J = 2.6, 9.2 Hz, 1H), 8.52 (d,
J = 2.6, 1H); 13C NMR (100 mHz, CDCI3): 5 30.7 (J C-f =
41.3, 45.9, 46.4, 50.0, 67.0 (J C-f =

6 .1

19.8 Hz, FCH 2 CH2-),

Hz, FCH 2CH 2 CH2-), 68.5, 81.0 (J C-f =

164.8 Hz, FCH2-), 111.1, 121.1, 123.6, 124.2, 127.1, 138.4, 141.8, 151.4, 158.7;
HRMS (ESI-TOF) m/z (M + H)+ calcd. for C 17H22N4 O 3 F 349.1676 found
349.1674.

H

H

(R)-(+)-2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline

(R)-

61. To a 0 °C solution of (R)- 127 (0.065 g, 0.214 mmol) in conc. H2SO4 (6 mL)
was added HNO3 (15.4 M, 0.028 mL, 0.431 mmol). The reaction was stirred for
17 min then quenched by pipetting onto ice. The solution was made basic with 4
M NaOH then diluted with saturated NaHC 0 3 (20 mL).

The bright yellow

aqueous mixture was extracted with CH2CI2 (3 x 20 mL) and the combined
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extracts dried (K2 CO 3) and concentrated to provide the crude product that was
purified

by

column

chromatography

(silica

gel,

four

column

lengths

EtOAc:Hexanes, 4:1, then MeOH:CH 2Cl2 , 1:39 - 1:9) to provide (R)-61 as a
bright yellow-orange oil (0.070 g, 93%). TLC Rf 0.16 (MeOH:CH 2Cl2 , 1:9). This
product was spectroscopically identical to the 61 formed via the alternate N-Boc
protected route. (R) - [a]^ +111 .6 (c 0 .0 0 2 1 , CHCI3).

NH
H

fS>)-(-)-2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline
61.

(S)-

The title compound was similarly prepared and provided identical

spectroscopic data. (S) - [ a ] * 5 -1 1 3 .2 (c 0.0011, CHCI3).

Allylbromide
NBoc

NBoc

2-[4-(ferf-Butoxycarbonyl)-2-(allyloxymethyl)piperazine-1-yl]-6nitroquinoline 63. To a 0 °C solution of Boc alcohol 58 (0.194 g, 0.50 mmol) in
dry DMF (8 mL) under argon was added NaH (95%, 0.046 g, 1.92 mmol) in one
portion. Allyl bromide (0.302 g, 2.5 mmol) was added (dropwise) to the deep red
mixture and the reaction warmed to ambient temperature. After stirring 1.5 h a
TLC showed consumption of starting material and the reaction mixture was
carefully added to a separatory funnel containing ether (30 mL) and 16 mL each
of water and saturated NaHC 0 3 - The aqueous phase was separated and the
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organic phase was washed with brine

(2

x

20

mL), dried (K2CO 3) and

concentrated to provide the crude material that was purified by column
chromatography (silica gel, EtOAc:Hexanes, 2:3) to afford 63 as a bright yellow
foam (0.192 g, 90%). TLC R f 0.33 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz,
CDCI3): 5 1.49 (s, 9H), 2.96 - 3.37 (bm, 3H, includes dd at 3.17), 3.49 - 3.68 (m,
2H, includes t at 3.61), 3.93 - 4.78 (bm,

6

H, includes bs at 4.00 and bd at 4.30),

5.04 - 5.31 (bm, 2H), 5.82 (bm, 1H), 7.08 (d, J = 9.2 Hz, 1H), 7.63 (d, J = 9.2 Hz,
1H), 7.95 (d, J = 9.2 Hz, 1H), 8.25 (dd, J = 2.6, 9.2 Hz, 1H), 8.49 (d, J = 2.6 Hz,
1H);

13C NMR (100 MHz, CDCI3): 5 28.3, 40.0 (broad), 42.6 (broad), 43.7

(broad), 51.6 (broad),

6 6 .6

(broad), 72.2, 80.1, 111.0,117.0, 121.1, 123.5, 124.1,

127.2, 134.3, 138.6, 141.9, 151.1, 154.9, 158.4; HRMS (ESI-TOF) m/z (M + H)+
calcd. for C 22H29N4 O 5 429.2138 found 429.2119.

(R)-63

(S)-6 3

H

(R)-{+)- and (S)-(-)-2-[4-(ferf-Butoxycarbonyl)-2-(allyloxymethyl)piperazine-1 yl]-6-nitroquinoline (R)-63 and (S)-6Z.

The title compounds were similarly

prepared and provided identical spectroscopic data. (R) - 63 - [a ] * 5 +89.4 (c
0.0086, CHCI 3 ); (S) - 63 - [a]*5-8 3 .0 (c 0.010, CHCI3 ).
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o 2n

NBoc

1.

THF, 9BB-N

2.

H20 2i NaOH

NBoc

2-[4-(fert-Butoxycarbonyl)-2-((3-hydroxypropoxy)methyl)piperazine-1-yl]-6nitroquinoline 64. To the allyl ether 63 (0.075 g, 0.175 mmol) in dry THF (600
pL) under argon was added a solution of 9-BBN in THF (0.5 M, 950 pL, 0.475
mmol). The reaction was heated to 55 °C and maintained for 1 h. After cooling
to 0 °C 0.6 mL of 1 M NaOH was added (dropwise) followed by 0.6 mL of 30%
H2O2 . The mixture was stirred for 5 min and a TLC confirmed consumption of
starting material. The mixture was poured into 20 mL of saturated N aH C 03 and
the aqueous phase extracted with CH 2CI2 ( 3 x 1 0 mL). The combined extracts
were dried (K2CO 3) and concentrated to give the crude material that was purified
by column chromatography (silica gel, EtOAc:Hexanes, 3:2) to afford 64 as a
bright yellow foam (0.057 g, 73%). TLC Rf 0.11 (EtOAc:Hexanes, 2:3). 1H NMR
(400 MHz, CDCI3): 5 1.49 (s, 9H), 1.73 (bm, 2H), 2.98 - 3.37 (bm, 3H), 3.41 3.89 (bm, 7H), 4 .0 2 -4 .5 3 (bm, 3H), 4.71 (bm, 1H), 7.06 (d, J = 9.2 Hz, 1H), 7.64
(d, J = 9.2 Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 8.25 (dd, J = 2.6, 9.2 Hz, 1H), 8.49
(d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 28.3, 32.1, 40.1, 42.5, 43.8,
51.7, 59.1, 61.2, 66.8, 67.6, 68.5, 70.3, 80.5, 110.8, 121.2, 123.6, 124.2, 127.2,
138.8, 142.0, 151.0, 154.9, 158.3; HRMS (ESI-TOF) m/z (M + H)+ calcd. for
C22H31N4 O6 447.2244 found 447.2226.
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OpN
‘N

N ^ |

H O ^ - ^ O ^ .^ N B o c
(R)-64

NBoc

H

(R)-(+)- and (,SJ)-(-)-2-[4-(tert-Butoxycarbonyl)-2-((3-hydroxypropoxy)methyl)

piperazine-1-yl]-6-nitroquinoline (R)-64 and (S)- 64. The title compounds were
similarly prepared and provided identical spectroscopic data. (R)- 64 - [a]“ +38.9
(c 0.0055, CHCI3); (S)-64 - [a]“ -3 7 .5 (c 0.0067, CHCI3).

Tl T

CH2CI2i Pyridine
I

I

H O -^/v^^O ^^jJ^^N B oc

Tosyl chloride

I
\

I

T s O ^ /^ O ^ A ^ N B o c

2-[4-(tert-Butoxycarbonyl)-2-((3-(4-methylbenzenesulfonate)propoxy)
methyl)piperazine-1-yl]-6-nitroquinoline 65. To a 0 °C solution of alcohol 64
(0.095 g, 0.213 mmol) in dry CH 2CI2 (1.2 mL) and pyridine (100 pL) was added
p-toluenesulfonyl chloride (0.170 g, 0.895 mmol) in one portion.

The reaction

was sealed under argon and maintained in an ice bath until the bath warmed to
ambient temperature. After 24 h the reaction contents were partitioned between
saturated NaHC 0 3 (20 mL) and CH 2CI2 (10 mL).

The organic phase was

separated and the aqueous phase was extracted with CH 2CI2 ( 2 x 1 0 mL). The
combined extracts were dried (K2CO 3) and concentrated to give the crude
material that was purified by column chromatography (silica gel, EtOAc:Hexanes,
1:3 - 2:3) to afford 65 as a bright yellow foam (0.103 g, 80%).

TLC Rf 0.22

(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.48 (s, 9H), 1.79 (bm, 2H),
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2.42 (s, 3H), 2.94 - 3.30 (bm, 3H), 3.44 - 3.60 (bm, d shaped, 4H), 4.02 (bm,
2H), 4.10 - 4.24 (m, 2H, includes d at 4.20), 4.50 (bm, 1H), 4.65 (bm, 1H), 7.07
(d, J = 9.2 Hz, 1H), 7.30 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 9.2 Hz, 1H), 7.72 (d, J =
8.1 Hz, 2H), 7.95 (d, J = 9.2 Hz, 1H), 8.26 (dd, J = 2.6, 9.2 Hz, 1H), 8.50 (d, J =
2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 21.6, 28.3, 29.2, 39.8 (broad), 42.6
(broad), 43.7 (broad), 51.4 (very broad), 66.7, 67.3, 68.0 (very broad), 80.2,
111.2, 121.2, 123.5, 124.2, 127.2, 127.7, 129.8, 133.0, 138.5, 141.9, 144.7,
151.1, 154.8, 158.5; HRMS (ESI-TOF) m/z (M + H)+ calcd. for C 29H36N4 O 8 S
601.2332 found 601.2336.

NBoc

(R)-(+)- and (rS>)-(-)-2-[4-(fert-Butoxycarbonyl)-2-((3-(4-methylbenzenesulfon-

ate)propoxy)methyl)piperazine-1-yl]-6-nitroquinoline (R)-65 and (S)-65. The
title compounds were similarly prepared and provided identical spectroscopic
data. (R)-65 - [a]“ +42.3 (c 0.00063, CHCI3 ); (Sj-65 .

[a £ 5

-

4 2 .1

(c 0.00057,

CHCI3 ).

Bn' N ^
H

1. SOCI2, DMSO
2. CH 3 -P(Ph)3l
n-BuLi

Bru

u

1,4-Dibenzyl-2-ethenylpiperazine 72. To a -78 °C solution of oxalyl chloride (2
M in CH 2 CI2 , 14 mL, 28 mmol) in dry CH 2 CI2 (60 mL) under argon was added
(dropwise) a solution of DMSO (4 mL, 56 mmol) in CH 2CI2 (10 mL). After stirring
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20 min at -78 °C, a solution of alcohol 30 (7.45 g, 25 mmol) in CH 2 CI2 (18 mL)
was added (dropwise), followed by triethylamine (17.6 mL, 127 mmol) after
another 20 min. After stirring for 10 min at -78 °C, the mixture was warmed to
ambient temperature over 2 h. The mixture was diluted with water (75 mL) and
the organic phase separated. The aqueous phase was extracted with CH 2CI2 (2
x 50 mL) and the combined extracts washed with saturated NaHC 0 3 (100 mL),
dried (K2CO 3) and concentrated to provide the crude aldehyde that was pumped
under high vacuum for 10 min and then used immediately in the next step.
To a 0 °C suspension of methyltriphenylphosphonium iodide (10.0 g, 24.8 mmol)
in dry THF (70 mL) was added a solution of n-BuLi in hexane (2.4 M, 10.0 mL, 24
mmol) producing a red-orange solution.

Following 1 h, a solution of aldehyde

(3.60 g, 12.3 mmol) in dry THF (15 mL) was added (dropwise) and the reaction
warmed slowly to ambient temperature overnight. The reaction was quenched
by the addition of saturated NaHC 0 3 solution (150 mL), and the THF evaporated.
The aqueous mixture was extracted with CH 2CI2 (3 x 50 mL) and the combined
extracts dried (K2CO 3) and concentrated to give the crude material that was
purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide
72 as an oil (2.73 g, 76%). TLC Rf 0.42 (EtOAc:Hexanes, 2:3). 1H NMR (400
MHz, CDCI3): 5 2.10 - 2.25 (m, 3H), 2.66 - 2.77 (m, 3H), 2.96 (td, J = 2.9, 9.2
Hz, 1H), 3.10 (d, part of AB pattern, J = 13.6, 1H), 3.51 (m, AB pattern, J = 13.2
Hz, 2H), 4.08 (d, part of AB pattern, J = 13.6 Hz, 1H), 5.21 (dd, J = 1.8, 10.3 Hz,
1H), 5.30 (dd, J = 1.8, 17.6 Hz, 1H), 5.86 (m, 1H), 7.22 - 7.40 (m, 10H); 13C
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NMR (100 MHz, CDCI3): 5 50.9, 53.0, 59.0, 59.1, 62.9, 65.0, 117.9, 126.7, 127.0,
128.1, 128.2, 129.07, 129.14, 137.9, 138.6.

1. THF, 9BB-N

2. H20 2> NaOH

HO

1,4-D,ibenzyl-2-(2-hydroxyethyl)piperazine 73.

H

To a solution of alkene 72

(2.62 g, 8.97 mmol) in dry THF (50 mL) under argon was added (dropwise) a
solution of 9-BBN in THF (0.5 M, 27 mL, 13.5 mmol). After stirring 5 min the
reaction was heated at 50 °C for 1 h then cooled to 0 °C in an ice bath. To the
reaction was added (dropwise) 1 M NaOH (23 mL), followed by 30% H2O 2 (23
mL). Following the additions, the reaction was warmed to ambient temperature
and a TLC confirmed consumption of starting material. The THF was evaporated
and the aqueous mixture extracted with CH 2CI2 (3 x 50 mL).

The combined

extracts were dried (K2CO 3) and concentrated to provide the crude material that
was purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3 - 3:2, to
remove non-polar material then EtOAc:CHCl3 , 4:1) to provide 73 as an oil (2.39
g,

8 6 %).

TLC Rf 0.34 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3):

1.91 (bm, 1H), 1.99 - 2. 09 (bm, 1H), 2.26 - 2.36 (m, 2H), 2.42 (dd, J =

6

1.81 -

6 .8

, 11.3

Hz, 1H), 2.51 (m, 1H), 2.64 (dd, J = 2.9, 11.3 Hz, 1H), 2.83 (m, 1H), 2.92 (m, 1H),
3.39 (bd, J = 12.6 Hz, 1H), 3.49 (m, AB pattern, J = 12.9 Hz, 2H), 3.74 (m, 1H),
3.87 (m, 1H), 4.17 (bd, J = 12.9 Hz, 1H), 4.87 (bs, 0.6H, -OH), 7.23 - 7.29 (m,
2H), 7.29 - 7.34 (m,

8

H); 13C NMR (100 MHz, CDCI3): 5 30.9, 49.3 (broad), 51.4,

55.7, 57.7, 58.0, 60.7, 63.0, 127.0 (2 overlapped peaks), 128.1, 128.2, 128.88,
128.93, 137.7, 138.1.
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DMF, NaH
HO

H

Bn

CHg-l

H

.2HCI

1,4-Dibenzyl-2-(2-methoxyethyl)piperazine 74. To a 0 °C solution of alcohol
73 (2.40 g, 7.7 mmol) in dry DMF (25 mL) was added NaH (95%, 0.461 g, 19.2
mmol) in one portion. After stirring 5 min, iodomethane (0.50 mL, 8.03 mmol)
was added (dropwise) and the reaction warmed to ambient temperature. After
stirring for 1 h, the excess NaH was destroyed by the careful addition of water
and the solution was diluted with 50 mL each of water and saturated NaHC 0 3
solution.

The aqueous mixture was extracted with ether (3 x 40 mL) and the

combined extracts dried (K2CO 3) and concentrated to give the crude material that
was purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3) to
afford 75 (free base form) as an almost colorless oil (1.74 g, 70%). TLC R f 0.52
(MeOH:CH 2Cl2 , 1:9). The oil was dissolved in ether and treated with HCI gas to
produce a white precipitate that was collected by filtration, washed with ether,
and dried in vacuo to give 74 as a white solid (2.0 g, 94% from free base). The
material was characterized as the free base. 1H NMR (400 MHz, CDCI3):

8

1.92

(bm, 2H), 2.25 (bm, 3H), 2.48 - 2.75 (bm, 4H), 3.22 - 3.32 (m, 4H, includes 3H s
at 3.28), 3.35 - 3.46 (m, 3H), 3.54 (bd, J = 13.2 Hz, 1H), 3.98 (m, 1H), 7.20 7.38 (m, 10H); 13C NMR (100 MHz, CDCI3):

8

29.2, 50.3, 52.8, 57.3, 57.5, 57.8,

63.0, 70.1, 126.7, 126.9, 128.1 (two overlapped peaks), 128.9, 129.0, 138.2,
139.1.
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MeOH, Pd/C,

H

Bn

HN'
H

.2HCI

.2HCI

2-(2-Methoxyethyl)piperazine dihydrochloride 75. To a solution of 74 (2.00 g,
5.0 mmol) in methanol (100 mL) was added Pd/C (5%, 0.30 g). The flask was
sealed with a rubber septa and hydrogen gas was bubbled through the solution
via balloon. The reaction was monitored by TLC until the starting matieral was
gone then the mixture was filtered (Celite) and the filtrate concentrated to provide

75 as a white solid (1.05 g, 97%). 1H NMR (400 MHz, D20): 5 1.75 - 1.90 (m,
2H), 3.06 (dd, J = 12.5, 14.3 Hz, 1H), 3.15 (s, 3H), 3.17 - 3.29 (m, 2H), 3.43 (t, J
= 5.8 Hz, 2H), 3.50 - 3.62 (m, 4H); 13C NMR (100 MHz, D20 , 1,4-dioxane int.
std.): 5 30.3, 40.7, 41.4, 45.1, 52.7, 59.1, 68.9.

1 . C H 2 CI2, Et3N
2

H

H N ^

. Trityl chloride

.2HCI

3-(2-Methoxyethyl)-1-triphenylmethylpiperazine 76. To a stirring suspension
of piperazine 75 (1.05 g, 4.83 mmol) in dry CH 2CI2 under argon (30 mL) was
added anhydrous triethylamine (2.7 mL, 19.4 mmol). The resultant clear solution
was cooled to 0 °C and a solution of trityl chloride (1.4 g, 5.02 mmol) in dry
CH 2CI2 (9 mL) was added (dropwise). The reaction was stirred 10 min at 0 °C
then warmed to am bient tem perature and stirred for 4 h.

T h e solution w as

washed with saturated NaHC 0 3 solution (30 mL) and brine (2 x 20 mL), dried
(K2C 0 3 ) and the solvent evaporated to provide 76 as a white solid (1.89 g,
quantitative). 1H NMR (400 MHz, CDCI3):

8

1.21 (bs, 1H), 1.63 (bm, 2H), 2.86 -
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3.22 (bm, 7H), 3.31 (s, 3H), 3.41 (m, 2H), 7.10 - 7.58 (m, 15H); 13C NMR (100
MHz, CDCI3): 5 34.1, 46.3, 48.8, 53.6, 54.6, 58.6, 70.0, 77.1, 125.9, 127.4, 129.3,
142.6.

1. Et2 0 , n-BuLi;
2 -chloroquinoline

HN^|
No / s ^ k ' NTrit
H

2

. HCI
H

2-[2-{2-Methoxyethyl)piperazin-1-yl]quinoline 77. To a 0 °C solution of trityl
piperazine 76 (0.530 g, 1.37 mmol) in dry ether (15 mL) under argon was added
(dropwise) n-butyllithium (2.45 M in hexane, 1.37 mmol) producing a slightly
colored turbid solution. After stirring for 20 min, a solution of 2-chloroquinoline
(0.150 g, 0.91 mmol) in ether (4 mL) was added (dropwise) and the solution
allowed to stir for 20 min at 0 °C then at ambient temperature for 14 h.

The

reaction was diluted with ether (10 mL), washed with saturated NaHC 0 3 (2 x 25
mL) and brine (1 x 25 mL), dried (K2CO3) and concentrated to give the crude
material that was purified by column chromatography (silica gel, EtOAc:Hexanes,
1:3) to provide the coupled product (TLC R f 0.54; EtOAc:Hexanes, 2:3) that was
not

spectroscopically

characterized

and

immediately

deprotected.

intermediate product was dissolved in acetone (3 mL) and 3 M HCI

(6

The

mL) and

the flask swirled. The mixture was further diluted with 1 M HCI (15 mL) and after
5 min was transferred to a separatory funnel and washed with CH 2 CI2 ( 4 x 1 5
mL).

The aqueous mixture was made basic with 4 N NaOH, diluted with

saturated NaHCOs solution (20 mL) and extracted with CH 2CI2 (4 x 20 mL). The
combined extracts were dried and concentrated to afford 77 as a pale colored oil
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(0.227 g, 92%). TLC R, 0.12 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5
1.76 (bs, NH, 1H), 2.01 (m, 1H), 2.11 (m, 1H), 2.86 (m, 1H), 3 .0 3 -3 .1 6 (m, 4H),
3.24 (s, 3H), 3.33 (m, 1H), 3.44 (m, 1H), 4.51 (bm, 1H), 4.62 (bm, d shaped, 1H),
7.03 (d, J = 9.5 Hz, 1H), 7.19 (m, 1H), 7.51 (m, 1H), 7.57 (bd, J = 8.1 hz, 1H),
7.66 (bd, J = 8.4 Hz, 1H), 7.86 (d, J = 9.5 Hz, 1H); 13C NMR (100 MHz, CDCI3):
5 28.3, 39.7, 46.3, 48.9, 49.3, 58.5, 69.5, 109.5, 121.9, 122.8, 126.3, 127.1,
129.3, 137.2, 147.9, 157.1.

1. ACE-CI, DCE
reflux

N

N ^ i

2. MeOH, A

2-[2-(2-Methoxyethyl)piperazin-1-yl]quinoline 77. To a 0 °C solution of methyl
ether 190 (0.370 g, 1.02 mmol) in dry dichloroethane (15 mL) under argon was
added 1-chloroethyl chloroformate (0.293 g, 2.05 mmol). After stirring 10 min,
the flask was heated at reflux for 3 h then cooled and the solvent evaporated.
The residue was dissolved in methanol (10 mL) and heated at 60 - 65 °C. After
1.25 h the methanol was evaporated and the residue was dissolved in 20 mL 1 M
HCI and washed with CH 2 CI2 ( 4 x 1 5 mL). The aqueous phase was made basic
with 4 M NaOH, diluted with saturated N aH C 0 3 (20 mL) and extracted with
CH 2CI2 (4 x 20 mL).

The combined extracts were dried (K2C 0 3) and

concentrated to give 77 as a pale colored oil (0.270 g, 97%). This product was
identical to that synthesized via the N-Trit protected piperazine.
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o 2n

H2 S 0 4i h n o 3

' - 0 ^ x 4 ^ NH
H

H

2-[2-(2-Methoxyethyl)piperazin-1-yl]-6-nitroquinoline 78. To a 0 °C solution
of 77 (0.196 g, 0.72 mmol) in conc. H2 SO 4
0.094 mL, 1.45 mmol).

(8

mL) was added HNO 3 (15.4 M,

The reaction was stirred for 15 min and was then

quenched by pouring onto ice. The solution was basified with 4 M NaOH and
diluted with saturated NaHC 0 3 (30 mL). The bright yellow aqueous mixture was
extracted with CH 2CI2 (3 x 30 mL) and the combined extracts dried (K2CO 3) and
concentrated to provide 78 as a yellow-orange oily solid (0.220 g, 96%). TLC R f
0.17 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3):

8

1.75 (bs, 1H, NH), 2.05

(m, 1H), 2.16 (m, 1H), 2.85 (m, 1H), 2.97 - 3.19 (m, 4H), 3.24 (s, 3H), 3.30 (m,
1H), 3.45 (m, 1H), 4.57 (bm, 1H), 4.78 (bm, 1H), 7.15 (d, J = 9.5 Hz, 1H), 7.61 (d,
J

= 9.5 Hz, 1H), 7.93 (d, J = 9.5 Hz, 1H), 8.27 (dd, J = 2.6, 9.5 Hz, 1H), 8.51 (d, J

= 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3):

8

28.8, 39.7, 46.2, 48.9, 49.5, 58.4,

69.1, 111.2, 120.8, 123.4, 124.1, 126.7, 138.3, 141.5, 151.5, 158.5; HRMS (ESITOF) m/z (M + H)+ calcd. for C 16H21N4 O 3 317.1614 found 317.1609.

1

. BBr3, CH 2 CI2
-78 °C

2. Boc2 0 , c h 2 c i 2
3. K2 C 0 3, MeOH

H

2-[4-(tert-Butoxycarbonyl)-2-(2-Hydroxyethyl)piperazin-1-yl]-6nitroquinoline 79. To a -78 °C stirring solution of 78 (0.200 g, 0.634 mmol) in
dry CH 2CI2 (100 mL) under argon was added (dropwise) boron tribromide
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solution (1 M in CH 2 CI2 , 3.17 mL, 3.17 mmol). The reaction was maintained at 78 °C until the bath warmed to ambient temperature over 15 h. The reaction was
quenched with saturated NaHC 0 3 (50 mL), transferred to a separatory funnel
and shaken vigorously.

The organic phase was separated and the aqueous

layer extracted with CH 2CI2 (40 mL) and CHCl3 :isopropyl alcohol, 4:1 (2 x 40
mL). The combined organic phases were dried (K2CO 3), concentrated and the
residue dissolved in about

20

mL of CH 2CI2 . To the yellow solution was added a

solution of di-ferf-butyldicarbonate (0.276 g, 0.1.27 mmol) in CH 2CI2 (5 mL). The
solution was stirred for

20

min, concentrated and the residue purified by column

chromatography (silica gel, EtOAc:Hexanes, 2:3 - 3:2) to afford the di-Boc 80
and mono-Boc 79 protected products that were combined and the solvent
evaporated.

The residue was dissolved in MeOH

(8

mL) treated with excess

K2CO 3 and heated at 60 °C until only the mono-Boc product 79 was present by
TLC. The methanol was evaporated and the residue partitioned between CH 2CI2
and saturated NaHC 0 3 (20 mL each). The organic phase was separated and the
aqueous phase extracted with CH 2 CI2 ( 2 x 1 0 mL). The combined extracts were
dried (K2CO 3) and concentrated to give the crude material that was purified by
column chromatography (silica gel, EtOAc:Hexanes, 2:3 - 3:2) to afford 79 as a
yellow foam (0.119 g, 47 %). TLC Rf 0.17 (EtOAc:Hexanes, 3:2). 1H NMR (400
MHz, CDCI3):

8

1.47 (s, 9H), 1.81 - 2.10 (bm, 2H, 2 humps), 2.97 - 2.48 (bm,

4H), 3.66 (bm, 1H), 3.92 - 4.28 (bm, 3H), 4.92 and 5.04 (bm, 1.6H), 7.08 (d, J =
9.2 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.95 (d, J = 9.2 Hz, 1H), 8.23 (dd, J = 2.6,
9.2 Hz, 1H), 8.44 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3):
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8

28.3, 32.3,

40.3, 42.6, 46.2, 47.6, 48.6, 58.0, 80.3, 110.9, 121.0, 124.05, 124.08, 126.1,
139.3, 142.0, 150.5, 154.8, 158.3.

THF, LiAIH4
reflux

HN^|
H

Bn

(^M-)-4-Benzyl-2-(hydroxymethyl)piperazine (R)-94. To a 0 °C suspension
of dione (S)- 97 (0.905 g, 3.86 mmol) in dry THF (90 mL) under argon was added
LiAIH4 (0.600 g, 15.8 mmol) in small portions. After the effervescence subsided
the flask was heated at reflux for 5 h.

The solution was cooled, stirred an

additional hour then the excess UAIH 4 was quenched by the careful, sequential
addition of 0.6 mL water, 1.2 mL 4 N NaOH and 0.6 mL water. The solids that
formed will filtered (Celite) and the filtrate concentrated to give (R)-B4 as a pale
colored oil (0.737 g, 92%).

This crude material was used without further

purification in subsequent reactions. A 0.170 g portion was purified (Biotage 12M
KP-NH column, MeOH:CHCl3 , 1:199) for spectroscopic purposes giving 0.148 g
of (7?)-94 as a pale colored oil. TLC R f 0.04 (MeOH:CH 2 Cl2 , 1:9). 1H NMR (400
MHz, CDCI3): 5 1.93 (m, 1H, triplet shape), 2.13 (dd, J = 2.9, 11.0 Hz, 1H), 2.54
(bs, 2H), 2.71 (m, 2H, doublet shape), 2 .8 7 -2 .9 8 (m, 2H), 3.03 (dt, 2.9, 12.1 Hz,
1H), 3.45 - 3.54 (m, 3H), 3.59 (dd, J = 4.0, 11.0 Hz, 1H), 7.23 - 7.35 (m, 5H);
13C NMR (100 MHz, CDCI3): S 44.9, 53.4, 55.6, 56.1, 63.3, 63.7, 127, 128.1,
129.1, 137.6; (R ) - [a]“ -1 6 .0 (c 0.015, CHCI3).
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ho ^

H N ^
C n
H

fS>)-(+)-4-Benzyl-2-(hydroxymethyl)piperazine (S )-94. The title compound was
similarly prepared and provided identical spectroscopic data. (S) - [a]“ +16.3 (c
0.018, CHCh).

N

CO H

^

.HCI

2

H2° ’ Dioxane
NaOH, Boc 20

"

Boc

0

Bn

_

N-fert-Butoxycarbonyl-N-benzylglycine 95. The synthesis of 95 is adopted
from the method of Le Bail.83 To a solution of benzyl glycine 100 (15.5 g, 76.8
mmol) in water and dioxane (190 mL each) was added NaOH (12.3 g, 307 mmol)
followed by di-fe/f-butyldicarbonate (18.4 g, 84.5 mmol) in portions. The reaction
was stirred at ambient temperature for 19 h then the contents were reduced to
half volume by evaporation in vacuo. To the reduced solution was added 140 mL
of CH2CI2 and the mixture stirred so the biphasic mixture was well mixed. The
mixture was cooled in an ice bath and 1 M HCI was added (dropwise) until a pH
of 3 - 4 was reached (~ 240 mL). The mixture was transferred to a separatory
funnel and the organic phase separated. The aqueous phase was extracted with
CH2CI2 (3 x 50 mL) and the combined extracts were dried (MgS 0 4 , do not use
K 2C O 3)

and concentrated to provide 95 as a pale solid (15.6 g, 76%). TLC Rf

0.24 (MeOH:CH 2Cl2 , 1:9). 1H NMR (400 MHz, CDCI3): (approximate

1 :1

mixture

of amide rotamers) 5 1.48 (s, 9H), 3.83 (s, 1H), 3.97 (s, 1H), 4.51 (s, 1H), 4.55 (s,
1H), 7.21 - 7.37 (m, 5H), 10.90 (bs, 0.7H, -CO 2 H); 13C NMR (100 MHz, CDCI3):

157

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

(approximate 1:1 mixture of amide rotamers)

6

28.2, 28.3, 47.5, 50.8, 51.6, 80.9,

81.2, 127.5, 127.6, 128.1, 128.6, 137.0, 137.1, 175.2, 175.8.

COzMe

(XI

C02 M6
J^O H

CH2CI2, Et3N,
r.t., 20 h

GENERAL PEPTIDE COUPLING PROCEDURE described for:
N-ferf-Butoxycarbonyl-N-benzylglycyl-D-serine Methyl Ester (R)-96.
synthesis of (R)-96 is adapted from the method of Naylor. 111
suspension of EDC.HCI (1.15 g,

6

The

To a stirring

mmol) in reagent grade CH 2CI2 (20 mL) was

added a solution of pentafluorophenol (1.5g, 8.1 mmol) in CH 2 CI2 (10 mL)
followed by a solution of N-Boc-N-Benzyl glycine 95 (1.32 g, 5.0 mmol) in CH 2CI2
(20 mL).

The solution was stirred at ambient temperature for 1 h then

triethylamine (2.5 mL,18 mmol) was added with additional CH 2CI2 (10 mL). The
amino acid methyl ester hydrochloride (serine methyl ester HCI for this example,
0.93 g,

6

for

h at ambient temperature and was then washed with aqueous sodium

20

mmol) was then added in small portions. The final solution was stirred

carbonate (1 M, 100 mL), aqueous citric acid (1 M, 100 mL) and water (50 mL).
The organic phase was dried (K2 CO 3) and concentrated to afford the crude
product that was purified by column chromatography (silica gel, EtOAc:Hexanes,
2:3 - 3:2) to afford (R)- 96 as a clear viscous oil (1.72 g, 94% yield). Rf = 0.52
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(MeOHiChfeCfe, 1:9). The spectroscopic data of (R)-96 was consistent with the
literature. 111

(^ 1 ° Y °
C 0 2Me

O ^N^>H
H

/
HO

N-tert-Butoxycarbonyl-N-benzylglycyl-L-serine Methyl Ester (S)-96. The title
compound was similarly prepared, and provided identical spectroscopic data.

1. MeOH, SOCI;
,Me

2. NH 4 OH, MeOH

.OH

(7?)-1-Benzyl-3-(hydroxymethyl)piperazine-2,5-dione (R)-97. The synthesis of
(R)-97 is adapted from the method of Naylor. 111 To a stirring 0 °C solution of
dipeptide (R)-B6 (1.76 g, 4.81 mmol) in methanol (10 mL) was slowly added
excess thionyl chloride (~ 1.7 mL) to avoid sputtering. Following the addition, the
solution was warmed to ambient temperature and allowed to stir for 2.5 h. The
solvent was evaporated and the residue triturated with ~20 mL diethyl ether to
produce a white solid that w as collected by filtration. T h e solid was dissolved in

methanol (20 mL) and treated with ammonium hydroxide (20 mL) at ambient
temperature. The solution was stirred for 16 h then the solvent was evaporated.
The

residue was

partitioned

between

saturated

NaHCC>3 (20
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mL) and

CHCI3:isopropyl alcohol, 4:1 (50 mL). The organic phase was separated and the
aqueous phase extracted with CHCI3 :isopropyl alcohol, 4:1 (4 x 30 mL).

The

combined organic phases were dried (K2CO 3) and concentrated to afford (R)-97
as a white solid ( 1 .0 1 g, 90%). R f = 0.19 (MeOhLChfeCh, 1:9). This material was
of sufficient purity for subsequent reactions and had spectroscopic data
consistent with the literature.111

HN

N -B n

HO\ ^
('S)-1-Benzyl-3-(hydroxymethyl)piperazine-2,5-dione

(S)-97.

The

title

compound was similarly prepared and provided identical spectroscopic data.

H2 N ^ C 0 2H

1. EtOH/H20 KOH
Benzylbromide ^
2. Acetic Acid

^
Bn

N,N-Dibenzylglycine 99. The synthesis of 99 is adopted from the method of
Velluz. 112 To a 45 °C solution of glycine (10 g, 133 mmol) and KOH (25 g, 445
mmol) in ethanol and water (75 mL each) was added (dropwise) benzyl bromide
(48.9 g, 286 mmol) from an addition funnel. Following the addition, the reaction
was heated at reflux for

2

h then cooled and stirred at ambient temp for 16 h.

The solvent was evaporated to a volume of 125 mL, transferred to a 400 mL
beaker and heated to boiling with stirring. To the boiling solution was carefully
added 10 mL of glacial acetic acid, producing a large mass of white precipitate.
The solids were collected by filtration, washed with 200 - 300 mL of cold water
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and then dried under vacuum give 99 as a white solid (27.2 g, 80%). 1H NMR
(400 MHz, DMSO-de): 5 3.16 (s, 2H), 3.74 (s, 4H), 7.21 - 7.38 (m, 10H), 12.4 (bs,
0.4H); 13C NMR (100 MHz, DMSO-d6): 5 52.9, 56.7, 127.0, 128.2, 128.5, 138.9,
172.2.

MeOH, HCI

Bn
Bn’

N

.C 0 2H

Bn’
H2, Pd/C

H
N

C 0 2H

.HCI

N-Benzylglycine Hydrochloride 100. The synthesis of 100 is adopted from the
method of Velluz . 112 To glycine 99 (10.26 g, 40.2 mmol) suspended in methanol
(140 mL) was added HCI (12 M, 5 mL, 60 mmol) and Pd/C (5%, 1.5 g). This
mixture was hydrogenated using a Parr apparatus until no more hydrogen was
consumed, repressurizing (max. 50 psi) the flask if necessary. The mixture was
filtered (Celite), and the filtrate concentrated to provide 100 as a white solid (7.8
g, 96%). 1H NMR (400 MHz, DMSO-d6): 5 3.79 (s, 2H), 4.15 (s, 2H), 7.40 (m,
3H), 7.57 (m, 2H), 9.87 (bs, 2H), 13.8 (bs, 0.5H); 13C NMR (100 MHz, DMSOd6): 5 46.2, 49.6, 128.6, 128.9, 130.2, 131.6, 167.6.

H N ^

c
h 2c
i2
CH
CI;

B o c N '^
H

(rRJ-4-Benzyl-1-(tert-butoxycarbonyl)-2-(hydroxymethyl)piperazine

(RJ-101.

To a stirring solution of alcohol (7?>94 (0.138 g, 0.669 mmol) in reagent grade

CH 2CI2

(1 0

mL) was added a solution of di-fe/f-butyldicarbonate (0.175 g, 0.803

mmol) in CH 2CI2 (4 mL). The reaction was stirred

20

h at ambient temperature

then the solvent was evaporated leaving an oily residue that was purified by
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column chromatography (silica gel, EtOAc:Hexanes, 2:3) to provide (R) - 101 as a
colorless oil (0.190 g, 93%). TLC R f 0.35 (EtOAc:Hexanes, 3:2). 1H NMR (400
MHz, CDCI3): 6 1.44 (s, 9H), 2.07 (td, J = 4.0, 11.7, 1H), 2.27 (dd, J = 4.0, 11.4,
1H), 2.80 (bd, 1H), 2.96 (m, 1H, bd shape), 3.30 - 3.55 (m, 3H, overlap of a
broad multiplit at 3.36 and singlet shape at 3.47), 3.87 (m, 2.5H, possible O H
overlap), 4.05 (bs, 1H), 7.23 - 7.35 (m, 5H); 13C NMR (100 MHz, CDCI3): 5 28.3,
41.3 (broad), 51.3 (broad), 52.4, 54.8, 62.9, 66.2, 79.8, 127.3, 128.4, 128.8,
137.0, 155.1 (broad).

o
B0Cf|l
HCL .ok
^

I
.NL

DMF, NaH
:____ ^
Bn

J ^ N ^ i
C>
I
I

n

Bn

(7?)-7-Benzyl-tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (7?>102. To a 0
°C solution of Boc alcohol (1R)-101 (0.046 g, 0.15 mmol) in dry DMF was added
sodium hydride (0.011 g, 0.45 mmol).

After stirring 5 min, the reaction was

stirred at ambient temperature for 4 h then the excess hydride was carefully
quenched with water and the mixture partitioned between water
(10 mL).

(8

mL) and ether

The organic phase was separated and the aqueous phase was

extracted with two additional portions of ether (15 mL). The combined organic
phases were dried (K2CO3) and concentrated to provide the crude product that
was purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3 - 4:1) to
provide (iRJ-102 as a colorless oil (0.025 g, 71%). TLC R f 0.14 (EtOAc:Hexanes,
3:2). 1H NMR (400 MHz, CDCI3): 5 1.93 (m, triplet shape, 1H), 2.10 (td, J = 3.7,
11.7 Hz, 1H), 2.78 - 2.91 (m, 2H), 3.11 (td, J = 3.7, 12.5 Hz, 1H), 3.55 (m, AB
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pattern, J = 13.2 Hz, 2H), 3.78 (m, dd shaped, 1H), 3.83 - 3.91 (m, 2H), 4.35 (m,
1H), 7.27 - 7.36 (m, 5H); 13C NMR (100 MHz, CDCI3): 5 41.0, 51.8, 53.1, 56.7,
62.8, 65.4, 127.4, 128.4, 129.0, 137.2, 156.9; GC/MS (El) m/z (M)+ 91 (base),
187, 232 (parent).

Formic Acid
•‘

N' Bn

Acetic Anhydride

n

HO\

N' gn
H

(RM+)-4-Benzyl-2-(hydroxymethyl)piperazine-1-carbaldehyde (7^-106. To a
0 °C solution of alcohol (R)- 94 (0.567 g, 2.75 mmol) in formic acid (8 8 %,

8

mL)

was added (dropwise) acetic anhydride (2.33 mL, 24.7 mmol). The reaction was
stirred for 30 min at 0 °C then warmed to ambient temperature. Following 1 h a
TLC showed consumption of starting material and the reaction was diluted with
ice, placed back in an ice bath and made basic with 4 N NaOH (~50 mL). The
aqueous mixture was further diluted with saturated N aH C 0 3 (30 mL) and
extracted with CH 2CI2 (4 x 20 mL). The combined extracts were dried (K2 C 0 3)
and concentrated to give an orange-brown oil that was purified by column
chromatography (silica gel, MeOH:CHCI3, 1:199 - 1:49) to afford (7?>106 as an
almost colorless oil (0.521g, 67%). TLC Rf 0.34 (MeOH:CH 2CI2, 1:9). 1H NMR
(400 MHz, CDCI3): (approximate 1:1 mixture of amide rotamers)

8

2.05 (td, J =

3.7, 11.7 Hz, 0.5H), 2.13 (td, J = 3.7, 11.7 Hz, 0.5H), 2.28 (dd, J = 4.0, 11.7 Hz,
1H), 2.87 (m, 1H), 2.90 - 3.02 (m, 1H, looks like dd), 3.12 (td, J = 4.0, 12.8 Hz,
0.5H), 3.41 - 3.59 (m, 3.5H), 3.64 - 3.75 (m, 1H), 3.85 (m, 0.5H, looks like dd),
3.97 (dd, J = 5.5, 11.4 Hz, 0.5H), 4.08 (dd, J = 7.3, 11.4 Hz, 0.5H), 4.20 (bd,
0.5H), 4.38 (m, 0.5H), 7.25 - 7.36 (m, 5H), 8.06 (s, 0.5H), 8.08 (s, 0.5H);
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13C

NMR (100 MHz, CDCI3): 5 37.3, 43.9, 49.1, 52.1, 52.9, 54.36, 54.44, 55.5, 62.7,
62.8, 63.6, 65.2, 127.5, 127.6, 128.4, 128.5, 128.8, 128.9, 136.8, 137.2, 161.8,
161.9; (R) - [a ] * 5 +56.1 (c 0.050, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ calcd.
for C 13H 19N2O 2 235.1447 found 235.1446.

0

HC' N ^
H

(S>(-)-4-Benzyl-2-(hydroxymethyl)piperazine-1 -carbaldehyde (S)-106.

The

title compound was similarly prepared and provided identical spectroscopic data.
(S) - [a ]*5 -5 3 .8 (c 0.052, CHCI3).

0

HCS

^

HCk . > ' ' l ^ N' Bn

DMF, NaH

° HC' N

^

CH3-I

H

H

(RM+)-4-Benzyl-2-(methoxymethyl)piperazine-1-carbaldehyde (RJ-107. To a
0 °C solution of alcohol fiRJ-106 (0.502 g, 2.14 mmol) in dry DMF (20 mL) was
added NaH (95%, 0.154 g, 6.43 mmol) in one portion.

After stirring 5 min,

iodomethane (0.319g, 2.25 mmol) was added (dropwise) and the mixture stirred
for 20 min at 0°C then at ambient temp for 1.5 h.

The excess NaH was

destroyed by the careful addition of water and the solution was diluted with 40
mL each of water and saturated NaHCCh. The aqueous mixture was extracted
with ether (2 x 40 mL) and ethyl acetate (2 x 40 mL). The combined extracts
were washed with brine (50 mL), dried (K2CO3) and concentrated to give a brown
oil that was purified by column chromatography (silica gel, MeOH.CHCb, 1:199 1:49) to afford (R) - 107 as an almost colorless oil (0.360 g, 69%). TLC Rf 0.49
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(MeOH:CH 2 CI2, 1:9).

1H NMR (400 MHz, CDCI3): (approximate 3:7 mixture of

amide rotamers) 5 2.00 - 2.12 (m, 1.3H), 2.18 (dd, J = 3.7, 11.7 Hz, 0.7H), 2.80 2.92 (m, 2H), 2.93 - 3.02 (m, 1H), 3.29 - 3.38 (m, 3H, two singlets overlapped),
3.41 - 3.76 (m, 5H, many intermixed peaks), 4.16 (bd, 0.7H), 4.60 (m, 0.3H),
7.25 - 7.35 (m, 5H, overlapped with CDCI3), 8.04 (s, 0.7H), 8.07 (s, 0.3H); 13C
NMR (100 MHz, CDCI3): 5 36.7, 42.7, 47.0, 52.3, 53.2, 53.7, 54.1, 58.8, 59.0,
62.5, 62.6, 69.5, 70.6, 127.2, 128.3, 128.7, 137.7, 161.3, 161.9; (R) - [a ]*5 +39.8
(c 0.036, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ calcd. for Ci 4 H2 iN 20 2 249.1603
found 249.1598.

OHC.

p

H

fS)-(-)-4-Benzy l-2-(methoxy methy l)piperazine-1 -carbaldehyde (S)-107. The
title compound was similarly prepared and provided identical spectroscopic data.
(S) - [ct]* 5 -3 7 .6 (c 0.036, CHCI3).

0

HC' V ^

THF, H SO
2

H

4

H

(R)-(-)-1-Benzyl-3-(methoxymethyl)piperazine (R)-108.

A solution of the

protected methylether (1R)-107 (0.320 g, 1.29 mmol) in THF (3 mL) and 4 M
H2 S 0 4 (9 mL) was heated at 55 °C for 5 h. After cooling, the reaction contents
were poured into 20 mL of cold (-1 0 °C) 4 M NaOH and diluted with 20 mL of
saturated NaHCC>3 . The mixture was extracted with CH 2 CI2 ( 4 x 1 5 mL) and the
combined extracts dried (K2 COs) and concentrated to provide (7?)-108 as a pale
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oily solid (0.274 g, 96%). This product was of adequate purity for the subsequent
transformations. TLC R ,0.14 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3):
6

1.85 (t, J = 10.3 Hz, 1H), 2.11 (td, J = 3.3, 11.0 Hz, 1H), 2.35 (bs, 1H, NH), 2.74

(m, 2H, triplet shape), 2.90 (m, 1H, td shape), 2.96 - 3.06 (m, 2H), 3.25 - 3.36
(m, 5H, OC /-/3 singlet present at 3.33), 3.50 (m, AB pattern, J = 13.2 Hz, 2H),
7.22 - 7.33 (m, 5H, overlapped with CDCI3); 13C NMR (100 MHz, CDCI3):

8

45.2,

53.8, 54.4, 55.9, 59.0, 63.4, 75.1, 126.9, 128.1, 129.1, 138.0; (R) - [ct]*5-1 7 .4 (c
0.027, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ calcd. for Ci 3 H2 iN 20 221.1654
found 221.1654.

H N ^
H

(,S>(+)-1-Benzyl-3-(methoxymethyl)piperazine (SJ-108.

The title compound

was similarly prepared and provided identical spectroscopic data.

(S) - [a]“

+14.4 (c 0.030, CHCI3).

HN'

Et2 0 , o-BuLi;
N

^

4*
H

Bn

N

2-chloroquinoline

(,R)-(+)-2-[4-Benzyl-2-(methoxymethyl)piperazin-1-yl]quinoline (7?J-109. To a
0 °C solution of piperazine (R)- 108 (0.273 g, 1.24 mmol) in dry ether (16 mL)
under argon was added (dropwise) a solution of n-butyllithium in hexane (2.45 M,
1.24 mmol) producing a clear yellow solution. After stirring 20 min a solution of
2-chloroquinoline (0.134 g, 0.821 mmol) in ether (3 mL) was added (dropwise)
and the solution allowed to stir for 10 min at 0 °C then at ambient temperature for
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16 h.

The reaction contents were diluted with ether (15 mL), washed with

saturated NaHC 0 3
concentrated

(2 x 20 mL) and brine (20 mL), dried (K2CO 3) and

to give the

crude

material that was

purified

by column

chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide (7?>109 as a thick,
light yellow oil (0.275 g, 96%). TLC Rf 0.42 (EtOAc:Hexanes, 2:3). 1H NMR (400
MHz, CDCI3): 5 2.17 - 2.27 (m, 2H), 2.95 (bd, J = 10.3 Hz, 1H), 3.11 (bd, J =
11.7

Hz, 1H), 3.21 (m, 1H), 3.33 (s, 3H), 3 .4 9 -3 .6 3 (m, 3H), 3.87 (m, 1H), 4.45

(bd, 1H), 4.57 (bs, 1H), 6.98 (d, J = 9.2 Hz, 1H), 7.21 (m, 1H), 7.27 (m, 1H,
overlapped with CDCI3), 7.31 - 7.39 (m, 4H), 7.52 (m, 1H), 7.59 (d, J = 8.1 Hz,
1H), 7.68 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz); 13C NMR (100 MHz, CDCI3): 5
40.8, 51.6, 53.1, 59.0, 62.7, 69.8, 109.4, 122.1, 122.9, 126.5, 127.0, 127.1,
128.2, 128.8, 129.4, 137.3, 138.3, 147.9, 156.8;

(R) - [cr]* 5 +53.2 (c 0.028,

CHCI3).

H

fS)-(-)-2-[4-Benzyl-2-(methoxymethyl)piperazin-1-yl]quinoline (S)-109.

The

title compound was similarly prepared and provided identical spectroscopic data.
(S) - [a ]* 5 -5 2 .8 (c 0.027, CHCI3).
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v

HN
N -B n
H0X „ W
H O

0

►
----------------cat. p-TsOH, CH2CI2

■ K

HN
THP0\ , . W
H

N -B n
O

fS)-1-Benzyl-3-((tetrahydro-2H-pyran-2-yloxy)methyl)piperazine-2,5-dione
(S)-119. To a 0 °C suspension of piperazinedione (SJ-97 (0.913 g, 3.90 mmol) in
HPLC grade CH 2CI2 (40 mL) under argon was added dihydropyran (1.64 g, 19.5
mmol) followed by p-toluenesulfonic acid monohydrate (0.025 g, 0.13 mmol).
The flask was swirled to remove solids stuck to the sides and the sides were
rinsed with CH 2CI2 as needed. After ~30 minutes, all solids had dissolved and
the reaction was shown complete by a TLC that showed a new, more non-polar
spot.

The reaction was poured into an aqueous mixture of 30 mL each of

saturated NaHC 0 3 , brine and water. The organic phase was separated and the
aqueous phase extracted with CH 2CI2 ( 3 x 1 5 mL). The combined extracts were
dried (K2 CO 3) and concentrated giving ~ 2 g of crude material.
material was dissolved in

~20

The crude

mL CH 2CI2 and 4 g of silica gel was added. The

mixture was concentrated and the solid was loaded onto a silica gel column and
chromatographed with MeOI-LChhCh, 1:39, as eluent. When the product began
to elute the solvent was switched to MeOhLChhCh, 1:19, to provide (SJ-119 as a
white solid (1.153 g, 93%) and a 6:4 diastereomeric mixture.

TLC Rf 0.32

(MeOH:CH 2CI2> 1:9). 1H NMR (400 MHz, CDCI3): (approximately 6:4 mixture of
diastereomers) 5 1.40 - 1.70 (m,

6

H), 3.50 (m, 1H), 3.69 - 3.77 (m, 2H), 3.79 -

3.85 (m, 1H), 3.92 (s, 0.6H), 3.96 (s, 0.4H), 4.05 (dd, J = 2.9, 9.9 Hz, 0.4H), 4.12
(dd, J = 5.5, 10.3 Hz, 0.6H), 4.23 (m, 1H), 4.33 (d, J = 14.7 Hz, 0.4H), 4.38 (d, J
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= 14.7 Hz, 0.6H), 4.62 (m, 1H), 4.83 (d, J = 14.7 Hz, 0.6H), 4.90 (d, J = 14.7 Hz,
0.4H), 6.41 (bs, 0.4H, NH), 6.52 (bs, 0.6H, NH), 7.24 - 7.36 (m, 5H); 13C NMR
(100 MHz, CDCI3): 5 18.9, 19.0, 25.1, 30.1, 30.2, 49.2, 49.3, 49.7, 49.8, 55.9,
62.0, 62.1, 69.5, 69.8, 98.9, 99.1, 128.1, 128.2, 128.5, 128.8, 128.9, 135.0,
164.4, 164.6, 166.0, 166.3.

‘K

HN

N -B n

THPCT

(7^-1-Benzyl-3-((tetrahydro-2H-pyran-2-yloxy)methyl)piperazine-2,5-dione
(R)-119.

The title compound was similarly prepared and provided identical

spectroscopic data.

O
/" V
HN
N -B n

T H P O ^ ,..^
H

THF, UAIH4
----------------►

HI)J^
THPCL

reflux2h

Bn

O

(R)A -Benzyl-3-[(tetrahydro-2H-pyran-2-yloxy)methyl]piperazine

20. To

a 0 °C suspension of THP ether (S) - 119 (1.153 g, 3.62 mmol) in dry THF (60 mL)
under argon was added LiAIH4 (0.566 g, 14.89 mmol) in small portions,
producing a gentle effervescence. The mixture was maintained on ice until the
bubbling stopped, then heated at reflux for 2 h. The solution was cooled, stirred
1

h then the excess LiAIH4 was quenched by the careful, sequential addition of

0.6 mL water, 1.2 mL 4 M NaOH solution and 0.6 mL water.

The solids that

formed will filtered (Celite) and the filtrate concentrated to give (R) - 120 as a pale
colored oil (1.076 g, quantitative). TLC Rf 0.14 (MeOH:CH 2 CI2, 1:9). 1H NMR
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(400 MHz, CDCI3): 6 1.44 - 1.62 (m, 4H), 1.64 - 1.74 (m, 1H), 1.74 - 1.94 (m,
2H), 2.08 - 2.17 (m, 1H), 2.35 (bs, 1H, NH), 2.71 - 2.79 (m, 2H), 2.87 - 2.95 (m,
1H), 2.95 - 3.08 (m, 2H), 3.26 (m, 0.5H), 3.36 (dd, J = 4.0, 9.9 Hz, 0.5H), 3.45 3.52 (m, 3H, large singlet like peak overlapped), 3.61 - 3.73 (m, 1H), 3.78 - 3.86
(m,

1 H),

4.56 (m, 1H);

13C NMR (100 MHz, CDCI3): 6 19.4, 19.5, 25.3, 30.5,

128.2, 129.1, 137.9.

T H P O ^ /N
H

fSJ-1 -Benzy l-3-[(tetrahydro-2H-pyran-2-y loxy)methyl]piperazine

fS)-120.

The title compound was similarly prepared and provided identical spectroscopic
data.

THPO^sJv^N

2-CI-quinoline

THPO^

N

(7?>2-[4-Benzyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]piperazin-1yl]quinoline (iRJ-121. To a 0 °C solution of THP piperazine (iRJ-120 (0.533 g,
1.84 mmol) in dry ether (25 mL) under argon was added (dropwise) n-butyllithium
(2.33 M in hexane, 1.84 mmol) producing a brown-yellow turbid solution that
stirred 20 min. A solution of 2-chloroquinoline (0.200 g, 1.22 mmol) in ether (5
mL) was slowly added (dropwise) and the solution was then allowed to stir for 20
min at 0 °C then at ambient temperature for 16 h. The reaction contents were
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diluted with ether (15 mL), washed with saturated NaHC 0 3 (2 x 20 mL) and brine
( 2 x 1 0 mL), dried (K2CO3) and concentrated to give the crude material that was
purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide
(R)- 121 as a light yellow oil (0.471 g, 93%). TLC Rf 0.41 (EtOAc:Hexanes, 2:3).
1H NMR (400 MHz, CDCI3): (approximately 6:4 mixture of diastereomers) 8 1.30
- 1.86 (m,

6

H), 2.18 - 2.34 (m, 2H), 2.99 (m, 1H), 3.13 (m, 0.6H, doublet shape),

3 .1 9 -3 .3 4 (m, 1.4H), 3 .4 2 -3 .5 9 (m, 2.3H), 3.60 - 3.71 (m, 1H), 3 .7 4 -3 .8 4 (m,
1H), 3.90 (m, 1.3H, leaning doublet shape), 4.19 (m, 0.3H, triplet shaped), 4.48 4.68 (m, 3H, broad overlaps), 7.04 (d, J = 9.2 Hz, 1H), 7.23 (m, 1H), 7.30 (m,
1H), 7 .3 4 -7 .4 4 (m, 4H), 7.55 (m, 1H), 7.60 (m, 1H, doublet shape), 7.73 (m, 1H,
doublet shape), 7.87 (m, 1H, two unsymmetrical doublets offset); 13C NMR (100
MHz, CDCI3): 8 18.9, 19.1, 25.2, 25.3, 30.3, 40.4, 40.5, 51.8, 52.0, 52.6, 53.1,
53.4, 61.6, 61.9, 62.7, 62.9, 64.2, 64.6, 98.2, 99.2, 109.4, 109.7, 121.9, 122.8,
126.4, 126.9, 127.0, 128.1, 128.8, 128.9, 129.2, 136.8, 137.0 138.2, 138.3,
147.8, 156.9.

N ^|
T H P O ^ ^ NN

Bn

H

fS)-2-[4-Benzyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]piperazin-1yl]quinoline (S)- 121. The title compound w as similarly prepared and provided
identical spectroscopic data.
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MeOH, HCI

N

T H P O ^ ...^ N .Bn
H

(R)-(+)-2-[4-Benzyl-2-(hydroxymethyl)piperazin-1-yl]quinoline (R)A22.

To a

solution of starting material (iRJ-121 (0.302 g, 0.723 mmol) in reagent grade
methanol (15 mL) was added conc. HCI (1.3 mL,1.6 mmol). The solution was
stirred overnight
mL).

(2 1

h) and was then diluted carefully with saturated NaHCC>3 ( 2 0

The methanol was evaporated and the aqueous mixture extracted with

CH 2CI2 ( 3 x 8 mL). The combined extracts were dried (K2CO 3) and concentrated
to give (R)-122 as an amber solid (0.250 g, quantitative). This material was pure
enough for subsequent transformations. TLC Rf 0.12 (EtOAc:Hexanes, 2:3). 1H
NMR (400 MHz, CDCI3):

8

2.26 (td, J = 3.7, 11.4 Hz, 1H), 2.41 (dd, J = 4.0, 11.4

Hz, 1H), 2.97 (m, 1H), 3.09 (m, 1H), 3.45 - 3.65 (m, 3H), 3.99 (dd, J = 3.3, 11
Hz, 1H), 4.10 (bd, 1H), 4.17 (dd, J = 5.9, 11 Hz, 1H, overlapped with previous bd
at 4.10), 4.80 (bm, 1H), 4.97 (bs, 0.2H, -OH), 6.96 (d, J = 9.2 Hz, 1H), 7.24 (m,
1H, overlapped with CDCI3), 7.31 (m, 1H), 7.33 - 7.40 (m, 4H), 7.54 (m, 1H),
7.60 (bd, J = 8.1 Hz, 1H), 7.69 (bd, J = 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H); 13C
NMR (100 MHz, CDCI3):

8

42.4, 52.5, 53.0, 55.4, 62.9, 65.2, 109.9, 122.4, 122.9,

126.1, 127.1, 127.3, 128.4, 128.8, 129.5, 137.4, 137.5, 147.2, 157.4; (R) - [0 ]“
+226.1 (c 0.025, CHCI3).
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H

('S>(-)-2-[4-Benzyl-2-(hydroxymethyl)piperazin-1-yl]quinoline (S)- 122.

The

title compound was similarly prepared and provided identical spectroscopic data.
(S) - [a ]* 5 -2 2 6 .3 (c 0.016, CHCI3).

DMF, NaH
Allyl bromide

(7?X+)-2-[4-Benzyl-2-(allyloxymethyl)piperazin-1-yl]quinoline (R)- 123. To a 0
°C solution of the alcohol (R)- 122 (0.241 g, 0.723 mmol) in dry DMF (11 mL)
under argon was added sodium hydride (95%, 0.052 g, 2.17 mmol). The turbid
solution was stirred 15 min then allyl bromide (0.092 g, 0.759 mmol) was added
(dropwise).

The reaction was stirred 10 min at 0 °C then warmed to ambient

temperature and stirred for 18 h.
careful addition of
further with

8

8

The excess hydride was destroyed by the

mL of saturated NaHC 0 3 solution and the mixture diluted

mL of water. This aqueous mixture was extracted with ether (4 x

15 mL) and the combined extracts were washed with brine ( 2 x 1 0 mL), dried
(K2CO3) and concentrated to give the crude product that was purified by column
chromatography (silica gel, EtOAc:Hexanes, 1:9 - 1:3) to provide (R^-123 an an
amber oil (0.214 g, 79%).

TLC Rf 0.46 (EtOAc:Hexanes, 2:3).

1H NMR (400

MHz, CDCI3): 5 2.20 - 2.29 (m, 2H), 2.98 (m, 1H, doublet shape), 3.17 - 3.27 (m,
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2 H), 3.51 - 3.66 (m, 3H), 3.94 - 4.05 (m, 3H), 4.48 (bd, J = 12.8 Hz, 1H), 4.61
(bs, 1H), 5.13 (dq, J = 1.5, 10.4 Hz, 1H), 5.20 (dq, J = 1.5, 17.2 Hz, 1H), 5.83 (m,
1H), 7.01 (d, J = 9.2 Hz, 1H), 7.23 (m, 1H), 7.30 (m, 1H), 7.34 - 7.42 (m, 4H),
7.55 (m, 1H), 7.61 (dd, J = 1.1, 8.1 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.87 (d, J =
9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 40.8, 51.8, 53.0, 53.1, 62.8, 67.2,
72.0, 109.4, 116.7, 122.1, 122.9, 126.5, 127.0, 127.1, 128.2, 128.8, 129.3, 134.7,
137.3, 138.3, 147.9, 156.8; (R) - [a ]* +51.3 (c 0.017, CHCI3).

H

Bn

('S>(-)-2-[4-Benzyl-2-(allyloxymethyl)piperazin-1-yl]quinoline (S)-123.

The

title compound was similarly prepared and provided identical spectroscopic data.
(S) - [a ]*5 -5 1 .4 (c 0.015, CHCI3).

..

N ^|

2. H20 2, NaOH

N ' R_

H

(iR>(+)-2-[4-Benzyl-2-[(3-hydroxypropoxy)methyl]piperazin-1-yl]quinoline
(iRJ-124. To a 0 °C solution of the allyl ether (R)-MZ (0.214 g, 0.57 mmol) in dry
THF

(6

mL) under argon was added 9-BBN (0.5 M in THF, 1.55 mmol).

Following the addition, the reaction was heated to 60 °C and maintained for 1 h.
The contents were cooled to 0 °C and 3.5 mL of 1 M NaOH was added
(dropwise) followed by an equal volume of 30% H2O 2 . After stirring ~10 min the
THF was evaporated and the residue partitioned between CH 2CI2 and saturated
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NaHC 0 3 (25 mL each).

The organic phase was separated and the aqueous

phase extracted with CH 2 CI2 ( 3 x 1 5 mL). The combined organic extracts were
dried (K2CO 3) and concentrated to give the crude material that was purified by
column chromatography (silica gel, EtOAc:Hexanes, 1:9 - 3:2) to afford (iRJ-124
as an amber oil (0.163g, 73%). TLC Rf 0.1 (EtOAc:Hexanes, 2:3). 1H NMR (400
MHz, CDCI3): 5 1.67 (p, J = 5.9 Hz, 2H), 2.17 - 2.27 (m, 2H), 2.40 (bs, 1H), 2.97
(bd, J = 11.0 Hz, 1H), 3.07 (bd, J = 11.4 Hz, 1H), 3.25 (td, J = 2.9, 12.5 Hz, 1H),
3.44 - 3.69 (m, 7H), 3.87 (m, 1H, triplet shape), 4.39 (bd, J = 12.8 Hz, 1H), 4.64
(bs, 1H), 6.97 (d, J = 9.2 Hz, 1H), 7.21 (m, 1H), 7.26 - 7.32 (m, 1H), 7.32 - 7.40
(m, 4H), 7.53 (m, 1H), 7.59 (m, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz,
1H); 13C NMR (100 MHz, CDCI3): 5 32.0, 40.8, 51.5, 53.1, 53.2, 61.3, 62.8, 68.5,
70.1, 109.4,

122.1, 122.9, 126.4, 127.06, 127.12, 128.2, 128.9, 129.4, 137.3,

138.2, 147.8, 156.8; (R) - [a]“ +46.3 (c 0.016, CHCI3).

H

(rS>(-)-2-[4-Benzyl-2-[(3-hydroxypropoxy)methyl]piperazin-1-yl]quinoline
(S)- 124.

The title compound was similarly prepared and provided identical

spectroscopic data. (S) - [a]“ -4 7 .2 (c 0.013, CHCI3).
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CH 2 CI2 , Pyridine
HO

Tosyl chloride
'Bn

'Bn

fSM-)-2-[4-Benzyl-2-[(3-(4-methylbenzenesulfonate)propoxy)methyl]
piperazin-1-yl]quinoline fSJ-125. To a 0 °C solution of alcohol (SJ-124 (0.196
g, 0.50 mmol) in dry CH 2CI2 (4 mL) and pyridine (400 pL) was added ptoluenesulfonyl chloride (0.114 g, 0.60 mmol) in one portion.

The flask was

sealed under argon and maintained in the ice bath until the ice bath warmed to
ambient temperature.

Following 26 h, the reaction contents were partitioned

between saturated NaHC 0 3 (20 mL) and CH 2CI2 (10 mL). The organic phase
was separated and the aqueous phase was extracted with CH 2 CI2 (3 x

10

mL).

The combined organic extracts were dried (K2CO 3) and concentrated to give the
crude material that was purified by column chromatography (silica gel,
EtOAc:Hexanes, 1:9 - 1:3) to afford fSJ-125 as a pale colored oil (0.127 g, 47%).
TLC Rf 0.27 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.73 (p, J =
6.2 Hz, 2H), 2 .1 6 -2 .2 5 (m, 2H), 2.4 (s, 3H), 2.94 (bd, J = 11.0 Hz, 1H), 3.02 (bd,
J = 11.4 Hz, 1H), 3.18 (m, 1H), 3 .3 8 -3 .6 2 (m, 5H), 3.78 (t, J =

8 .8

Hz, 1H), 3.97

(t, J = 6.2 Hz, 2H), 4.42 (bd, 1H), 4.52 (bs, 1H), 6.95 (d, J = 9.5 Hz, 1H), 7.19 7.24 (m, 1H), 7.25 - 7.30 (m, 3H, tosylate doublet dominates shape), 7.30 - 7.38
(m, 4H), 7.52 (m, 1H), 7.59 (m, 1H), 7.67 (bd, J = 8.1 Hz, 1H), 7.73 (d, J = 8.1
Hz, 2H), 7.85 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 21.5, 29.2, 40.6,
51.5, 53.0, 53.1, 62.7, 66.4, 67.6, 67.9, 109.4, 122.1, 122.8, 126.4, 127.0, 127.1,
127.8, 128.2, 128.8, 129.3, 129.7, 133.0, 137.2, 138.3, 144.5, 147.8, 156.8; (S) [a]“ -2 5 .0 (c 0.0075, CHCI3).
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fR>(+)-2-[4-Benzyl-2-[(3-(4-methylbenzenesulfonate)propoxy)methyl]
piperazin-1-yl]quinoline (R)-125.

The title compound was similarly prepared

and provided identical spectroscopic data.

(R) - [a f* This compounds optical

rotation was never evaluated.

THF, TBAF

('Sy)-(-)-2-[4-Benzyl-2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline

(S)-

126. To a solution of tosylate (SJ-125 (0.128 g, 0.234 mmol) in dry THF (2.5 mL)
was added a solution of TBAF in THF (1 M, 0.35 mL, 0.352 mmol). The flask
was sealed under argon and heated at 55 - 60 °C for 3.5 h. After cooling, the
solvent was evaporated and the residue purified by column chromatography
(silica gel, EtOAc:Hexanes, 1:9 - 1:3) to afford (S)-126 as a pale colored oil
(0.071 g, 78%). TLC Rf 0.45 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3):
5

1.80 (dp,

J F- h

= 25.6 Hz, FCH 2CH2-,

J H- h

= 6.2 Hz, 2H), 2.20 - 2.28 (m, 2H),

2.98 (m, 1H), 3.11 (m, 1H), 3.23 (td, J = 3.7, 12.8 Hz, 1H), 3.46 - 3.66 (m, 5H),
3.89 (t, J

= 8 .8

Hz, 1H), 4.35 (dt,

J F-h

= 46.9, FCH2-, Jh-h = 5.9 Hz,

2

H), 4.45 (bd,

1H, overlapped with signal at 4.35), 4.59 (bm, 1H), 6.99 (d, J = 9.2 Hz, 1H), 7.22
(m, 1H), 7.26 - 7.32 (m, 1H), 7.32 - 7.41 (m, 4H), 7.53 (m, 1H), 7.60 (m, 1H),
7.70 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3):
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6

30.7 (d, J C-f = 19.8 Hz, FCH 2 CH2-), 40.7, 51.6, 52.9, 53.3, 62.8, 66.7 (d, JC-f =
4.6 Hz, FCH 2 CH 2 CH2-), 67.8, 81.1 (d, J C-f = 163.3 Hz, FCH2-), 109.4, 122.1,
122.9, 126.5, 127.0, 127.1, 128.2, 128.8, 129.4, 137.2, 138.3, 147.8, 156.8; (S) [a £ 5 -3 9 .9 (c 0.0048, CHCI3).

'B n

(7?>(+)-2-[4-Benzyl-2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline
126.

(R)-

The title compound was similarly prepared and provided identical

spectroscopic data. (R) - [a]“ +40.2 (c 0.0098, CHCI3).

CH2CI2, DAST

(ft)-(+)-2-[4-Benzyl-2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline

(R)-

126. ALTERNATE ROUTE To a -78 °C solution of alcohol (R )-U 4 (0.111 g,
0.283 mmol) in dry CH 2CI2 (9 mL) under argon was added DAST (0.061 g, 0.38
mmol). The insulated bath was allowed to warm to ambient temperature over 24
h then the reaction was diluted with CH 2CI2 (10 mL) and saturated NaHC 0 3
solution (20 mL).

The organic phase was separated and the aqueous phase

extracted with CH 2CI2 ( 2 x 1 0 mL). The combined organic extracts were dried
(K2C 0 3 ), and concentrated to give the crude product that was purified by column
chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide (R)- 126 as a pale oil
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(0.069 g, 62%). TLC Rf 0.45 (EtOAc:Hexanes, 2:3). Spectroscopic data for (R)-

126 with DAST was identical to that reported for (SJ-126 generated via TBAF
fluorination.

2. MeOH, A

fR>(+)-2-[2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (RJ-127. To a
0 °C solution of fluoride (R)- 126 (0.098 g, 0.249 mmol) in dry dichloroethane (5
mL) under argon was added 1-chloroethyl chloroformate (0.142 g, 0.994 mmol).
After stirring 5 min, the reaction was heated at reflux for 7 h, cooled, then stirred
at ambient temperature for 10 h. The volatile components were evaporated and
the residue was dissolved in methanol (10 mL) and heated at 60 °C for 1.5 h.
The solvent was evaporated to dryness and the residue partitioned between
CH 2CI2 and saturated NaHCC>3

(1 0

mL each). The organic phase was separated

and the aqueous phase was extracted with three additional portions of CH 2CI2 .
The combined organic extracts were dried (K2CO 3) and concentrated to give the
crude product that was immediately purified by column chromatography (silica
gel, EtOAc:Hexanes, 4:1, then MeOH:CH 2Cl2 , 1:39 - 1:9) to provide (7?>127 as a
pale colored oil (0.065 g, 87%). TLC Rf 0.13 (MeOH:CH 2CI2, 1:9). 1H NMR (400
MHz, CDCI3):

6

1.89 (dp,

J F- h

= 25.6 Hz, FCH 2 CH2-,

J H- h

= 6.2 Hz, 2H), 2.20 (bs,

1H, NH), 2.88 (m, 1H), 3.00 (m, 1H), 3.12 - 3.21 (m, 2H), 3.32 (bd, J = 12.1 Hz,
1H), 3.55 - 3.61 (m, 3H), 3.90 (m, 1H), 4.36 (bd, 1H), 4.47 (dt,
J h -h

J F- h

= 47.2, FCH2,

= 5.9 Hz, 2H), 4.59 (bm, 1H), 6.97 (d, J = 9.5 Hz, 1H), 7.21 (m, 1H), 7.52 (m,
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1H), 7.59 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H);
13C NMR (100 MHz, CDCI3): 5 30.7 (d, JC-f = 19.8 Hz, FC H 2 CH2-), 41.3, 46.0,

46.2, 50.7, 66.9 (d, JC-f = 6.1 Hz, FCH 2 CH 2 CH2-), 68.0, 81.2 (d, JC- f = 163.2 Hz,
FCH2-), 109.2, 122.2, 122.9, 126.5, 127.1, 129.4, 137.3, 147.8, 156.9; ( R ) - [cr] * 5

+56.2 (c 0.0065, CHCI3 ).

n

fS>(-)-2-[2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (SJ-127.

The

title compound was similarly prepared and provided identical spectroscopic data.
(S)

- [«]£ -5 6 .7 (c 0.0031, CHCI3 ).

CH 2 CI2, Pyr,
DMAP (cat.)

Ac20

(7?>2-[2-(acetoxymethyl)-4-benzylpiperazin-1-yl]quinoline (R )-i28. To a 0 °C
solution of alcohol (R )-M 2 (0.212 g, 0.64 mmol) in dry CH 2CI2 (14 mL) under
argon was added pyridine (0.1 mL, 1.27 mmol), acetic anhydride (0.072 mL, 0.76
mmol) and 4-dimethylaminopyridine (DMAP, 0.004 g, 0.03 mmol). After stirring
at

0

°C for 4 h, the reaction was shown complete by TLC, with the formation of a

new, non-polar spot. The reaction contents were diluted with 10 mL of CH 2CI2
and washed with saturated NaHCC>3

(2

x 20 mL). The organic phase was dried

(K2CC>3) and concentrated to provide the crude material that was purified by
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column chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide (R)- 128 as
an oil that slowly formed a pale solid upon standing (0.226 g, 95%). TLC R f 0.42
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.76 (s, 3H), 2.21 - 2.30
(m, 2H), 2.96 - 3.03 (m, 2H), 3.35 (td, J = 3.3, 12.5 Hz, 1H), 3.45 (d, J = 13.2 Hz,
1H), 3.65 (d, J = 13.2 Hz, 1H), 4.37 - 4.51 (m, 3H), 4.85 (bm, 1H), 6.99 (d, J =
9.2 Hz, 1H), 7.23 (m, 1H), 7.29 (m, 1H), 7.32 - 7.41 (m, 3H), 7.54 (m, 1H), 7.60
(bd, J = 8.1 Hz, 1H), 7.70 (bd, J = 8.4 Hz, 1H), 7.89 (bd, J = 9.2 Hz, 1H); 13C
NMR (100 MHz, CDCI3):

8

20.7, 40.4, 50.3, 52.8, 53.2, 61.4, 62.7, 109.2, 122.2,

122.9, 126.6, 127.1, 128.2, 128.8, 129.4, 137.3, 138.2, 147.7, 156.8, 171.0.

1. ACE-CI, DCE
reflux
2. MeOH, A

O

fiR)-2-[2-(acetoxymethyl)piperazin-1-yl]quinoline (R)- 129. To a 0 °C solution
of acetate (R)- 128 (0.150 g, 0.4 mmol) in dry dichloroethane

(6

mL) under argon

was added 1-chloroethyl chloroformate (0.114 g, 0.8 mmol). After stirring 10 min,
the flask was heated at reflux for

2

h then cooled and the solvent evaporated.

The residue was dissolved in methanol

(6

mL) and heated at 60 - 65 °C for 1.25

h then the methanol was evaporated. The residue was dissolved in 20 mL 1 M
HCI and washed with CH 2CI2 ( 3 x 1 0 mL).

The aqueous phase was carefully

made basic with saturated N aH C 0 3 and extracted with CH 2CI2 ( 4 x 1 0 mL). The
combined extracts were dried (Na 2 SC>4) and concentrated to give (R )-M 9 as a
pale colored oil that formed a solid upon standing (0.108 g, 95%). TLC R f 0.22
(MeOH:CH 2 CI2, 1:9). 1H NMR (400 MHz, CDCI3):

8

1.80 (bs, 1H), 1.86 (s, 3H),
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2.84 (td, J = 2.9, 11.7 Hz, 1H), 2.99 (dd, J = 3.3, 12.5 Hz, 1H), 3.09 - 3.23 (m,
3H), 4 .3 0 - 4 .4 0 (m, 2H), 4.46 (dd, J = 8.1, 11.0 Hz, 1H), 4.77 (bm, 1H), 6.96 (d,
J = 9.2 Hz, 1H), 7.20 (m, 1H), 7.51 (m, 1H), 7.58 (bd, J = 7.7 Hz, 1H), 7.68 (bd, J
= 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H);

13C NMR (100 MHz, CDCI3): 5 20.7,

40.8, 45.9, 46.0, 49.7, 60.5, 109.0, 122.2, 122.8, 126.5, 127.0, 129.4, 137.3,
147.6, 156.9, 170.9.

0 2N

o 2n

1. ACE-CI, DCE
reflux
Bn

NH

2. MeOH, A

2-[2-Phenylpiperazin-1-yl]-6-nitroquinoline 135.

To a solution of quipazine

174 (0.097 g, 0.23 mmol) in dry dichloroethane (4 mL) under argon was added 1chloroethyl chloroformate (0.066 g, 0.46 mmol).

After stirring for 5 min the

reaction was heated at reflux for 2 h, then stirred at ambient temp for 16 h. The
solvent was evaporated and the residue dissolved in methanol

(8

mL) and

heated at 65 °C for 2 h. The methanol was evaporated and the residue was
dissolved in 1 M HCI (20 mL) and washed with CH 2CI2 ( 4 x 1 5 mL). The aqueous
phase was made basic with 4 M NaOH, diluted with saturated N aH C 0 3 (20 mL)
and extracted with CH 2CI2 (4 x 20 mL).

The combined organic extracts were

dried (K2 C 0 3) and concentrated to give 135 as a yellow foam (0.070 g, 91%).
TLC

0.31 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.89 (bs, NH,

1H), 3.02 (td, J = 3.7, 12.1 Hz, 1H), 3.18 (bm, doublet shape, J = 12.1 Hz, 1H),
3.32 - 3.42 (m, 2H), 3.71 (bd, J = 13.2 Hz, 1H), 4.68 (bd, J = 13.2 Hz, 1H), 5.69
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(bs, 1H), 6.98 (d, J = 9.5 Hz, 1H), 7.24 - 7.29 (m, 1H, overlapped with CDCI3),
7.29 - 7.38 (m, 4H), 7.65 (d, J = 9.5 Hz, 1H), 7.93 (d, J = 9.2 Hz, 1H), 8.29 (dd, J
= 2.6, 9.5 Hz, 1H), 8.52 (d, J = 2.6 Hz, 1H); 13C NMR (400 MHz, CDCI3): 5 41.3,
45.7, 49.5, 54.8, 110.7, 121.1, 123.6, 124.2, 127.0, 127.1, 127.2, 128.9, 138.8,
138.9, 141.8, 151.5, 158.8; HRMS (ESI-TOF) m/z (M + H)+ calcd. for C i 9 H i 9 N40 2
355.1508 found 355.1507.

1. ACE-CI, DCE
reflux
NH

2. MeOH, A

2-[2-Benzylpiperazin-1-yl]-6-nitroquinoline 136.

To a solution of quipazine

175 (0.083 g, 0.19 mmol) in dry dichloroethane (4 mL) under argon was added 1chloroethyl chloroformate (0.054 g, 0.38 mmol).

The reaction was heated at

reflux for 2 h then stirred at ambient temperature for 16 h.
evaporated and the residue dissolved in methanol

(8

The solvent was

mL) and heated at 65 °C for

2 h. The mixture was concentrated and the residue was dissolved in 20 mL 1 M
HCI and washed with CH 2CI2 ( 4 x 8 mL). The aqueous phase was made basic
with 4 M NaOH, diluted with saturated N aH C 0 3 (10 mL) and extracted with
CH 2CI2 ( 3 x 8 mL). The combined extracts were dried (K2C 0 3) and concentrated
to give 136 as a yellow-orange foam (0.056 g, 85%). Rf 0.24 (MeOH:CH 2 Cl2 ,
1:9). 1H NMR (400 MHz, CDCI3): 5 2.05 (bs, NH, 1H), 2.83 - 2.98 (m, 3H), 3.05
(m, broad doublet shape, 1H), 3.21 - 3.29 (m, 2H), 3.38 (td, J = 2.9, 12.8 Hz,
1H), 4.45 (bs, 1H), 4.78 (bs, 1H), 6.96 (d, J = 9.2 Hz, 1H), 7.19 (m, 1H), 7.27 7.35 (m, 4H), 7.69 (d, J = 9.5 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 8.31 (d, J = 2.6,
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9.5 Hz, 1H), 8.52 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 34.4, 40.9,
46.2, 46.8, 54.0, 110.8, 121.0, 123.6, 124.2, 126.4, 127.1, 128.5, 129.4, 138.4,
138.9, 141.8, 151.5, 158.4; HRMS (ESI-TOF) m/z (M + H)+ calcd. for C 20H21N4 O 2
349.1665 found 349.1678.

Ethyl Bromophenylacetate 147.

The synthesis of 147 is adapted from the

method of Epstein. 138 To a solution of ethyl phenylacetate (1.03 g, 6.28 mmol) in
CCU (16 mL) was added NBS (1.15 g, 6.47 mmol) and two drops of HBr (48%).
The mixture was heated to reflux and maintained until the solids floated on top of
the solvent.

This mixture was cooled and filtered through a pad of Fluorosil

(Magnesium silicate) the pad was rinsed with CH 2 CI2 and the filtrate concentrated
to give the crude product that was purified by column chromatography (silica gel,
EtOAc:Hexanes, 1:3) to afford 147 as a clear, loose oil (1.50 g, 98%). TLC Rf
0.60 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.28 (t, 3H), 4.24 (m,
AB pattern 0 -C H 2-CH3, 2H), 5.35 (s, 1H), 7.34 - 7.40 (m, 3H), 7.53 - 7.58 (m,
2H); 13C NMR (100 MHz, CDCI3): 5 13.9, 46.8, 62.5, 128.6, 128.8, 129.2, 135.8,
168.2.

1,4-Dibenzyl-3-phenylpiperazine-2-one 151.

To a stirred solution of N,N-

dibenzyl ethylenediamine (10.2 g, 42.5 mmol) in acetonitrile (55 mL) under argon
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was added a solution of bromo ester 147 (5.17 g, 21.3 mmol). This solution was
heated at reflux for

6

h then stirred for 38 h at ambient temperature. The solvent

was evaporated and the residue partitioned between 1 M NaOH (60 mL) and
ether (50 mL).

The organic phase was separated and the aqueous phase

extracted with ether (2 x 40 mL). The combined organic phases were washed
with brine (2 x 30 mL), dried (Na 2 SC>4) and the solvent evaporated to give 12.5 g
of crude material that was purified by column chromatography (silica gel,
EtOAc:Hexanes, 1:9 - 1:3) to afford 151 as a very thick oil (5.85 g, 77%). TLC Rf
0.29 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3):

8

2.47 (td, J = 3.7, 12.1

Hz, 1H), 2.97 (dt, J = 3.3, 12.1 Hz, 1H), 3.09 - 3.18 (m, 2H), 3.47 (td, J = 3.7,
11.0, 1H), 3.75 (d, J = 13.2 Hz, 1H), 4.14 (s, 1H), 4.59 (m, AB pattern, J = 14.3
Hz, 2H), 7.22 - 7.42 (m, 15H); 13C NMR (400 MHz, CDCI3):

8

45.8, 46.6, 50.2,

58.8, 71.2, 127.2, 127.5, 127.8, 128.2 (two overlapped peaks), 128.4, 128.6,
128.7, 129.0, 136.8, 137.7, 139.4, 168.3.

LiAlH4, Et20

1,4-Dibenzyl-2-phenylpiperazine 152. To a solution of amide 151 (1.19 g, 3.34
mmol) in dry THF (20 mL) was added LiAIH4 (0.597 g, 15.7 mmol) in one portion.
The mixture was heated at reflux for 5 h. After cooling, the excess LiAIH4 was
quenched by the careful, sequential addition of 0.25 mL water, 0.5 mL 4 N NaOH
and 0.25 mL water. The mixture was stirred 15 min and the solids that formed
were filtered (Celite) and the filtrate concentrated to give the crude material that
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was purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3) to
provide 152 as a white solid 0.922 g, 81%). TLC Rf 0.52 (EtOAc:Hexanes, 2:3).
1H NMR (400 MHz, CDCI3): 5 2.14 - 2.21 (m, 1H), 2.22 - 2.32 (m, 2H), 2.78 (m,
1H), 2 .8 3 -2 .9 1 (m, 3H), 3.43 (dd, J = 2.6, 10.3 Hz, 1H), 3.50 (m, singlet shape,
2H), 3.79 (d, J = 13.2 Hz, 1H), 7.17 - 7.52 (m, 15H);

13C NMR (100 MHz,

CDCI3): 5 51.7, 53.2, 58.9, 62.0, 62.9, 67.3, 126.7, 127.0, 127.4, 128.0, 128.2,
128.4, 128.7, 129.2, 137.8, 139.0, 142.2.

MeOH, HCI

2-Phenylpiperazine dihydrochloride 153.

To a suspension of dibenzyl

piperazine 152 (0.500 g, 1.46 mmol) in methanol (25 mL) was added HCI (12 M,
0.24 mL, 2.92 mmol) and 5% Pd/C (0.075 g). The flask was sealed with a septa
and H2 was bubbled through the solution via balloon.

The reaction was

monitored by TLC until 152 was consumed, refilling H2 if necessary.

The

reaction mixture was filtered (Celite) and the filtrate concentrated to provide 153
as a white solid (0.345 g, quantitative). 1H NMR (400 MHz, D2 0): 5 3.37 (m, 1H),
3.49 (m, 1H), 3.57 (m, 1H), 3.63 - 3.76 (m, 3H), 4.59 (m, 1H, overlapped with
HOD), 7.31 - 7.40 (m, 5H); 13C NMR (100 MHz, DMSO-cfe): 5 39.0, 41.0, 44.5,
55.4, 128.1, 129.0, 129.8, 133.1.
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HN^|
^

l H

1 .C H 2 CI2 . B 3N

H

.2HCI

2. Trityl chloride

3-Phenyl-1-triphenylmethylpiperazine 154.

NTrit

To a stirring suspension of

piperazine 153 (0.433 g, 1.84 mmol) in dry CH 2CI2

(2 0

mL) under argon was

added anhydrous triethylamine (1.0 mL, 7.4 mmol). The resultant clear solution
was cooled to 0 °C and a solution of trityl chloride (0.514 g, 1.84 mmol) in dry
CH 2CI2 (5 mL) was added (dropwise). The reaction was stirred an additional 10
min at 0 °C then warmed to ambient temperature and stirred for 1.5 h.

The

solution was washed with saturated NaHC 0 3 (30 mL) and the aqueous solution
extracted with CH 2CI2 ( 2 x 1 5 mL). The combined organic extracts were dried
(K2CO 3) and concentrated to provide 154 as a white solid (0.760 g, quantitative).
TLC Rf 0.50 (MeOH:CH 2 CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.23 (bs, 1H),
1.53 (m, t shape, 1H), 1.67 (m, t shape, 1H), 3.06 - 3.14 (m, 2H), 3.20 (m, 1H),
3.35 (m, 1H), 4.20 (m, 1H), 7 .1 5 -7 .6 5 (m, 20H); 13C NMR (100 MHz, CDCI3):

8

46.7, 48.2, 56.0, 61.2, 77.1, 126.0, 126.9, 127.3, 127.5, 127.9, 128.3, 129.3
(broad), 142.6.

1. Et2 0 , n-BuLi, 0 °C;
2 -chloroquinoline
NH
2. HCI, EtOH

2-(2-Phenylpiperazin-1-yl)quinoline 155.

To a 0 °C solution of N-trityl

piperazine 154 (0.605 g, 1.49 mmol) in dry ether (20 mL) under argon was added
(dropwise) a solution of n-butyllithium in hexanes (2.33 M, 0.64 mL, 1.49 mmol).
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The orange turbid solution was stirred for 20 min. then a solution of

2-

chloroquinoline (0.163 g, 1.0 mmol) in dry ether (4 mL) was added dropwise
forming a green-blue solution.

The reaction was maintained at 0 °C for an

additional 50 min then stirred at ambient temperature for 19 h. The solution was
diluted with ether (10 mL) and washed with saturated NaHC 0 3 (2 x 20 mL) and
brine ( 2 x 1 5 mL), dried (K2CO 3) and concentrated to provide the crude material
that was purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3) to
afford a yellow foam intermediate (0.555 g, 104%) TLC R f 0.58 (EtOAc:Hexanes
2:3) that was not spectroscopically characterized and immediately deprotected.
To a suspension of the crude intermediate (0.555g, 1.04 mmol) in 95% ethanol
(20 mL) was added

6

M HCI (4 mL). The flask was swirled until the sides were

cleared of solids and a homogenous solution resulted.
ambient temperature for

10

Stirring continued at

min then the reaction contents were diluted with

~20

mL of CH 2CI2 . The mixture was made basic with 4 M NaOH and diluted with 20
mL saturated NaHC 0 3 - The organic phase was separated and the aqueous
phase extracted with CH 2 CI2 ( 3 x 1 5 mL). The combined organic extracts were
dried (K2CO 3) and concentrated to provide the crude product that was purified by
column chromatography (silica gel, eluting first with EtOAc:CHCl3 , 4:1, to remove
non-polar impurities, then MeOH:CH 2Cl2 , 1:9) to provide 155 as a pale colored oil
(0.260 g,

86

%). TLC R f 0.24 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5

1.79 (bs, NH, 1H), 3.02 (td, J = 3.7, 12.1 Hz, 1H), 3.15 (m, 1H), 3.32 - 3.41 (m,
2H), 3.65 (m, 1H), 4.63 (m, 1H), 5.56 (m, singlet shape, 1H), 6.87 (d, J = 9.2 Hz,
1H), 7.17 - 7.25 (m, 2H), 7.29 - 7.34 (m, 4H), 7.53 (m, 1H), 7.58 (m, doublet
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shape, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H); 13C NMR (100
MHz, CDCIs): 5 41.4, 45.9, 50.0, 54.7, 109.1, 122.1, 122.9, 126.5, 126.7, 127.1,
127.2, 128.7, 129.5, 137.6, 139.7, 147.9, 157.3.

3,4-Dihydro-6-nitroquinolin-2(1H)-one 158.

To a -5 °C solution of hydro-

carbostyril 157 (1.089 g, 7.4 mmol) in conc. H2SO 4 (20 mL) was slowly added
water (5 mL). After the solution cooled back to -5 °C, nitric acid (15.4 M, 0.49
mL, 7.5 mmol) was added, three drops at a time, in three minute increments to
minimize heating. Ten minutes following the addition, the reaction contents were
transferred to a beaker and 60 mL of cold water was slowly added with stirring,
forming a white precipitate. The precipitate mixture was cooled on ice for 15 min,
and the solids were collected by filtration and washed sparingly with a few
portions of cold EtOAc. The solids were dried under high vacuum providing 158
as a pale colored solid (1.258 g,

8 8 %).

1H NMR (400 MHz, CDCI3):

6

2.73 (m,

2H, triplet shape), 3.10 (m, 2H, triplet shape), 6.93 (m, 1H, doublet shape), 8.08
- 8.13 (m, 2H), 9.28 (bs, NH, 1H); 13C NMR (100 MHz, CDCI3 ): 5 25.0, 29.9,
115.5, 123.85, 123.93, 124.1, 142.8, 143.2, 171.7.

D D Q , P O C I3

2-Chloro-6-nitroquinoline 159. To a suspension of 158 (1.06 g, 5.5 mmol) in
benzene (20 mL) under argon was added DDQ (1.25 g, 5.5 mmol) followed by
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POCb (2.55 mL, 4.20 g, 27.4 mmol) in a dropwise manner. The bright yelloworange mixture was heated at reflux for 3 h. After cooling, 20 mL of cold water
was added and the mixture was brought to neutral pH with 4 M NaOH.

The

solids were collected by filtration and washed with cold water and -2 0 mL of cold
ether.

The filtrate was extracted with EtOAc (3 x 60 mL) and the combined

extracts were dried (K2 CO 3) and concentrated to give a solid. Both batches of
solids were combined and dissolved with heating in -3 0 mL of THF. Silica gel

(6

g) was added and the solvent evaporated to adsorb the crude product onto the
silica gel. The material was loaded onto a chromatography column, and purified
(silica gel, EtOAc:Hexane, 1:9) to provide 159 as a tan solid (1.13 g, 98 %). TLC
Rf

0.45 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, DMSO-de): 5 7.84 (d, J =

Hz, 1H), 8.16 (d, J = 9.2 Hz, 1H), 8.52 (dd, J = 2.6, 9.2 Hz, 1H), 8.79 (d, J =
Hz, 1H), 9.14 (d, J = 2.6 Hz, 1H);

8 .8

8 .8

13C NMR (100 MHz, DMSO-d6): 5 124.1,

124.4, 125.1, 125.9, 129.7, 141.9, 145.3, 149.2, 153.6.

CO2MG

C H 2 CI2, r.t.,

1

h

N-ferf-Butoxycarbonyl-N-benzylglycyl-DL-phenylglycine Methyl Ester 162.
The general peptide coupling procedure was used as described above for 96.
Column chromatography of the crude product (silica gel, EtOAc:Hexanes, 1:3, to
remove non-polar material, then EtOAc:Hexanes, 2:3, to elute the product)
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provided 162 as a clear, viscous oil (1.87 g, 93%, solvent heavy). TLC Rf 0.33
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.47 (bs, 9H), 3.71 (s, 3H),
3.76 - 3.94 (bm, 2H), 4.42 (d, J = 15 Hz, 1H), 4.52 - 4.68 (bm, 1H), 5.50 (d, J =
7.3 Hz, 1H), 6.78 (bs, NH, 0.4H), 7.18 - 7.42 (m, 10H);

13C NMR (100 MHz,

CDCI3): 5 28.2, 50.7, 51.7 (broad), 52.7, 56.1, 81.2, 127.1, 127.6, 128.2, 128.5,
128.7, 128.8, 136.2, 137.1, 155.4 (broad), 168.7 (broad), 170.8.

nv-

1

C02Me

. MeOH, SOCI2

2. NH 4 OH, MeOH

1-Benzyl-3-phenylpiperazine-2,5-dione 163. To a 0 °C solution of dipeptide
162 (1.873 g, 4.54 mmol) in methanol (25 mL) was slowly added excess thionyl
chloride (1.5 mL) to avoid sputtering. Following the addition, the solution stirred
at ambient temperature for 21 h. The solvent was evaporated and the residue
was triturated with -3 0 mL of ether to produce a solid that was collected by
filtration.

The solid was dissolved in methanol (~30 mL) and treated with

ammonium hydroxide (29%, 10 mL) at ambient temperature. The solution was
stirred for
The

20

h then concentrated (the flask sat sealed, in the hood for 2 months).

residue was partitioned

between

saturated

N aH C 0 3 (20

mL)

and

C H C I3:isopropyl alcohol, 4:1 (50 mL). T h e organic phase w as separated and the

aqueous phase extracted with CHCI3:isopropyl alcohol, 4:1 (4 x 50 mL).

The

combined organic phases were dried (K2C 0 3) and concentrated to afford 163 as
a white solid (1.098 g,

8 6 %)

with adequate purity for subsequent transformations.

191

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

TLC R f 0 . 5 4 (MeOH:CH 2 CI2, 1:9). 1H NMR (400 MHz, CDCI3):

8

3.87 (m, quartet

shape, AB pattern, J = 17.9 Hz, 2H), 4.55 (m, AB pattern, J = 14.3 Hz, 2H), 5.17
(bd, 1H), 6.89 (bs, NH, 1H), 7.14 - 7.18 (m, 2H), 7.26 - 7.41 (m,
(100 MHz, CDCI3 ):

8

8

H); 13C NMR

48.7, 49.8, 59.5, 126.4, 128.1, 128.2, 128.8, 128.9, 129.1,

135.0, 137.0, 164.6, 166.0.

O
□ A im , THF

1-Benzyl-3-Phenylpiperazine 164. To a suspension of diamide 163 (1.16 g,
4.15 mmol) in dry THF (75 mL) was added L1AIH4 (0.630 g, 16.6 mmol) in one
portion, producing a gentle effervescence. The mixture was maintained on ice
until the bubbling stopped, then the flask was heated at reflux for 5 h.

The

mixture was cooled and stirred an additional hour, then the excess UAIH 4 was
quenched by the careful, sequential addition of 0.6 mL water, 1.2 mL 4 M NaOH
solution and 0.6 mL water. After stirring 10 min, the solids were filtered (Celite)
and the filtrate concentrated.

The crude material was purified by column

chromatography (silica gel, MeOHiCHCb, 1:49) to provide 164 as a pale colored
oily solid (0.780 g, 74 %). TLC R f 0.24 (MeOH:CH 2 CI2, 1:9). 1H NMR (400 MHz,
CDCI3):

8

2.08 (m, triplet shape, 1H), 2.20 (dd, J = 4.4, 11 Hz, 1H, overlapped

with bs, NH, 1H), 2.84 (m, doublet shaped, 1H), 2.91 (m, doublet shape, 1H),
3.02 - 3.12 (m, 2H), 3.55 (s, 2H), 3.89 (dd, J = 2.9, 10.3 Hz, 1H) 7.22 - 7.40 (m,
10H); 13C NMR (100 MHz, CDCI3):

8

46.2, 53.1, 60.3, 61.1, 63.3, 127.0, 127.4,

128.2, 128.3, 129.2, 137.8, 142.4
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co2M©

.0

0

F

CH 2 CI2, r.t.,

C 0 2Me

OH

1

CH 2 CI2, Et3 N,
r.t., 2 0 h

h

N-te/t-Butoxycarbonyl-N-benzylglycyl-DL-phenylalanine Methyl Ester 166.
The general peptide coupling procedure was used as described above for 96.
Column chromatography of the crude product (silica gel, EtOAc:Hexanes, 1:3, to
remove non-polar material, then EtOAc:Hexanes, 3:2, to elute the product)
provided 166 as a clear, viscous oil (2.17 g, 102%, solvent heavy). TLC R f 0.33
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.45 (s, 9H), 2.99 - 3.16
(bm, 2H), 3.72 (s, 3H), 3.79 (bd, J = 16.1 Hz, overlapped with bm, 2H), 4.30 4.50 (bm, 2H), 4.85 (m, 1H, quartet shaped), 6.27 (bs, 0.3H), 6.63 (bs, 0.3H),
7.05 - 7.11 (bm, 2H), 7.17 - 7.34 (m,

8

H); 13C NMR (100 MHz, CDCI3): 5 28.2,

37.8, 50.2, 51.2 (v. broad), 52.3, 52.8 (broad), 81.1, 127.1, 127.6, 128.1 (broad),
128.6, 129.1, 135.6, 136.9, 155.3 (broad), 168.9 (broad), 171.5.

O
1

. MeOH, SOCI2

2. NH4OH, MeOH

Bn

O

1,3-Dibenzylpiperazine-2,5-dione 167.

To a 0 °C solution of dipeptide 166

(2.18 g, 5.11 mmol) in methanol (30 mL) was slowly added excess thionyl
chloride (1.9 mL) to avoid sputtering. Following the addition, the solution stirred
at ambient temperature for 2.5 h. The solvent was evaporated and the residue
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was triturated with -3 0 mL of ether, producing a white solid that was collected by
filtration.

The solid was dissolved in methanol (40 mL) and treated with

ammonium hydroxide (29%, 10 mL) at ambient temperature. The solution was
stirred for 18 h then concentrated.

The solid residue was partitioned between

saturated NaHC 0 3 (40 mL), water (20 mL) and CHCbiisopropyl alcohol, 4:1 (40
mL). The organic phase was separated and the aqueous phase extracted with
CHCbMsopropyl alcohol, 4:1 (3 x 40 mL). The combined organic phases were
dried (K2 CO3 ) and concentrated to afford 167 as a white solid (1.382 g, 92%) with
adequate purity for subsequent transformations.

TLC Rf 0.49 (MeOH:CH 2Cl2 ,

1:9). 1H NMR (400 MHz, CDCI3): 5 2.99 (d, part of AB pattern, J = 17.6 Hz, 1H),
3.17 (m, AB pattern, 2H), 3.52 (d, part of AB pattern, J = 17.6 Hz, 1H), 4.35 (m,
1H), 4.48 (m, AB pattern, J = 14.7 Hz, 1H), 6.39 (bs, NH, 1H), 7.13 - 7.35 (m,
10H, overlapped with CDCI3); 13C NMR (100 MHz, CDCI3): 5 40.5, 48.2, 49.6,
56.4, 127.4, 128.1, 128.59, 128.63, 128.8, 130.0, 134.65, 134.68, 165.2, 166.3.

O

1,3-Dibenzylpiperazine 168. To a 0 °C suspension of dione 167 (1.38 g, 4.7
mmol) in dry THF (120 mL) was added LiAIH4 (0.713 g, 18.8 mmol) in two
portions, producing a gentle effervescence. The mixture was maintained on ice
until the bubbling stopped, then the reaction was heated at reflux for 2.5 h. The
solution was cooled and stirred for an additional 19 h then the excess LiAIH4 was
quenched by the careful, sequential addition of 0.7 mL water, 1.3 mL 4 M NaOH
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and 0.7 mL water.

The solids that formed will filtered (Celite) and the filtrate

concentrated to provide 168 as a pale colored solid (1.29 g, 103%, with THF) that
slowly formed from an oil. TLC R f 0.21 (MeOH:CH 2Cl2 , 1:9). 1H NMR (400 MHz,
CDCI3): S 1.93 (m, triplet shape,
with bs, NH, 1H), 2.58 (dd,

8 .8

1 H),

2.11 (td, J = 2.9, 11.0 Hz, 1H, overlapped

, 13.2 Hz, 1H), 2.70 - 2.77 (m, 2H), 2.79 - 2.87

(m, 2H), 2.92 (dt, J = 2.3, 11.7 Hz, 1H), 3.02 (m, 1H), 3.51 (dd, AB pattern, J =
12.8 Hz, 2H), 7.18 - 7.33 (m, 10H); 13C NMR (100 MHz, CDCI3): 5 40.7, 45.6,
53.3, 56.2, 59.6, 63.3, 126.3, 127.0, 128.1, 128.4, 129.2, 137.9, 138.5.

MeOH, HCI

2-Benzylpiperazine dihydrochloride 169. To a solution of piperazine 168 (1.25
g, 4.69 mmol) in methanol (20 mL) was added HCI (12 M, 0.78 mL, 9.38 mmol)
and 5% Pd/C (0.188 g). The flask was sealed with a sepum and H2 was bubbled
through the solution via balloon. The reaction was monitored by TLC until 168
was consumed, refilling H2 if necessary. The mixture was filtered (Celite) and the
filtrate concentrated to provide 169 as a white solid (1.10 g, 94%). 1H NMR (400
MHz, D2 0): 5 2.90 (dd, AB pattern, J = 7.7, 14.3 Hz, 1H), 2.97 (dd, AB pattern, J
= 7.0, 14.3 Hz, 1H), 3.13 (m, triplet shape, 1H), 3.22 (m, 2H), 3.52 - 3.59 (m,
3H), 3.72 (m, 1H), 7.15 - 7.32 (m, 5H); 13C NMR (100 MHz, D20 , dioxane int.
std 67.4 ppm): 5 36.8, 40.9, 41.4, 45.1, 54.6, 129.0, 130.3 (overlapped peaks),
133.9.

195

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CH 2 CI2, Et3N
H

2HCI

methylformate

3-Phenylpiperazine-1-carbaldehyde 170.
piperazine 153 (0.206 g,

0 .8 8

HN^|
CHO

To a suspension of powdered

mmol) in CH 2CI2 (2 mL) was added triethylamine

(0.26 mL, 1.85 mmol) followed by additional CH 2CI2 to facilitate stirring.

The

mixture was cooled to 0 °C and methylformate (0.06 mL, 0.96 mmol) was added.
Stirring continued for 20 min at 0 °C then 24 h at ambient temperature.
mixture was diluted with saturated NaHC 0 3
x 10 mL).

(6

The

mL) and extracted with CH 2 CI2 (3

The combined extracts were dried (K2CO 3) and concentrated to

provide the crude material that was purified by column chromatography (silica
gel, MeOH:CH 2CI2, 1:39) to provide 170 as a oil (0.103 g, 62%). TLC Rf 0.35
(MeOH:CH 2 Cl2 , 1:9).

1H NMR (400 MHz, CDCI3): (approximate 1:1 mixture of

amide rotamers) 5 2.71 (dd, J = 10.6, 12.8 Hz, 0.5H), 2.83 - 2.93 (m, 1.5H), 3.11
- 3.22 (m, 1.5H), 3.34 (td, J = 2.9, 11.7 Hz, 0.5H), 3.55 (m, 1H), 3.70 (td, J = 3.3,
10.6 Hz, 1H), 4.40 (m, 1H), 7.27 - 7.44 (m, 5H), 8.07 (s, CHO, 0.5H), 8.10 (s,
CHO, 0.5H); 13C NMR (100 MHz, CDCI3): 5 40.2, 45.5, 45.9, 46.8, 47.2, 53.1,
59.8, 61.4, 126.8, 126.9, 127.9, 128.1, 128.5, 128.6, 140.4, 140.7, 160.7, 160.8.

methylformate

3-Benzylpiperazine-1-carbaldehyde 171.

To a suspension of powdered

piperazine 169 (0.304 g, 1.22 mmol) in dimethoxyethane (1.5 mL) was added
triethylamine (0.35 mL, 2.56 mmol). The stirred mixture was cooled to 10 °C,
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methylformate (0.11 mL, 1.83 mmol) was added and stirring was continued for 1
h at 10 °C then 24 h at ambient temperature.
saturated NaHC 0 3

(6

The mixture was diluted with

mL) and extracted with CHCb-isopropyl alcohol, 4:1 ( 3 x 1 5

mL). The combined extracts were dried (K2 CO 3) and concentrated and the crude
product was purified by column chromatography (silica gel, MeOH:CH 2 CI2, 1:19 —
1:9) to provide 171 as an oil (0.189 g, 76%). TLC Rf 0.27 (MeOH:CH 2 CI2, 1:9).
1H NMR (400 MHz, CDCI3): (approximate 1:1 mixture of amide rotamers) 5 2.0
(bs, NH, 1H), 2.54 - 2.72 (m, 2.5H), 2.75 - 2.89 (m, 2.5H), 2.96 (m, dd shape,
0.5H), 3.00 - 3.06 (m, 1H), 3.24 (td, J = 3.3, 11.7 Hz, 0.5H), 3.45 - 3.52 (m, 1H),
4.25 (m, doublet shape, 0.5H), 4.35 (m, doublet shape, 0.5H), 7.17 - 7.36 (m,
5H), 7.98 (s, 0.5H), 8.04 (s, 0.5H);

13C NMR (100 MHz, CDCI3): 5 39.9, 40.0,

40.4, 45.0, 45.7, 46.1, 46.3, 51.3, 55.8, 57.1, 126.6, 126.7, 128.6, 128.7, 129.0,
129.1, 137.0, 137.3, 160.70, 160.75.

Trityl chloride

3-Benzyl-1-triphenylmethylpiperazine 172.

To a stirred suspension of

piperazine 169 (0.396 g, 1.59 mmol) in dry CH 2CI2 (20 mL) under argon was
added anhydrous triethylamine (0.88 mL, 6.4 mmol). The resultant clear solution
was cooled to 0 °C and a solution of trityl chloride (0.443 g, 1.59 mmol) in dry
CH 2CI2 (7 mL) was added (dropwise). The reaction was stirred an additional 5
min at 0 °C then warmed to ambient temperature and stirred for 16 h.

The

solution was washed with saturated NaHC 0 3 (40 mL) and brine (40 mL), and
then dried (K2C 0 3 ) and concentrated to provide 172 as a white solid (0.650 g,
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98%). TLC Rf 0.42 (MeOH:CH 2CI2) 1:9). 1H NMR (400 MHz, CDCI3):

8

1.35 (bs,

1H), 1.59 (bs, 2H), 2.42 (bs, 1H), 2.65 (dd, J = 3.7, 13.2 Hz, 1H), 2.85 - 3.16
(bm, 4H), 3.27 (m, 1H), 7.12 - 7.56 (m, 20H);

13C NMR (100 MHz, CDCI3):

8

40.8, 46.4, 48.3, 54.4, 56.9 (all broad), 77.05, 125.9, 126.2, 127.4 (broad, 2
peaks), 128.4, 129.1,129.3 (broad), 138.7.

DMSO

2-(4-Benzyl-2-phenylpiperazin-1-yl)-6-nitroquinoline 174. A suspension of
quinoline 159 (0.0382 g, 0.183 mmol) and piperazine 164 (0.092 g, 0.365 mmol)
in dry DMSO (0.5 mL) was sealed under argon in a vial and placed in a 120 °C
oil bath for 24 h.

The reaction mixture was pipetted into water (20 mL) and

saturated N aH C 0 3 (10 mL), then extracted with ether (2 x 20 mL).

The

combined ether extracts were washed with water ( 5 x 8 mL) and brine (20 mL),
then dried (K2 C 0 3) and concentrated. The crude material was purified by column
chromatography (silica gel, EtOAc:Hexanes, 1:19 - 1:9) to provide 174 as an
orange oil (0.060 g, 76%). TLC Rf 0.50 (EtOAc:Hexanes, 2:3).
MHz, CDCI3):

8

1H NMR (400

2.36 (td, J = 2.9, 11.4 Hz, 1H), 2.58 (dd, J = 3.7, 11.7 Hz, 1H),

3.02 (bd, J = 10.3 Hz, 1H), 3.66 (bd, J = 12.8 Hz, 1H), 3.41 - 3.54 (m, 3H), 4.54
(bd, J = 12.8 Hz, 1H), 5.86 (bs, 1H), 7.03 (d, J = 9.2 Hz, 1H), 7.22 - 7.43 (m,
10H), 7.65 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 9.2 Hz, 1H), 8.29 (dd, J = 2.6, 9.2 Hz,
1H), 8.51 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3):

8

40.9, 53.3, 54.1,
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55.5, 62.8, 110.8, 121.0, 123.6, 124.3, 126.9, 127.0, 127.2, 127.5, 128.2, 128.3,
129.0, 137.6, 138.8, 139.7, 141.7, 151.5, 158.3.

0 2N
o 2n

DMSO
+

Cl

H

Bn 120 °C

Bn

2-(2,4-Dibenzylpiperazin-1-yl)-6-nitroquinoline 175. A suspension of quinoline
159 (0.035 g, 0.172 mmol) and piperazine 168 (0.090 g, 0.338 mmol) in dry
DMSO (1.0 mL) was sealed under argon in a vial and placed in a 120 °C oil bath
for 24 h. The reaction was pipetted into water (20 mL) and saturated NaHC 0 3
(10 mL), and then extracted with ether (2 x 20 mL). The combined extracts were
washed with water ( 5 x 5 mL) and brine (20 mL), then dried (K2CO 3) and
concentrated. The crude material was purified by column chromatography (silica
gel, EtOAc:Hexanes, 1:9 - 2:3) to provide 175 as an orange oil (0.056 g, 74%).
TLC Rf 0.39 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 2.08 (dd, J =
3.7, 11.7 Hz, 1H), 2.26 (td, J = 3.7, 11.7 Hz, 1H), 2.80 - 2.87 (m, 2H), 3.07 (m,

bd shaped, 1H), 3.27 (dd,
doublet is overlapped here

= 9.9, 12.5 Hz, 1H), 3.40 - 3.50 (m, 2H, an AB

J
J

= 12.8 Hz), 3.62 (d, part of AB pattern, J = 12.8 Hz,

1H), 4.45 (bs, 1H), 4.71 (bs, 1H), 6.98 (d, J = 9.2 Hz, 1H), 7.09 - 7.19 (m, 5H),
7.31 - 7.43 (m, 5H), 7.70 (d, J = 9.2 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 8.31 (dd, J

= 2.6, 9.2 Hz, 1H), 8.53 (d,

J=

2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 8 35.3,

40.7, 53.4, 54.5, 62.9, 110.8, 120.9, 123.6, 124.3, 126.2, 127.1, 127.3, 128.31,
128.34, 129.3, 129.4, 138.0, 138.4, 139.1, 141.7, 151.6, 158.1.
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o 2n

Polar column
fraction from
Entry 1 (Table 4.1)

CH 2 CI2, Boc2 0 ;
------------------------ *■
Chromatography
Boc

2-[4-(tert-Butoxycarbonyl)-3-phenylpiperazin-1 -yl]-6-nitroquinoline 176.

To

the polar column fraction from Entry 1 , Table 4.1 (0 . 1 1 1 g) dissolved in CH 2CI2 (5
mL) is added a solution of di-fe/f-butyldicarbonate (~0 . 1 1 g, 0.5 mmol) in CH 2CI2
(2 mL). The reaction was allowed to proceed for 5 h and TLC analysis showed
the formation of a non-polar product ( R f 0.38, EtOAc:Hexanes, 2:3) consistent
with Boc-protected quipazines.

The solvent was evaporated and the residue

purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3) to provide

176 as a yellow foam (0.045 g). TLC

Rf

0.38 (EtOAc:Hexanes, 2:3). 1H NMR

(400 MHz, CDCI3): 5 1.40 (s, 9H), 3.43 - 3.53 (bm, 2H), 4.05 - 4.16 (bm, 2H),
4.21 - 4.28 (bm, 1H), 4.57 - 4.67 (bm, 1H), 5.32 (bs, 1H), 6.97 (d, J = 9.2 Hz,
1H), 7.21 - 7 .2 6 (m, 1H), 7 .2 8 -7 .3 7 (m, 4H), 7.72 (bs, 1H), 7.98 (d, J = 9.2 Hz,
1H), 8.32 (dd, J = 2.6, 9.2 Hz, 1H), 8.55 (d, J = 2.6 Hz, 1H).

2-(3-Phenylpiperazin-1-yl)-6-nitroquinoline 177. A solution of quipazine 176
(0.045 g, 0.10 mmol) in THF (0.5 mL) and 4 M

H 2SO 4

(3 mL) was stirred at

ambient temperature. The deprotection of the Boc group was found to be slow,
so 3 drops of conc.

H 2SO 4

was added. After

1

h, the reaction was complete (176

gone by TLC) and the reaction was pipetted onto ice, made basic with 4 M

NaO H

and diluted with saturated NaHCOs (10 mL). The aqueous mixture was extracted
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with CH 2CI2

(2

x

20

mL) and the combined extracts dried (K2CO 3) and

concentrated to provide 177 as a yellow-orange solid (0.032 g, 94%). TLC R f
0.44 (MeOH:CH 2 CI2 , 1:9). 1H NMR (400 MHz, CDCI3): 5 2.12 (bs, NH, 1H), 3.00
-3 .1 1 (m, 2H), 3 .1 9 -3 .3 2 (m, 2H), 3.88 (dd, J = 2.9, 10.6 Hz, 1H), 4.63 (bd, J =
12.8 Hz, 2H), 7.08 (d, J = 9.2 Hz, 1H), 7.31 - 7.43 (m, 3H), 7.50 (m, doublet
shape, 2H), 7.64 (d, J = 9.2 Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 8.28 (dd, J = 2.6,
9.2 Hz, 1H), 8.52 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 44.9, 46.1,
52.1, 60.5, 110.9, 121.0, 123.6, 124.2, 127.1 (shouldered, 2 overlapping peaks),
128.1, 128.7, 138.7, 141.2, 141.9, 151.5, 158.4.

C 0 2Me

Oy l

i^ 00^ ULX

c o 2m ©

CH2CI2. Et3N,
r.t., 20 h

N-ferf-Butoxycarbonyl-N-benzylglycyl-DL-aspartate Dimethyl Ester 183. The
general peptide coupling procedure was used as described above for 96.
Column chromatography of the crude product (silica gel, EtOAc:Hexanes, 1:3, to
remove non-polar material, then EtOAc:Hexanes, 2:3, to elute product) provided
183 as a clear, viscous oil (1.96 g, 96%). TLC Rf 0.18 (EtOAc:Hexanes, 2:3). 1H
NMR (400 MHz, CDCI3):

8

1.49 (s, 9H), 2.72 (bm, 1H), 2.99 (dd, J = 3.6, 16.8,

1H), 3.67 (s, 3H), 3.74 (s, 3H), 3.77 - 3.97 (bm, 2H), 4.42 (d, J = 15.4, 1H), 4.59
(bd, J = 15.4, 1H), 4.82 (bm, 1H), 6.82 (bs, 0.4H), 7.12 (bs, 0.3H), 7.20 - 7.34
(m, 5H); 13C NMR (100 MHz, CDCI3) : 8 28.2, 35.9, 48.1, 50.3, 51.6 (broad), 51.9,
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52.7, 81.1, 127.6, 128.2 (broad), 128.6, 137.1, 155.3 (broad), 169.1, 170.8
(broad), 171.2 (broad).

1. MeOH, SOCI2
0 °C - r.t., 2 h
HN
C 0 2Me

4 \ ^ C 0 2Me

N -B n

2 . MeOH, NH4OH

r.t. 20 h

M e 0 2C

'

O

H H

Methyl 2-(1 -Benzyl-2,5-dioxopiperazin-3-yl)acetate 184. To a 0 °C solution of
dipeptide 183 (1.9 g, 4.4 mmol) in methanol (25 mL) was added slowly excess
thionyl chloride (2 mL) to avoid sputtering. Following the addition, the solution
stirred at ambient temperature for 4.5 h. The solvent was evaporated and the
oily residue was triturated with ether (20 mL). The ether was decanted and the
process repeated. The still oily residue was dissolved in methanol (~45 mL) and
treated with ammonium hydroxide (29%, 10 mL) at ambient temperature. The
solution stirred for 16 h and the solvent was evaporated.

The residue was

partitioned between saturated NaHC 0 3 (25 mL) and CHCb:isopropyl alcohol, 4:1
(20 mL). The organic phase was separated and the aqueous phase extracted
with CHCI3 :isopropyl alcohol, 4:1 (3 x 20 mL).

The combined organic phases

were dried (K2CO 3) and concentrated to afford 184 as a white solid (1.15 g, 97%)
of adequate purity for subsequent steps. TLC Rf 0.38 (MeOH:CH 2CI2, 1:9). 1H
NMR (400 MHz, CDCI3): 5 2.86 (dd, J = 8.1, 17.2 Hz, 1H), 3.06 (dd, J = 3.7, 17.2
Hz, 1H), 3.68 (s, 3H), 3.87 (m, 2H, qd shape), 4.40 (m, 1H), 4.59 (m, AB pattern,
s shape), 7.05 (bs, 1H), 7.24 - 7.37 (m, 5H); 13C NMR (100 MHz, CDCI3) : 6 25.3,
38.0, 48.8, 49.8, 51.8, 52.2, 128.1, 128.4, 128.9, 134.8, 164.6, 165.2, 170.9.
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o
/“ A
HN
N -B n
"--7

M e 0 2 C —'

\\
O

THF, UAIH4
------------------- ►

H N ^ I
7
1

reflux, 5 h
H

1-Benzyl-3-(2-hydroxyethyl)piperazine-2,5-dione 186. To a 0 °C suspension
of amide 184 (1.15 g, 4.16 mmol) in dry THF (100 mL) under argon was added
UAIH4 (0.949 g, 25 mmol) in 3 small portions. The mixture was heated at reflux
for 5 h, then cooled. The excess LiAIH4 was destroyed by the careful, sequential
addition of 1 mL water, 2 mL 4 N NaOH and 1 mL water. After stirring 1h, the
solids that formed were filtered (Celite) and the filtrate concentrated to give 186
as a pale colored oil (0.896 g, 98%).

The crude material was used without

purification in subsequent reactions.
A pure sample of 186 was generated through the deprotection of N-formyl
protected alcohol 187 (0.067g, 0.27 mmol) by dissolving 187 in THF (1 mL) and 4
M H2SO 4 (3 mL) and heating at 55 °C for 3 h. The reaction was made basic with
4 M NaOH, diluted with saturated NaHC 0 3 (10 mL) and extracted with CH 2 CI2 (5
x 10 mL).

The combined extracts were dried (K2CO 3) and concentrated to

provide pure 186 as an oily solid that solidified upon standing (0.052 g,

8 8 %).

TLC Rf 0.07 (MeOH:CH 2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.55 (m, 2H),
1.80 (m, 1H), 1.99 (m, 1H), 2.70 - 3.06 (m,
2H), 3.76 (m, 2H), 7.20 - 7.36 (m, 5H);

6

H, overlapped d at 2.73), 3.47 (s,

13C NMR (100 MHz, CDCI3):

45.3, 54.0, 55.4, 59.6, 61.7, 63.4, 127.0, 128.1, 129.1, 137.8.
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6

35.3,

Formic Acid

H N ^j

ohc' n ^

Acetic anhydride

HO

H

H

4-Benzyl-2-(2-hydroxyethyl)piperazine-1-carbaldehyde

Bn

187.

To a 0 °C

solution of amino alcohol 186 (0.853 g, 3.87 mmol) in formic acid (8 8 %, 11 mL)
was added (dropwise) acetic anhydride (3.25 g, 31.8 mmol). The reaction stirred
at 0 °C for 30 min then at ambient temperature for an additional 45 min. Ice (~15
g) was added and the contents were transferred to a beaker and placed in an ice
bath before the solution was brought to basic pH by the addition of 4 N NaOH.
The contents were diluted with saturated NaHCOs (20 mL) and extracted with
CH 2CI2 (5 x

20

mL).

The combined extracts were dried (K2CO 3) and

concentrated

to give the

crude

material that was

purified

by column

chromatography (silica gel, MeOHiCHCb, 1:49) to afford 187 as an almost
colorless oil (0.582g, 61%).

TLC Rf 0.47 (MeOH:CH 2 CI2, 1:9).

MHz, CDCI3): (approximate 7:3 mixture of amide rotamers)

6

1H NMR (400

1.66 - 1.85 (m, 1H),

1.95 - 2.12 (m, 1H), 2.14 - 2.34 (m, 2H), 2.72 - 2.97 (m, 2.7H), 3.08 (bm, 0.3H),
3.26 - 3.74 (m, 5.7H), 3.84 (m, 0.3H), 4.20 (m, 0.3H), 4.50 (m, 0.7H), 7.21 - 7.37
(m, 5H), 8.07 (m, 2 overlapped -C H O , 1H); 13C NMR (100 MHz, CDCI3):

8

32.6,

33.6, 36.5, 42.6, 45.3, 51.0, 52.3, 52.9, 56.1, 56.7, 58.1, 58.2, 62.5, 62.6, 127.3,
128.3, 128.7, 128.8, 137.5, 161.6, 162.2.
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OHC' N

^

DMF, NaH

0H C ' N ^ |

CHg-l

^

H O ^ ^ I ^ N 'Bn
H

rl

N ' Bn

4-Benzyl-2-(2-methoxyethyl)piperazine-1-carbaldehyde 188.
solution of alcohol 187 (0.500 g, 2.01 mmol) in dry DMF
(95%, 0.145 g, 6.04 mmol) in one portion.

(8

To a 0 °C

mL) was added NaH

After stirring 5 min, iodomethane

(0.300 g, 2.11 mmol) was added and the mixture stirred for 15 min at 0°C then at
ambient temperature for 1.5 h. The excess NaH was destroyed by the careful
addition of water and the mixture was diluted with 20 mL each of water and
saturated NaHC 0 3 . The aqueous mixture was extracted with EtOAc (4 x 30 mL)
and the combined extracts washed with brine (2 x 20 mL), dried (K2CO 3) and
concentrated

to

give the

crude

product that was

purified

by

column

chromatography (silica gel, MeOH:CHCI3, 1:199 - 1:49) to afford 188 as a loose,
almost colorless oil (0.493 g, 93%). TLC Rf 0.Q2 (MeOH:CH 2 CI2, 1:9). 1H NMR
(400 MHz, CDCI3): (approximate 7:3 mixture of amide rotamers)

6

1.81 (m, 0.7H),

1.91 (m, 0.3H), 1 .9 7 -2 .1 1 (m, 1.3H), 2.14 - 2.34 (m, 1.7H), 2.74 (m, 1H), 2 .7 9 2.95 (m, 1.7H), 3.17 - 3.36 (m, 5.7H), 3.39 - 3.57 (m, 2H), 3.75 (m, 0.7H), 4.20
(m, 0.7H), 4.50 (m, 0.3H), 7.22 - 7.38 (m, 5H), 8.03 (s, 1H); 13C NMR (100 MHz,
CDCI3): 5 29.8, 30.2, 36.2, 42.3, 46.0, 51.2, 52.7, 53.8, 55.7, 56.7, 58.5, 58.6,
62.7, 68.5, 69.9, 127.2, 128.3, 128.7, 138.0, 161.0, 161.4.
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ohc' n

^
THF, H 2 S 0 4
Bn

H

HN'

''j
Bn

H

1-Benzyl-3-(2-methoxyethyl)piperazine 189.

The N-formyl methylether 188

(0.493 g, 1 . 8 8 mmol) was dissolved in THF (3 mL) and 4 M H2 SO 4

(8

mL) and

heated at 60 °C for 4 h. After cooling, the reaction was poured into 16 mL of cold
(0 °C) 4 M NaOH and diluted with 10 mL of saturated NaHC 0 3 . The mixture was
extracted with CH 2CI2 (4 x

20

mL) and the combined extracts were dried (K2CO 3)

and concentrated to provide 189 as a pale colored oil (0.420 g, 95%) with
adequate purity for the subsequent transformations. TLC R f 0.16 (MeOH:CH 2Cl2 ,
1:9). 1H NMR (400 MHz, CDCI3):

8

1 .5 4 -1 .6 3 (m, 3H), 1.75 (m, 1H), 2.02 (td, J

= 3.7, 10.6 Hz, 1H), 2.69 - 2.79 (m, 2H), 2.83 - 2.95 (m, 3H), 3.29 (s, 3H), 3.44
(t, J =

6 .6

Hz, 2H), 3.47 (m, AB pattern, J = 13.2 Hz, 2H), 7.20 - 7.33 (m, 5H);

13C NMR (100 MHz, CDCI3):

6

34.2, 45.7, 53.3, 53.8, 58.6, 60.0, 63.3, 70.3,

126.9, 128.1, 129.0, 138.1.

Et2 0 , n-BuLi, 0 °C;
'Bn

2-chloroquinoline, Et20
H

2-[4-Benzyl-2-(2-methoxyethyl)piperazin-1-yl]quinoline 190.

Bn

To a 0 °C

solution of piperazine 189 (0.420 g, 1.79 mmol) in dry ether (20 mL) under argon
was added (dropwise) a solution of n-butyllithium in hexane (2.45 M, 1.79 mmol)
producing a clear amber solution. After stirring at 0 °C for 20 min, a solution of 2chloroquinoline (0.195 g, 1.20 mmol) in ether (3.5 mL) was added (dropwise),
producing a blood red solution. The reaction was stirred at 0 °C for 20 min then
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at ambient temperature for 3 h.

The solution was diluted with ether (10 mL),

washed with saturated NaHC 0 3 (1 x 20 mL) and brine (1 x 20 mL), then dried
(K2CO3) and concentrated.

The crude product was purified by column

chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide 190 as a thick yellow
oil (0.378 g,

88

%). TLC Rf 0.37 (EtOAc:Hexanes, 2:3).

1H NMR (400 MHz,

CDCI3): 5 2.12 (m, 1H), 2 .1 7 -2 .3 2 (m, 3H), 2.89 (m, 1H), 2.99 (m,

1 H),

3.23 (s,

3H, overlapped with), 3.22 - 3.41 (m, 3H), 3.46 (d, J = 13.2 Hz, 1H), 3.65 (d, J =
13.2 Hz, 1H), 4.59 (bm, 1H), 4.72 (bm, 1H), 7.06 (d, J = 9.2 Hz, 1H), 7.24 (m,
1H), 7.32 (m, 1H), 7.36 - 7.46 (m, 4H), 7.56 (m, 1H), 7.62 (m, 1H), 7.75 (d, J =
8.4

Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3):

8

29.2, 39.3,

49.4, 53.5, 55.6, 58.2, 62.8, 69.5, 109.5, 121.8, 122.7, 126.3, 126.9 (two peaks),
128.1, 128.7, 129.2, 137.0, 138.4, 147.9, 156.8.
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APPENDIX:
Select 1H and 13C NMR Spectra of Target Compounds.

0 ,N

1T

55 H O M -N Q P
H

2-[2-(Hydroxymethyl)piperzin-1 -yl]-6-nitroquinoline 55.
1H NMR:

1
13C NMR:
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40

30

N'

'N

''j

58 N-Boc-HOM-NQP

H

2-[4-(ferf-Butoxycarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline
58.
1H NMR:
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30

20

N'

61 MeProF-NQP
' _ NH
H ^

2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline 61.
1H NMR:
Full spectrum:
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1.5

OoN
61 MeProF-NQP

13C NMR:
Full spectrum:
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30

N

65 MeProF-Tosylate-NQP

N ^ ^ |

Boc

2-[4-(fert-Butoxycarbonyl)-2-((3-(4-methylbenzenesulfonate)propoxy)
methyl)piperazine-1-yl]-6-nitroquinoline 65.
1H NMR:

13C NMR:
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N

N '^ 'l

78 EtOMe-NQP

\
H

2-[2-(2-Methoxyethyl)piperazin-1-yl]-6-nitroquinoline 78.
1H NMR:

13C NMR:
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NH

2-[2-Phenylpiperazin-1 -y l]-6-nitroquinoline 135.
'H NMR:
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2-[2-Benzylpiperazin-1-yl]-6-nitroquinoline 136.
1H NMR:

13C NMR:

l» l» 'I* —I

160

150

140

130

120

110

100

>« M>

90

80

70

60

50

215

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

40

30

LITERATURE CITED
1.

Perrine, D. M., The Chemistry of Mind-Altering Drugs. 1st ed.; American
Chemical Society: Washington D.C., 1996; p 480.

2.

von Bohlen und Halbach, O.; Dermietzel, R., Neurotransmitters and
Neuromodulators: Handbook of Receptors and Biological Effects. 1st ed.; WileyVCH Verlag GmbH: 2002; p 107-115.

3.

Randall, D.; Burggren, W.; French, K., Eckert Animal Physiology Mechanisms
and Adaptations. 4th ed.; W. H. Freeman and Company: New York, 1997; p 728.

4.

Childers, W. E. J.; Robichaud, A. J., Recent Advances in Selective Serotonergic
Agents. In Annual Reports in Medicinal Chemistry, Doherty, A. M., Ed. Elsevier:
Amsterdam, 2005; Vol. 40, pp 17-33.

5.

Glennon, R. A., Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J
Med Chem 2003, 46, (14), 2795-812.

6.

Pauwels, P. J., 5-HT Receptors and their Ligands, Tocris Review No. 25. In
2003.

7.

Muller-Oerlinghausen, B.; Roggenbach, J.; Franke, L., Serotonergic platelet
markers of suicidal behavior-do they really exist? J Affect Disord 2004, 79, (1-3),
13-24.

8.

Tonini, M.; Vicini, R.; Cervio, E.; De Ponti, F.; De Giorgio, R.; Barbara, G.;
Stanghellini, V.; Dellabianca, A.; Sternini, C., 5-HT7 receptors modulate
peristalsis and accommodation in the guinea pig ileum. Gastroenterology 2005,
129, (5), 1557-66.

9.

Chapman, M. E.; Wideman, R. F., Jr., Evaluation of the serotonin receptor
blockers ketanserin and methiothepin on the pulmonary hypertensive responses
of broilers to intravenously infused serotonin. Poult Sci 2006, 85, (4), 777-86.

10.

Sommer, C., Serotonin in pain and analgesia: actions in the periphery. Mol
Neurobiol 2004, 30, (2), 117-25.

11.

Ravna, A. W.; Sylte, I.; Dahl, S. G., Molecular mechanism of citalopram and
cocaine interactions with neurotransmitter transporters. J Pharmacol Exp Ther
2003, 307, (1), 34-41.

12.

Ramamoorthy, S.; Bauman, A. L.; Moore, K. R.; Han, H.; Yang-Feng, T.; Chang,
A. S.; Ganapathy, V.; Blakely, R. D., Antidepressant- and cocaine-sensitive
human serotonin transporter: molecular cloning, expression, and chromosomal
localization. Proc Natl Acad Sci U S A 1993, 90, (6), 2542-6.

13.

Henry, L. K.; Field, J. R.; Adkins, E. M.; Parnas, M. L.; Vaughan, R. A.; Zou, M.
F.; Newman, A. H.; Blakely, R. D., Tyr-95 and lle-172 in transmembrane
segments 1 and 3 of human serotonin transporters interact to establish high
affinity recognition of antidepressants. J Biol Chem 2006, 281, (4), 2012-23.
216

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

14.

Plenge, P.; Wiborg, 0 ., High- and low-affinity binding of S-citalopram to the
human serotonin transporter mutated at 20 putatively important amino acid
positions. Neurosci Lett 2005, 383, (3), 203-8.

15.

Ravna, A. W.; Edvardsen, O., A putative three-dimensional arrangement of the
human serotonin transporter transmembrane helices: a tool to aid experimental
studies. J Mol Graph Model 2001, 20, (2), 133-44.

16.

Barker, E. L.; Blakely, R. D., Identification of a single amino acid, phenylalanine
586, that is responsible for high affinity interactions of tricyclic antidepressants
with the human serotonin transporter. Mol Pharmacol 1996, 50, (4), 957-65.

17.

Chen, J. G.; Sachpatzidis, A.; Rudnick, G., The third transmembrane domain of
the serotonin transporter contains residues associated with substrate and
cocaine binding. J Biol Chem 1997, 272, (45), 28321-7.

18.

Sur, C.; Betz, H.; Schloss, P., A single serine residue controls the cation
dependence of substrate transport by the rat serotonin transporter. Proc Natl
Acad Sci U S A 1997, 94, (14), 7639-44.

19.

Huang, Y.; Lemieux, M. J.; Song, J.; Auer, M.; Wang, D. N., Structure and
mechanism of the glycerol-3-phosphate transporter from Escherichia coli.
Science 2003, 301, (5633), 616-20.

20.

Abramson, J.; Smirnova, I.; Kasho, V.; Verner, G.; Kaback, H. R.; Iwata, S.,
Structure and mechanism of the lactose permease of Escherichia coli. Science
2003, 301, (5633), 610-5.

21.

Ravna, A. W.; Sylte, I.; Kristiansen, K.; Dahl, S. G., Putative drug binding
conformations of monoamine transporters. Bioorg M ed Chem 2006,14, (3), 66675.

22.

Yamashita, A.; Singh, S. K.; Kawate, T.; Jin, Y.; Gouaux, E., Crystal structure of
a bacterial homologue of Na+/CI-dependent neurotransmitter transporters.
Nature 2005, 437, (7056), 215-23.

23.

Hesse, S.; Barthel, H.; Schwarz, J.; Sabri, O.; Muller, U., Advances in in vivo
imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci
Biobehav Rev 2004, 28, (6), 547-63.

24.

Stockmeier, C. A., Involvement of serotonin in depression: evidence from
postmortem and imaging studies of serotonin receptors and the serotonin
transporter. J Psychiatr Res 2003, 37, (5), 357-73.

25.

Battaglia, G.; Zaczek, R.; De Souza, E. B., MDMA effects in the brain:
pharmacological profile and evidence of neurotoxicity from neurochemical and
autoradiographic studies. In Ecstacy: the clinical, pharmacological and
neurotoxilogical effects o f the drug MDMA, Peroutka, S. J., Ed. Kluwer Academic
Press: Boston, 1990; pp 171-199.

217

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

26.

Rosel, P.; Menchon, J. M.; Oros, M.; Vallejo, J.; Cortadellas, T.; Arranz, B.;
Alvarez, P.; Navarro, M. A., Regional distribution of specific high affinity binding
sites for 3H-imipramine and 3H-paroxetine in human brain. J Neural Transm
1997, 104, (1), 89-96.

27.

Plenge, P.; Mellerup, E. T.; Laursen, H., Regional distribution of the serotonin
transport complex in human brain, identified with 3H-paroxetine, 3H-citalopram
and 3H-imipramine. Prog Neuropsychopharmacol Biol Psychiatry 1990,14, (1),
61-72.

28.

Backstrom, I.; Bergstrom, M.; Marcusson, J., High affinity [3H]paroxetine binding
to serotonin uptake sites in human brain tissue. Brain Res 1989, 486, (2), 261-8.

29.

Cortes, R.; Soriano, E.; Pazos, A.; Probst, A.; Palacios, J. M., Autoradiography of
antidepressant binding sites in the human brain: localization using
[3H]imipramine and [3H]paroxetine. Neuroscience 1988, 27, (2), 473-96.

30.

Dahlstrom, M.; Ahonen, A.; Ebeling, H.; Torniainen, P.; Heikkila, J.; Moilanen, I.,
Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in
depressive drug-naive children and adolescents. Mol Psychiatry 2000, 5, (5),
514-22.

31.

Malison, R. T.; Price, L. H.; Berman, R.; van Dyck, C. H.; Pelton, G. H.;
Carpenter, L.; Sanacora, G.; Owens, M. J.; Nemeroff, C. B.; Rajeevan, N.;
Baldwin, R. M.; Seibyl, J. P.; Innis, R. B.; Charney, D. S., Reduced brain
serotonin transporter availability in major depression as measured by [123l]-2
beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission
computed tomography. Biol Psychiatry 1998, 44, (11), 1090-8.

32.

Frazer, A., Pharmacology of antidepressants. J Clin Psychopharmacol 1997,17
Suppl 1, 2S-18S.

33.

Poe, T. E., Fluoxetine. A new antidepressant. N C M ed J 1988, 49, (7), 391-2.

34.

Schyler, D. J., PET Tracers and Radiochemistry. Ann. Acad. Med. Singapore
2004, 33, 146-154.

35.

Berkheij, M.; van der Sluis, L.; Sewing, C.; den Boer, D. J.; Terpstra, J. W.;
Hiemstra, H.; Bakker, W. 1.1.; van den Hoogenband, A.; van Maarseveen, J. H.,
Synthesis of 2-substituted piperazines via direct alpha-lithiation. Tet Lett 2005,
46, 2369-2371.

36.

Lundkvist, C.; Loc'h, C.; Halldin, C.; Bottlaender, M.; Ottaviani, M.; Coulon, C.;
Fuseau, C.; Mathis, C.; Farde, L.; M aziere, B., Characterization of brom ine-76labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter.
Nucl M ed Biol 1999, 26, (5), 501-7.

37.

Pirotte, B.; Goldman, S.; Dewitte, O.; Massager, N.; Wikler, D.; Lefranc, F.; Ben
Taib, N. O.; Rorive, S.; David, P.; Brotchi, J.; Levivier, M., Integrated positron
emission tomography and magnetic resonance imaging-guided resection of brain

218

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

tumors: a report of 103 consecutive procedures. J Neurosurg 2006, 104, (2),
238-53.
38.

Mason, N. S.; Mathis, C. A., Positron Emission Tomography Agents for Central
Nervous System Drug Development Applications. In Annual Reports in Medicinal
Chemistry, Doherty, A. M., Ed. Elsevier: Amsterdam, 2005; Vol. 40, pp 49-68.

39.

Mathis, C. A.; Wang, Y.; Klunk, W. E., Imaging beta-amyloid plaques and
neurofibrillary tangles in the aging human brain. CurrPharm Des 2004,10, (13),
1469-92.

40.

Laruelle, M.; Slifstein, M.; Huang, Y., Relationships between radiotracer
properties and image quality in molecular imaging of the brain with positron
emission tomography. Mol Imaging Biol 2003, 5, (6), 363-75.

41.

Wong, D. F.; Pomper, M. G., Predicting the success of a radiopharmaceutical for
in vivo imaging of central nervous system neuroreceptor systems. Mol Imaging
Biol 2003, 5, (6), 350-62.

42.

Neumeyer, J. L.; Wang, S. Y.; Milius, R. A.; Baldwin, R. M.; Zea-Ponce, Y.;
Hoffer, P. B.; Sybirska, E.; al-Tikriti, M.; Charney, D. S.; Malison, R. T.; et al.,
[123l]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT
radiotracer of monoamine reuptake sites in brain. J M ed Chem 1991, 34, (10),
3144-6.

43.

Frankie, W. G.; Narendran, R.; Huang, Y.; Hwang, D. R.; Lombardo, I.;
Cangiano, C.; Gil, R.; Laruelle, M.; Abi-Dargham, A., Serotonin transporter
availability in patients with schizophrenia: a positron emission tomography
imaging study with [11C]DASB. Biol Psychiatry 2005, 57, (12), 1510-6.

44.

Szabo, Z.; Kao, P. F.; Scheffel, U.; Suehiro, M.; Mathews, W. B.; Ravert, H. T.;
Musachio, J. L.; Marenco, S.; Kim, S. E.; Ricaurte, G. A.; et al., Positron emission
tomography imaging of serotonin transporters in the human brain using
[11 C](+)McN5652. Synapse 1995, 20, (1), 37-43.

45.

Reivich, M.; Amsterdam, J. D.; Brunswick, D. J.; Shiue, C. Y., PET brain imaging
with [11C](+)McN5652 shows increased serotonin transporter availability in major
depression. J Affect Disord 2004, 82, (2), 321-7.

46.

McCann, U. D.; Szabo, Z.; Seckin, E.; Rosenblatt, P.; Mathews, W. B.; Ravert, H.
T.; Dannals, R. F.; Ricaurte, G. A., Quantitative PET studies of the serotonin
transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.
Neuropsychopharmacology 2005, 30, (9), 1741-50.

47.

Huang, Y.; Hwang, D. R.; Narendran, R.; Sudo, Y.; Chatterjee, R.; Bae, S. A.;
Mawlawi, O.; Kegeles, L. S.; Wilson, A. A.; Kung, H. F.; Laruelle, M.,
Comparative evaluation in nonhuman primates of five PET radiotracers for
imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB,
[11 CjDAPA, and [11 CjAFM. J Cereb Blood Flow Metab 2002, 22, (11), 1377-98.

219

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48.

Brust, P.; Zessin, J.; Kuwabara, H.; Pawelke, B.; Kretzschmar, M.; Hinz, R.;
Bergman, J.; Eskola, O.; Solin, O.; Steinbach, J.; Johannsen, B., Positron
emission tomography imaging of the serotonin transporter in the pig brain using
[11 C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse 2003, 47,
(2), 143-51.

49.

Brust, P.; Hinz, R.; Kuwabara, H.; Hesse, S.; Zessin, J.; Pawelke, B.; Stephan,
H.; Bergmann, R.; Steinbach, J.; Sabri, O., In vivo measurement of the serotonin
transporter with (S)-([18F]fluoromethyl)-(+)-McN5652.
Neuropsychopharmacology 2003, 28, (11), 2010-9.

50.

Meyer, J. H.; Houle, S.; Sagrati, S.; Carella, A.; Hussey, D. F.; Ginovart, N.;
Goulding, V.; Kennedy, J.; Wilson, A. A., Brain serotonin transporter binding
potential measured with carbon 11-labeled DASB positron emission tomography:
effects of major depressive episodes and severity of dysfunctional attitudes. Arch
Gen Psychiatry 2004, 61, (12), 1271-9.

51.

Huang, Y.; Hwang, D. R.; Bae, S. A.; Sudo, Y.; Guo, N.; Zhu, Z.; Narendran, R.;
Laruelle, M., A new positron emission tomography imaging agent for the
serotonin transporter: synthesis, pharmacological characterization, and kinetic
analysis of [11 C]2-[2-(dimethylaminomethyl)phenylthio]-5fluoromethylphenylamine ([11C]AFM). Nucl M ed Biol 2004, 31, (5), 543-56.

52.

Huang, Y.; Bae, S. A.; Zhu, Z.; Guo, N.; Roth, B. L.; Laruelle, M., Fluorinated
diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity
relationship study, and in vivo evaluation of fluorine-18-labeled compounds as
PET imaging agents. J M ed Chem 2005, 48, (7), 2559-70.

53.

Frankie, W. G.; Huang, Y.; Hwang, D. R.; Talbot, P. S.; Slifstein, M.; Van
Heertum, R.; Abi-Dargham, A.; Laruelle, M., Comparative evaluation of serotonin
transporter radioligands 11C-DASB and 11 C-McN 5652 in healthy humans. J
Nucl M ed 2004, 45, (4), 682-94.

54.

Lee, B. S.; Chu, S.; Lee, K. C.; Lee, B. S.; Chi, D. Y.; Choe, Y. S.; Kim, S. E.;
Song, Y. S.; Jin, C., Syntheses and binding affinities of 6-nitroquipazine
analogues for serotonin transporter: Part 3. A potential 5-HT transporter imaging
agent, 3-(3-[18F]fluoropropyl)-6-nitroquipazine. Bioorg M ed Chem 2003,11, (23),
4949-58.

55.

Sandell, J.; Halldin, C.; Sovago, J.; Chou, Y. H.; Gulyas, B.; Yu, M.; Emond, P.;
Nagren, K.; Guilloteau, D.; Farde, L., PET examination of [(11)C]5-methyl-6nitroquipazine, a radioligand for visualization of the serotonin transporter. Nucl
M ed Biol 2002, 29, (6), 651-6.

56.

Karramkam, M.; Dolle, F.; Valette, H.; Besret, L.; Bramoulle, Y.; Hinnen, F.;
Vaufrey, F.; Franklin, C.; Bourg, S.; Coulon, C.; Ottaviani, M.; Delaforge, M.;
Loc'h, C.; Bottlaender, M.; Crouzel, C., Synthesis of a fluorine-18-labelled
derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin
transporter imaging with PET. Bioorg M ed Chem 2002,10, (8), 2611-23.

220

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

57.

Jagust, W. J.; Eberling, J. L.; Biegon, A.; Taylor, S. E.; VanBrocklin, H. F.;
Jordan, S.; Hanrahan, S. M.; Roberts, J. A.; Brennan, K. M.; Mathis, C. A.,
Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin
transporter. J Nucl Med 1996, 37, (7), 1207-14.

58.

Jensen, S. B.; Bender, D.; Smith, D. F.; Scheel-Kruger, J.; Nielsen, E. O.; Olsen,
G. M.; Peter, D.; Gjedde, A., Synthesis of (+/-) 3-(6-nitro-2-quinolinyl)-[9-methyl11C]-3,9-diazabicyclo-[4.2.1]-nonane ([11 C-Methyl]NS 4194). J Label Cmpd
Radiopharm 2002, 45, 181-189.

59.

Jensen, S. B.; Smith, D. F.; Bender, D.; Jakobsen, S.; Peters, D.; Nielsen, E. O.;
Olsen, G. M.; Scheel-Kruger, J.; Wilson, A.; Cumming, P., [11C]-NS 4194 versus
[11 C]-DASB for PET imaging of serotonin transporters in living porcine brain.
Synapse 2003, 49, (3), 170-7.

60.

Vaatstra, W. J.; Deiman-Van Aalst, W. M.; Eigeman, L., Du 24565, a quipazine
derivative, a potent selective serotonin uptake inhibitor. Eur J Pharmacol 1981,
70, (2), 195-202.

61.

Hashimoto, K.; Goromaru, T., Preparation of [3H]6-nitroquipazine, a potent and
selective 5-hydroxytryptamine uptake inhibitor. Radioisotopes 1990, 39, (4), 1689.

62.

Hashimoto, K.; Goromaru, T., High-affinity binding of [3H]6-nitroquipazine to 5hydroxytryptamine transporter in human platelets. Eur J Pharmacol 1990,187,
(3), 295-302.

63.

Hashimoto, K.; Goromaru, T., High-affinity [3H]6-nitroquipazine binding sites in
rat brain. E u rJ Pharmacol 1990,180, (2-3), 273-81.

64.

Gerdes, J. M.; DeFina, S. C.; Wilson, P. A.; Taylor, S. E., Serotonin transporter
inhibitors: synthesis and binding potency of 2'-methyl- and 3'-methyl-6nitroquipazine. Bioorg Med Chem Lett 2000,10, (23), 2643-6.

65.

Wilson, P. A. A Simple Methodology for the Production of Three-Dimensional
Models: Serotonin Transporter as an Example. PhD Dissertation. University of
Montana, Missoula, MT, 2004.

66.

Bolstad, E. S. D. Comparative Analysis of Serotonin and Norepinephrine
Reuptake Inhibitor Pharmacophore Constructs for Ligand Designs. PhD
Dissertation. University of Montana, Missoula, MT, 2006.

67.

Walker, M. A. Serotonin Transporter Inhibitors: Studies of Z-substituted-6nitroquipazine Agents. M asters Thesis. Central W ashington University,

Ellensburg, WA, 2001.
68.

Rondu, F.; Le Bihan, G.; Wang, X.; Lamouri, A.; Touboul, E.; Dive, G.;
Bellahsene, T.; Pfeiffer, B.; Renard, P.; Guardiola-Lemaitre, B.; Manechez, D.;
Penicaud, L.; Ktorza, A.; Godfroid, J. J., Design and synthesis of imidazoline
derivatives active on glucose homeostasis in a rat model of type II diabetes. 1.

221

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Synthesis and biological activities of N-benzyl-N,-(arylalkyl)-2-(4,,5'-dihydro-1'Himidazol-2'-yl)piperazines. J Med Chem 1997, 40, (23), 3793-803.
69.

Gilman, H.; Crounse, N. N.; Massie Jr., S. P.; Benkeser, R. A.; Spatz, S. M.,
Rearrangement in the Reaction of alpha-Halogenonaphthalenes with Lithium
Diethyl-amide. J Am Chem Soc 1945, 67, 2106-2108.

70.

Bolstad, D. B.; Chandler-Ferguson, D.; Davis, E. S.; DeFina, S. C.; Gerdes, J.
M.; Walker, M. A.; Weller, M. L.; Wilson, P. A.; Ono, M. Y.; Taylor, S. E„
Serotonin Transporter Inhibitor Ligands: Synthesis and Biochemical Studies of
2'-Methoxymethyl-6-nitroquipazine. In The 221st American Chemical Society
National Meeting, Chicago, IL, 2001.

71.

Lee, B. S.; Chu, S.; Lee, B. C.; Chi, D. Y.; Choe, Y. S.; Jeong, K. J.; Jin, C.,
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin
transporter. Part 1. Bioorg Med Chem Lett 2000,10, (14), 1559-62.

72.

Se Lee, B.; Chu, S.; Lee, B. S.; Yoon Chi, D.; Song, Y. S.; Jin, C., Syntheses and
binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2:
4-substituted 6-nitroquipazines. Bioorg Med Chem Lett 2002,12, (5), 811-5.

73.

Moon, B. S.; Lee, B. S.; Chi, D. Y., Syntheses and binding affinities of 6nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6nitroquipazines. Bioorg Med Chem 2005,13, (16), 4952-9.

74.

Kusche, B. R. Serotonin Transporter Inhibitor Ligands: Synthesis of 2-(2-alkylpiperazin-1-yl)-6-nitroquipazine Analogs as Potential Positron Emission
Tomography Imaging Agents. PhD Dissertation. University of Montana,
Missoula, MT, 2006.

75.

Olah, G. A.; Narang, S. C., lodotrimethylsilane - A versatile synthetic reagent.
Tetrahedron 1982, 38, (15), 2225-2277.

76.

Jung, M. E.; Lyster, M. A., Quantitative Dealkylation of Alkyl Ethers via Treatment
with Trimethylsilyl Iodide. A New Method for Ether Hydrolysis. J Org Chem 1977,
42, (23), 3761-3764.

77.

Olah, G. A.; Narang, S. C.; Balarma Gupta, B. G.; Malhotra, R., Synthetic
Methods and Reactions. 62. Transformations with Chlorotrimethylsilane/Sodium
Iodide, a Convenient in Situ lodotrimethylsilane Reagent. J Org Chem 1979, 44,
(8), 1247-1251.

78.

McOmie, J. F. W.; Watts, M. L.; West, D. E., Demethylation of Aryl Methyl Ethers
by Boron Tribromide. Tetrahedron 1968, 24, 2 2 8 9 -2 2 9 2 .

79.

Greene, T. W.; Wuts, P. G. M., Protective groups in Organic Synthesis. 3rd ed.;
John Wiley & Sons, Inc.: New York, 1999; p 779.

80.

Demuynck, M.; De Clercq, P.; Vandewalle, M., (+/-)-Hysterin: RevisedStructure
and Total Synthesis. J Org Chem 1979, 44, (26), 4863-4866.

222

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

81.

Personal communication (E-mail) with Dr. Hong Fan, 2001.

82.

Jacobsen, E. J.; Stelzer, L. S.; TenBrink, R. E.; Belonga, K. L.; Carter, D. B.; Im,
H. K.; Im, W. B.; Sethy, V. H.; Tang, A. H.; VonVoigtlander, P. F.; Petke, J. D.;
Zhong, W. Z.; Mickelson, J. W., Piperazine imidazo[1,5-a]quinoxaline ureas as
high-affinity GABAA ligands of dual functionality. J Med Chem 1999, 42, (7),
1123-44.

83.

Le Bail, M.; Aitken, D. J.; Vergne, F.; Husson, H.-P., Alkylation of chiral 2(aminomethyl)oxazolines. J Chem Soc Perk T 1 1997,11, 1681-1689.

84.

Green, T. W.; Wuts, P. G. M., Protective Groups in Organic Synthesis. 3rd ed.;
John Wiley & Sons: New York, 1999; p 779.

85.

Frank, R.; Schutkowski, M., Extremely mild reagent for Boc deprotection
applicable to the synthesis of peptides with thioamide linkages. Chem. Commun.
1996, (22), 2501-2510.

86.

Kaiser, E.; Picart, F.; Kubiak, T.; Tam, J. P.; Merrifield, R. B., Selective
Deprotectcion of the N-tert-Butylooxycarbonyl Group in Solid Phase Peptide
Synthesis with Chlorotrimethylsilane and Phenol. J Org Chem 1993, 58, 5167SI 75.

87.

Brown, H. C.; Knights, E. F.; Scouten, C. G., Hydroboration. XXXVI. A Direct
Route to 9-Borabicyclo[3.3.1]nonane via the Cyclic Hydroboration of 1,5Cyclooctadiene. 9-Borabicyclo[3.3.1]nonane as a Uniquely Selective Reagent for
the Hydroboration of Olefins. J Am Chem Soc 1974, 96, (25), 7765-7770.

88.

Cox, D. P.; Terpinski, J.; Lawrynowicz, W., "Anhydrous" Tetrabutylammonium
Fluoride: A Mild but Highly Efficient Source of Nucleophilic Fluoride Ion. J Org
Chem 1984, 49, (17), 3216-3219.

89.

Bishop, J. E.; Mathis, C. A.; Gerdes, J. M.; Whitney, J. M.; Eaton, A. M.;
Mailman, R. B., Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors. J
Med Chem 1991, 34, (5), 1612-24.

90.

Le Bihan, G.; Rondu, F.; Pele-Tounian, A.; Wang, X.; Lidy, S.; Touboul, E.;
Lamouri, A.; Dive, G.; Huet, J.; Pfeiffer, B.; Renard, P.; Guardiola-Lemaitre, B.;
Manechez, D.; Penicaud, L.; Ktorza, A.; Godfroid, J. J., Design and synthesis of
imidazoline derivatives active on glucose homeostasis in a rat model of type II
diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and
1-benzyl-4-alkyl-2-(4',5,-dihydro-TH-imidazol-2'-yl)piperazines and isosteric
analogues of imidazoline. J Med Chem 1999, 42, (9), 1587-603.

91.

Bunnett, J. F.; Happer, D. A. R.; Patsch, M.; Pyun, C.; Takayama, H.,
Orientation, Reactivity, and Mechanism in the Addition of Methanol to 4Chlorobenzyne. J Am Chem Soc 1966, 88, (22), 5250-5254.

223

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

92.

Carey, F. C.; Sundberg, R. J., Advanced Organic Chemistry Part A: Structure
and Mechanism. 4th ed.; Kluwer Academic / Plenum Publishers: New York,
2000; p 823.

93.

Roberts, J. D.; Semenow, D. A.; Simmons, H. E.; Carlsmith, J. L. A., The
Mechanism of Aminations of Halobenzenes. J Am Chem Soc 1956, 78, (3), 601611.

94.

Biehl, E. R.; Nieh, E.; Hsu, K. C., Substituent effects on the reactivity of arynes.
Product distributions as an index of relative reactivities of arynes in methylamine
and dimethylamine solvents. J Org Chem 1969, 34, (11), 3595-3599.

95.

Cannon, S. J.; Hegarty, A. F., Diels-Alder cycloadditions of stabilised 2,3pyridynes. Tet Lett 2001, 42, (4), 735-737.

96.

Mock, B. H.; Vavrek, M. T.; Mulholland, G. K., Solid-phase reversible trap for
[11 CJcarbon dioxide using carbon molecular sieves. Nucl Med Biol 1995, 22, (5),
667-70.

97.

Langstrom, B.; Lundquist, H., Int. J. Appl. Radiat. Isot. 1976, 27, 357.

98.

Kretzschmar, M.; Brust, P.; Zessin, J.; Cumming, P.; Bergmann, R.; Johannsen,
B., Autoradiographic imaging of the serotonin transporter in the brain of rats and
pigs using S-([18F]fluoromethyl)-(+)-McN5652. Eur Neuropsychopharmacol
2003, 13, (5), 387-97.

99.

Jones, F. N.; Velasquez, V., Effect of repeated discriminations on the
identifiability of the enantiomers of carvone. Percept Mot Skills 1974, 38, (3),
1001- 2 .

100.

Matthews, S. J.; McCoy, C., Thalidomide: a review of approved and
investigational uses. Clin Ther 2003, 25, (2), 342-95.

101.

Manning, B. H.; Mao, J.; Frenk, H.; Price, D. D.; Mayer, D. J., Continuous co
administration of dextromethorphan or MK-801 with morphine: attenuation of
morphine dependence and naloxone-reversible attenuation of morphine
tolerance. Pain 1996, 67, (1), 79-88.

102.

Stinson, S. C., Chiral Pharmaceuticals. Chemical & Engineering News 2001, 79,
(40), 79-97.

103.

Davis, E. S.; Gerdes, J. M.; Walker, M. A.; Weller, M. L.; Wilson, P. A.; DeVietti,
T. L.; Renk, K. J.; Ono, M. Y.; Taylor, S. E., Studies of the Serotonin Transporter:
Synthetic, Pharm acological and W hole Anim al Investigations of Inhibitor 2'Methyl-6-nitroquipazine. In The 221st American Chemical Society National
Meeting, Chicago, IL, 2001.

104.

Wu, G.; Zhao, H.; Luo, R. G.; Wei, D.; Malhotra, S. V., Chiral synthesis and
enzymatic resolution of (S)-(-)piperazine-2-carboxylic acid using enzyme
alcalase. Enantiomer 2001, 6, (6), 343-5.

224

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

105.

Binisti, C.; Assogba, L.; Touboul, E.; Mounier, C.; Huet, J.; Ombetta, J. E.; Dong,
C. Z.; Redeuilh, C.; Heymans, F.; Godfroid, J. J., Structure-activity relationships
in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase
A(2) inhibition: syntheses and structure-activity relationships in 1-arylsulfamido-2alkylpiperazines. E u rJ Med Chem 2 0 01, 36, (10), 809-28.

106.

Weigl, M.; Wunsch, B., Synthesis of 6,8-diazabicyclo[3.2.2]nonanes:
Conformationally Restricted Piperazine Derivatives. Org Lett 2 0 00, 2, (9), 11779.

107.

Dinsmore, C. J.; Bergman, J. M.; Bogusky, M. J.; Culberson, J. C.; Hamilton, K.
A.; Graham, S. L., 3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics:
synthesis of a conformationally restricted inhibitor of farnesyltransferase. Org Lett
2 0 01 , 3, (6), 865-8.

108.

Dinsmore, C. J.; Zartman, C. B., Efficient synthesis of substituted piperazinones
via tandem reductive amination-cyclization. Tet Lett 2000, 41, 6309-6312.

109.

Soukara, S.; Wunsch, B., A Facile Synthesis of Enantiomerically Pure 1(Piperazin-2-yl)ethan-1-ol Derivatives from (2S,3R)-Threonine. Synthesis 1 999,
1999, (10), 1739-1746.

110.

Bedurftig, S.; Wunsch, B., Synthesis and receptor binding studies of 3substituted piperazine derivatives. E u rJ Med Chem 2 0 0 6 , 41, (3), 387-396.

111.

Naylor, A.; Judd, D. B.; Lloyd, J. E.; Scopes, D. I.; Hayes, A. G.; Birch, P. J., A
potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2[(dialkylamino)methyl]piperazines. J Med Chem 1993, 36, (15), 2075-83.

112.

Velluz, L.; Amiard, G.; Heymes, R., Utilization of N-benzyl intremediates in
peptide synthesis. 1. Benzylamino acid chlorides. Bull Soc Chim Fr 1954, 10121015.

113.

Andurkar, S. V.; Stables, J. P.; Kohn, H., Synthesis and anticonvulsant activities
of (R)-(0)-methylserine derivatives. TetAsym 1998, 9, 3841-3854.

114.

Sheehan, J. C.; Yang, D.-D. H., The Use of N-Formylamino Acids in Peptide
Synthesis. J Am Chem Soc 1 958, 80, 1154-1158.

115.

Ghosh, S.; Santulli, R. J.; Kinney, W. A.; Decode, B. L.; Liu, L.; Lewis, J. M.;
Proost, J. C.; Leo, G. C.; Masucci, J.; Hageman, W. E.; Thompson, A. S.; Chen,
I.; Kawahama, R.; Tuman, R. W.; Galemmo, R. A., Jr.; Johnson, D. L.; Damiano,
B. P.; Maryanoff, B. E., 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3
integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett
2 0 04 , 14, (23), 5937-41.

116.

Olofson, R. A.; Martz, J. T.; Senet, J.-P.; Piteau, M.; Malfroot, T., A New Reagnet
for the Selective, High-Yield N-Dealkylation of Tertiary Amines: Improved
Synthesis of Naltrexone and Nalbuphine. J Org Chem 1 984, 49, 2081-2082.

225

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

117.

Gilbert, S.; Braojos, C.; Sacristan, A.; Ortiz, J. A., A Convenient Synthesis of
Parent and 2-Substituted Octahydro-2H-pyrazino[1,2-alpha]-pyrazines. Synthesis
1991, 1991, (4), 318-320.

118.

Kudzma, L. V.; Severnak, S. A.; Benvenga, M. J.; Ezell, E. F.; Ossipov, M. H.;
Knight, V. V.; Rudo, F. G.; Spencer, H. K.; Spaulding, T. C., 4-Phenyl- and 4heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
J Med Chem 1989, 32, (12), 2534-42.

119.

Bernady, K. F.; Brawner Floyd, M.; Poletto, J. F.; Weiss, M. J., Prostaglandins
and Congeners. 20. Synthesis of Prostaglandins via Conjugate Addition of
Lithium trans-1-Alkenyltrialkylalanate reagents. A Novel reagent for Conjugate
1,4-Additions. J Org Chem 1979, 44, (9), 1438-1447.

120.

Middleton, W. J., New Fluorinating Reagents. Dialkylaminosulfur Fluorides. J
Org Chem 1975, 40, (5), 574-578.

121.

Strazzolini, P.; Giumanini, A. G.; Runcio, A., Nitric acid in dichloromethane
solution. Facile preparation from potassium nitrate and sulfuric acid. Tet Lett
2001,42, 1387-1389.

122.

Dale, J. A.; Mosher, H. S., Nuclear Magnetic Resonance Enantiomer Reagents.
Configurational Correlations via Nuclear Magnetic Resonance Chemical Shits of
Diastereomeric Mandelate, O-Methylmandelate, and alpha-Methoxy-alphatrifluoromethylphenylacetate (MTPA) Esters. J Am Chem Soc 1973, 95, 512-519.

123.

Plenge, P.; Mellerup, E. T., Antidepressive drugs can change the affinity of
[3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes.
E urJ Pharmacol 1985, 119, (1-2), 1-8.

124.

Plenge, P.; Mellerup, E. T.; Laursen, H., Affinity modulation of [3H]imipramine,
[3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and
platelets. Eur J Pharmacol 1991, 206, (3), 243-50.

125.

Plenge, P.; Mellerup, E. T., An affinity-modulating site on neuronal monoamine
transport proteins. Pharmacol Toxicol 1997, 80, (4), 197-201.

126.

Chang, A. S.; Chang, S. M., Nongenomic steroidal modulation of high-affinity
serotonin transport. Biochim Biophys Acta 1999,1417, (1), 157-66.

127.

Weller, M. L.; Gerdes, J. M., Neurosteroids and Bioflavonoid Steroid Mimics as
SSRI Binding Affinity Modulators for the Serotonin Transporter. In 32nd Society
for Neuroscience National Meeting, Orlando, FL, 2002.

128.

Katzenellenbogen, J. A., The structural pervasiveness of estrogenic activity.
Environ Health Perspect 1995, 103 Suppl 7, 99-101.

129.

Griffin, L. D.; Mellon, S. H., Selective serotonin reuptake inhibitors directly alter
activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999, 96, (23),
13512-7.

226

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

130.

Woodrum, S. T.; Brown, C. S., Management of SSRI-induced sexual dysfunction.
Ann Pharmacother 1998, 32, (11), 1209-15.

131.

Rosen, R. C.; Lane, R. M.; Menza, M., Effects of SSRIs on sexual function: a
critical review. J Clin Psychopharmacol 1999,19, (1), 67-85.

132.

Morrell, M. J.; Flynn, K. L.; Done, S.; Flaster, E.; Kalayjian, L.; Pack, A. M.,
Sexual dysfunction, sex steroid hormone abnormalities, and depression in
women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 2005, 6,
(3), 360-5.

133.

Gardner, E. A.; Johnston, J. A., Bupropion-an antidepressant without sexual
pathophysiological action. J Clin Psychopharmacol 1985, 5, (1), 24-9.

134.

Waldinger, M. D.; van De Plas, A.; Pattij, T.; van Oorschot, R.; Coolen, L. M.;
Veening, J. G.; Olivier, B., The selective serotonin re-uptake inhibitors
fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic
treatment. Psychopharmacology (Berl) 2002,160, (3), 283-9.

135.

Modell, J. G.; Katholi, C. R.; Modell, J. D.; DePalma, R. L., Comparative sexual
side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol
Ther 1997, 61, (4), 476-87.

136.

Roderick, W. R.; Platte, H. J.; Pollard, C. B., Derivatives of Piperazine. XXXV.
Synthesis of 2-Phenylpiperazine and Some Derivatives. J Med Chem 1966, 9,
(2), 181-185.

137.

Blythin, D. J.; Chen, X.; Piwinski, J. J.; Shih, N. Y.; Shue, H. J.; Anthes, J. C.;
McPhail, A. T., Synthesis and NK(1)/NK(2) binding activities of a series of diacylsubstituted 2-arylpiperazines. Bioorg Med Chem Lett 2002,12, (21), 3161-5.

138.

Epstein, J. W.; Brabander, H. J.; Fanshawe, W. J.; Hofmann, C. M.; McKenzie, T.
C.; Safir, S. R.; Osterberg, A. C.; Cosulich, D. B.; Lovell, F. M., 1-Aryl-3azabicyclo[3.1.0]hexanes, a New Series of Nonnarcotic Analgesic Agents. J Med
Chem 1981, 24, 481-490.

139.

Se Lee, B.; Chul Lee, B.; Jun, J.-G.; Yoon Chi, D., A New Efficient Synthesis of
6-Nitroquipazine. Heterocycles 1998, 48, (12), 2637-2641.

140.

Meyers, A. I.; Williams, D. R.; Erickson, G. W.; White, S.; Druuelinger, M.,
Enantioselective Alkylation of Ketones via Chiral, Nonracemic Lithioenamines.
An Asymmetric Synthesis of alpha-Alkyl and alpha,alpha'-Dialkyl Cyclic Ketones.
J Am Chem Soc 1981, 103, 3081-3087.

141.

Fujino, T.; Morii, S.; H., S. Preparation of 1-substituted 2-alkylpiperazines. JP
2003342264, 2003.

142.

Habert, E.; Graham, D.; Tahraoui, L.; Claustre, Y.; Langer, S. Z.,
Characterization of [3H]paroxetine binding to rat cortical membranes. E urJ
Pharmacol 1985,118, (1-2), 107-14.

227

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

143.

Mathis, C. A.; Gerdes, J. M.; Enas, J. D.; Whitney, J. M.; Taylor, S. E.; Zhang, Y.;
McKenna, D. J.; Havlik, S.; Peroutka, S. J., Binding potency of paroxetine
analogues for the 5-hydroxytryptamine uptake complex. J Pharm Pharmacol
1992,44, (10), 801-5.

144.

Cheng, Y.; Prusoff, W. H., Relationship between the inhibition constant (K1) and
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an
enzymatic reaction. Biochem Pharmacol 1973, 22, (23), 3099-108.

145.

Gerdes, J. M.; Bolstad, D. B.; Davis, E. S.; Kusche, B. R.; Weller, M. L.; Wilson,
P. A., Serotonin Transporter Inhibitor Probes: Synthesis and Pharmacological
Profile of (rac)-[3H]2'-propyl-6-nitroquipazine. In 33rd National Meeting of the
Society for Neuroscience, New Orleans, LA, 2003.

146.

Armarego, W. L. F.; Chai, C., Purification of Laboratory Chemicals. 5th ed.;
Butterworth-Heinemann: London, 2003; p 608.

147.

Kofron, W. G.; Baclawski, L. M., A Convenient Method for Estimation of
Alkyllithium Concentrations. J Org Chem 1976, 41, (10), 1879-80.

148.

McCortney, B. A.; Jacobson, B. M.; Vreeke, M.; Lewis, E. S., Methyl Transfers.
14. Nucleophilic Catalysis of Nucleophilic Substitution. J Am Chem Soc 1990,
112, 3554-3559.

228

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

